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ABSTRACT
cis-Diamminedichloroplatinum(II) (cis-DDP or cisplatin) is a widely used anticancer drug
that is most effective against tumors of the testis. Although cisplatin is believed to mediate its
cytotoxicity through the formation of DNA adducts, the precise biochemical mechanisms
underlying its antitumor activity and selectivity for testicular tumors remain elusive. Of
significance are high mobility group (HMG)-domain and other proteins that bind specifically to
DNA modified with cisplatin, but not to DNA adducts of the clinically ineffective isomer trans-
DDP. The work in this dissertation examined the interaction of the testis-specific HMG-domain
protein human SRY (Sex-Determining Region Y) with cisplatin-modified DNA. The full-length
hSRY protein and its HMG domain region alone were expressed in Escherichia coli and purified
to homogeneity. The affinities and specificities of full-length hSRY and the hSRY-HMG domain
for a 20 bp DNA probe containing a single cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] intrastrand
cross-link were determined in electrophoretic mobility shift assays. Full-length hSRY bound to
the 1,2-d(GpG) cisplatin adduct with a Kd(~pp) of 120 ±10 nM and exhibited a 20-fold specificity
over unmodified DNA. The HMG domain of hSRY was sufficient for this interaction. The
hSRY-HMG domain recognized the 1,2-d(GpG) intrastrand cross-link with higher affinity (Kd4,)
= 4 ±0.7 nM) but with lower specificity (5-fold) compared to the full-length protein. The
affinities of full-length hSRY and the hSRY-HMG domain for a single cisplatin-DNA adduct were
comparable to those for the putative hSRY target sequence AACAAAG (Kd(~pp) (hSRY) = 15 ± 3
nM; K(,pp) (hSRY-HMG domain) = 3 ± 0.4 nM). These data suggest that cisplatin-DNA adducts
may compete with specific DNA sequences in vivo for the binding of human SRY. A possible
role for this testis-specific protein in the cytotoxicity and organotropic specificity of cisplatin for
testicular tumors is proposed. hSRY, in combination with other testis-expressed HMG-domain
proteins, could act to shield cisplatin-DNA adducts from the DNA repair machinery of the cell,
allowing the lesions to persist to exert their cytotoxic effects. Alternately, if hSRY has a critical
function in the growing tumor cell, titration away from its natural interaction site might lead to
cell death.
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I. INTRODUCTION
Although the platinum coordination complex cis-diamminedichloroplatinum(II) (cis-DDP
or cisplatin; Figure 1) was first synthesized in 1845, its effect on biological systems was not
discovered until over a century later, in 1965. The serendipitous discovery was made by the
biophysicist Barnett Rosenberg, who was studying the effects of electrical fields on bacterial
cultures (Rosenberg et al., 1965). Rosenberg observed that the growth of bacteria between
charged platinum electrodes stopped cell division and resulted in the growth of individual cells
into very long filaments. Cisplatin, which had been produced during electrolysis at the electrodes,
was one of the compounds responsible for this phenomenon. The inhibitory effect of cisplatin on
cell division suggested that it may have potential use as an anticancer agent. Since its approval by
the FDA in 1979, cisplatin has been one of the most widely used therapies to treat human cancers.
By contrast, the geometric isomer of cisplatin, trans-diamminedichloroplatinum(II) (trans-DDP;
Figure 1) is ineffective as a chemotherapeutic agent.
Cisplatin displays activity against several human cancers, but it is most effective against
tumors of the testis. Although testicular cancer accounts for less than 1% of all male
malignancies, it is the most common cancer in men aged 20-34 (Peckham, 1988; Einhorn, 1990;
Feuer et al., 1993). By recent estimates, approximately 96% of all testicular cancers are cured
(Feuer et al., 1993), largely through the use of chemotherapy with cisplatin as the principal
cytotoxic agent (Peckham, 1988; Einhorn, 1990). The success of cisplatin against other types of
tumors, however, has been limited by both intrinsic and drug-induced resistance. Elucidation of
the biochemical mechanisms underlying both the antitumor activity and organotropic specificity of
cisplatin may lead to more successful treatments of all types of cancers.
The antitumor activity of cisplatin is generally attributed to its covalent interaction with
DNA (Bruhn et al., 1990). Cisplatin-DNA adducts are primarily 1,2-d(GpG) (65%) and 1,2-
d(ApG) (25%) intrastrand cross-links and, at a lower frequency, 1,3-d(GpNpG) intrastrand and
DNA interstrand cross-links (Eastman, 1983; Fichtinger-Schepman et al., 1985; Eastman, 1986).
In each case, the platinum is coordinated to the N7 atom of the purine base. By contrast, trans-
DDP, the clinically ineffective isomer of cisplatin, cannot form the 1,2-intrastrand adducts owing
to geometric constraints. This observation led to the suggestion that the 1,2-intrastrand cross-
links, formed uniquely by cisplatin, are responsible for its antitumor activity (Pinto and Lippard,
1985a). Cisplatin-DNA adducts block DNA synthesis in vitro (Pinto and Lippard, 1985b) and in
vivo (Alazard et al., 1982; Salles et al., 1983; Ciccarelli et al., 1985). However, at equivalent
levels of damage, cis- and trans-DDP are equally effective at inhibiting DNA replication
(Ciccarelli et al., 1985; Heiger-Bernays et al., 1990), suggesting that the antitumor activity of
cisplatin cannot be explained solely by the inhibition of DNA synthesis in proliferating tumor cells.
Rather, the differences in toxicity of cis- and trans-DDP may stem from differential cellular
processing of the DNA adducts formed by these isomers.
Recently, several mammalian proteins possessing a common DNA binding motif, the high
mobility group (HMG) domain, have been shown to bind selectively to DNA modified with
cisplatin, but not to DNA adducts of trans-DDP (Chu, 1994; Whitehead and Lippard, 1996). An
unusual property of the HMG domain is its ability to interact with bent DNA structures such as
four-way junctions and to induce bends in linear DNA (Lilley, 1992; Grosschedl et al., 1994;
Read et al., 1995). Structural distortions induced in DNA by the major 1,2-intrastrand cross-links
of cisplatin (Takahara et al., 1996), including bending and unwinding of the DNA helix (Rice et
al., 1988; Bellon and Lippard, 1990; Bellon et al., 1991), are believed to serve as structure-
specific recognition signals for these proteins (Bruhn et al., 1992; Pil and Lippard, 1992; Treiber
et al., 1994; Chow et al., 1994). By contrast, the cisplatin 1,3-d(GpNpG) intrastrand cross-links,
which unwind the DNA to a greater degree than the 1,2-intrastrand adducts (Bellon et al., 1991),
fail to attract HMG-domain proteins (Pil and Lippard, 1992).
Several models may explain how HMG-domain proteins could effect cisplatin cytotoxicity
(Toney et al., 1989; Donahue et al., 1990; Brown et al., 1993; Treiber et al., 1994). One model
proposes that the binding of HMG-domain proteins to cisplatin-DNA adducts may impede
removal of the lesions by the nucleotide excision repair machinery. Indeed, studies in vivo
(Brown et al., 1993; McA'Nulty and Lippard, 1996) and in vitro (Huang et al., 1994; Zamble et
al., 1996) have supported the hypothesis that HMG-domain proteins can sensitize cells to cisplatin
by a repair-shielding mechanism. A second model proposes that cisplatin-DNA adducts may act
as molecular decoys in cells, titrating HMG-domain proteins from their natural binding sites and
thereby disrupting their function. In support of this model (Treiber et al., 1994), the binding of
the ribosomal RNA transcription factor hUBF to its cognate promoter sequence was competed
with a cisplatin-DNA adduct concentration much lower than that found in the DNA of cancer
patients (Reed et al., 1993).
The objective of my thesis research was to try to understand why cisplatin is more
effective in treating testicular tumors than tumors of other tissues. The current evidence suggests
that the hypersensitivity of testicular tumors to cisplatin may be related to a reduced capacity to
repair cisplatin-induced DNA damage since several testicular tumor cell lines are deficient in their
ability to remove DNA adducts of cisplatin (Bedford et al., 1988; Kelland et al., 1992a; Hill et al.,
1994a; Sark et al., 1995; Koberle et al., 1996). Several HMG-domain proteins are specifically
expressed in the testis (Sinclair et al., 1990; Denny et al., 1992b; Boissonneault and Lau, 1993;
Connor et al., 1995; Takamatsu et al., 1995; Kanai et al., 1996; Larsson et al., 1996) and could
potentially contribute to the specificity of cisplatin for testicular tumors by one or both of the
mechanisms described above. The work in this dissertation has examined the interaction of the
testis-specific HMG-domain protein human SRY (Sex-Determining Region Y) with cisplatin-
modified DNA. SRY, the proposed testis-determining factor (Sinclair et al., 1990), is expressed in
the genital ridge of the human embryo (Poulat et al., 1995) where it is responsible for testis
formation. SRY is also present in the adult testis although its role is uncertain (Sinclair et al.,
1990; Clepet et al., 1993). Human SRY (hSRY) recognizes certain AT-rich sequences in DNA
(Harley et al., 1992; Haqq et al., 1993; Giese et al., 1994; Cohen et al., 1994; Harley et al., 1994)
and activates transcription in the context of certain reporter gene constructs (Cohen et al., 1994;
Haqq et al., 1994). Upon DNA binding, hSRY induces a 60-83o bend in the DNA helix as
demonstrated by circular permutation assays (Ferrari et al., 1992; Giese et al., 1994; Pontiggia et
al., 1994) and by a recent NMR structure of a hSRY-HMG domain/DNA complex (Werner et al.,
1995). hSRY also recognizes four way junction DNAs irrespective of their sequence (Ferrari et
al., 1992; Peters et al., 1995) and (CA)n repeats that can adopt such structures (Vriz et al., 1995).
The ability of hSRY to interact with bent DNA structures and to bend linear DNA has suggested
that the protein may modulate transcription by acting architecturally in the assembly of a
nucleoprotein complex (Pontiggia et al., 1994).
In the work described below, full-length hSRY and its HMG domain region alone were
expressed in E. coli and purified to homogeneity. The affinities and specificities of full-length
hSRY and the hSRY-HMG domain for the major 1,2-d(GpG) adduct of cisplatin and the putative
target sequence AACAAAG were determined. The results demonstrate that human SRY
recognizes these DNAs with comparable affinities and that the HMG domain is sufficient for
DNA binding. In collaboration with D.B. Zamble of the Lippard laboratory, it was also shown
that the binding of hSRY to the 1,2-d(GpG) cross-link inhibits its repair in an in vitro excision
repair assay. These results suggest that, if hSRY and other testis-specific HMG-domain proteins
are expressed in testicular tumors and are able to inhibit repair of cisplatin-DNA adducts, these
proteins may contribute to the deficient ability of testicular tumor cells to remove cisplatin-DNA
adducts.
Figure 1: Structures of the therapeutically active compound cisplatin (cis-DDP) and the clinically
ineffective isomer of cisplatin, trans-DDP.
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H. LITERATURE SURVEY
A. DNA adducts formed by cis- and trans-DDP
Although cisplatin can bind to several biological macromolecules including DNA, RNA,
and protein, its principal cellular target is widely believed to be DNA (Sherman and Lippard,
1987; Bruhn et al., 1990; Pil and Lippard, 1997). Several lines of evidence support this view.
First, mammalian and bacterial cells deficient in DNA repair are hypersensitive to the cytotoxic
effects of cisplatin (Beck and Brubaker, 1973; Fraval et al., 1978; Hoy et al., 1985; Chu and Berg,
1987; Dijt et al., 1988). Second, cisplatin was found to damage a larger fraction of DNA
molecules than protein or RNA molecules when HeLa cells were treated with the drug at its mean
lethal dose (Akaboshi et al., 1992). An earlier study reported similar results (Pascoe and Roberts,
1974). Third, cisplatin treatment preferentially reduces DNA synthesis over RNA and protein
synthesis in vitro (Harder and Rosenberg, 1970) and in vivo (Howle and Gale, 1970). Fourth, the
levels of platinum-DNA adducts in the leukocytes of cancer patients undergoing cisplatin therapy
correlate with disease response to treatment (Reed et al., 1987; Reed et al., 1990; Reed et al.,
1993). Finally, studies in E. coli with site-specifically modified phage genomes have
demonstrated that DNA adducts of cisplatin are cytotoxic as well as mutagenic (Burnouf et al.,
1990; Bradley et al., 1993; Yarema et al., 1995).
1. Cisplatin-DNA adducts
Cisplatin is administered intravenously to patients. In the bloodstream where the
concentration of chloride ions is high (100 mM), cisplatin is relatively unreactive. Inside the cell,
however, the low ambient chloride concentration (-4 mM) facilitates hydrolysis of the chloride
ligands of the drug. The resulting aquated, electrophilic species can react by ligand substitution
with cellular nucleophiles, including DNA (Sherman and Lippard, 1987). Cisplatin binds to DNA,
primarily at the N7 positions of purine bases, in two successive reactions, forming initial
monofunctional adducts that subsequently close to bifunctional intrastrand or interstrand cross-
links (Bancroft et al., 1990) (summarized in Figure 2). The major DNA adducts formed by
cisplatin in vitro include 1,2-d(GpG) (65%), 1,2-d(ApG) (25%), and 1,3-d(GpNpG) (6%) (where
N is any nucleotide) intrastrand cross-links (Eastman, 1983; Fichtinger-Schepman et al., 1985;
Eastman, 1986) (Figure 3). Interstrand cross-links, which form between guanine bases at d(GpC)
/ d(GpC) sites (Eastman, 1985; Lemaire et al., 1991; Zou et al., 1994), and monofunctional
adducts at dG residues occur at a lower frequency (-1-2%) (Eastman, 1983;
Fichtinger-Schepman et al., 1985). Significantly, a very similar DNA adduct profile was obtained
when DNA isolated from the leukocytes of cancer patients was analyzed following cisplatin
treatment (Fichtinger-Schepman et al., 1987).
2. trans-DDP-DNA adducts
trans-DDP, the clinically inactive isomer of cisplatin, also reacts with DNA to form
intrastrand and interstrand cross-links (Eastman et al., 1988), as well as monofunctional adducts
(Eastman and Barry, 1987) (summarized in Figure 2). trans-DDP, however, cannot form the 1,2-
intrastrand cross-links for steric reasons (Pinto and Lippard, 1985a). Instead, the primary DNA
adducts formed by trans-DDP are intrastrand cross-links at bases separated by one or more
intervening nucleotides (Eastman et al., 1988). In general, the adduct spectrum of trans-DDP is
less well characterized than that of cisplatin. Analysis of trans-DDP-treated DNA following
enzymatic digestion revealed that dG-Pt-dG and dG-Pt-dC bifunctional cross-links comprise 40%
and 50%, respectively, of the adducts formed by trans-DDP (Eastman et al., 1988). In these
experiments, interstrand cross-links could not be distinguished from intrastrand cross-links,
however. More recent work has shown that interstrand cross-links form preferentially between
complementary guanine and cytosine residues and account for up to 20% of the total adduct
profile of trans-DDP (Brabec and Leng, 1993).
3. Structures of cis- and trans-DDP-DNA adducts
The structures of cis- and trans-DDP-DNA adducts have been investigated by several
methods. Gel electrophoresis studies (Rice et al., 1988; Bellon and Lippard, 1990; Bellon et al.,
1991) demonstrated that the 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-links of cisplatin bend
the DNA helix 340 in the direction of the major groove and unwind it by 130. The 1,3-d(GpTpG)
intrastrand adduct also produces a bend of 34', but it unwinds the DNA to a greater extent (230)
than the 1,2-intrastrand adducts (summarized in Table 1). X-ray crystallography of cisplatin
coordinated to the dinucleotide d(GpG) reveals that the base stacking of the guanines is
completely disrupted; the dihedral angle between the guanine ring planes is 76-87' (Sherman et
al., 1985). Recently, an X-ray crystal structure of the 1,2-d(GpG) cisplatin intrastrand cross-link
in a duplex DNA dodecamer has been determined (Takahara et al., 1995; Takahara et al., 1996).
As in the dinucleotide structure, the guanine bases are destacked and the sugars to the 5' and 3'
side of the adduct have C3'-endo and C2'-endo conformations, respectively. The overall DNA
conformation contains a unique juxtaposition of A- and B-type helical segments; this unusual
structure may have been influenced by crystal packing. Within the cisplatin-modified duplex, base
pairing is maintained. The minor groove is significantly widened and resembles that of A-DNA.
The platinum atom is significantly distorted within its coordination sphere owing to a roll angle of
only 260 between the planes of the guanine ligands. The structure of the 1,2-d(GpG) adduct
within a 8 base pair duplex has also been solved recently by NMR spectroscopy (Yang et al.,
1995) As in the crystal structure, the minor groove is significantly widened and a switch occurs in
sugar pucker conformation at the site of the adduct. However, base pairing of the 5'-platinated
guanine is disrupted. The NMR structure also reveals a greater degree of DNA helix bending
(-~580) and unwinding (-21 ) than the earlier gel electrophoresis studies (Bellon and Lippard,
1990; Bellon et al., 1991) and the crystal structure (Takahara et al., 1996). Interestingly, in the
presence of chloride ion, the 1,2-d(GpG) intrastrand cross-link within the duplex slowly
isomerized to an interstrand adduct (Yang et al., 1995). The biological relevance of this
isomerization is not known.
Gel electrophoresis studies indicated that the 1,3-d(GpTpG) intrastrand cross-link of
trans-DDP does not produce a directed bend, but rather imparts a degree of flexibility to the
DNA helix (Bellon and Lippard, 1990). Additionally, the 1,3-intrastrand trans-DDP adduct
unwinds the DNA helix to a lesser extent (-9o) than the cisplatin-DNA intrastrand adducts (Keck
and Lippard, 1992; Bellon et al., 1991). These results are in agreement with an earlier finding that
trans-DDP is less effective at unwinding supercoiled DNA than cisplatin (Scovell and Collart,
1985). Monofunctional adducts formed by the platinum compound [Pt(dien)Cl] (dien,
diethylenetriamine) do not bend the DNA, but unwind the DNA helix by 60 (Keck and Lippard,
1992) (summarized in Table 1).
The structures of cis- and trans-DDP interstrand cross-links have also been investigated
(summarized in Table 1). DNase I footprinting studies revealed that interstrand adducts of both
cis- and trans-DDP distort the DNA helix over a larger region than the cisplatin intrastrand
adducts (Schwartz and Leng, 1994). Recently, the solution structure of a cisplatin d(G*pC) /
d(G*pC) interstrand cross-link (where the asterisks denote sites of platinum coordination) in a 10
bp DNA duplex was determined by NMR spectroscopy (Huang et al., 1995; Paquet et al., 1996).
Most striking is the finding that the cisplatin bridge lies in the minor groove, rather than the major
groove as is the case for the 1,2-d(GpG) intrastrand adduct (Takahara et al., 1996). The
complementary cytosine bases are extrahelical and the DNA helix is bent toward the minor groove
-20'-40'. The DNA helix is unwound by -800 , in agreement with earlier gel electrophoresis
studies (Malinge et al., 1994). Finally, Leng and colleagues demonstrated that the trans-DDP
d(G*pC) / d(GpC*) interstrand cross-link also induces significant distortion in the DNA helix.
Gel electrophoresis and chemical reactivity studies showed that the trans-DDP interstrand adduct
produces a bend of 260 toward the major groove and unwinds the DNA helix 12'. In addition, the
adduct introduces a considerable amount of flexibility to the helix (Brabec et al., 1993).
4. Roles of specific adducts in the antitumor activity of cisplatin
The most striking difference in the DNA adduct spectra of cis- and trans-DDP (Figure 2)
is that trans-DDP cannot form the 1,2-intrastrand cross-links, which comprise greater than 90%
of all cisplatin-DNA adducts. Thus, it has been proposed that the 1,2-intrastrand adducts are
responsible for the antitumor activity of cisplatin (Pinto and Lippard, 1985a). The selective
affinity of cellular proteins for the 1,2-intrastrand adducts of cisplatin and other therapeutically
active platinum compounds (vide infra) lends support to this view. In addition, high levels of
intrastrand adducts in the leukocyte DNA of cancer patients correlate well with favorable
response to cisplatin treatment (Reed et al., 1987; Reed et al., 1990; Reed et al., 1993). Similarly,
it has been suggested that DNA interstrand cross-links, which are formed to a much greater extent
by trans-DDP than by cis-DDP (Figure 2), may play a relatively minor role in the therapeutic
activity of cisplatin. Contrary to this view, the formation of interstrand cross-links has been
correlated with cisplatin cytotoxicity in some studies (Zwelling et al., 1979; Fram et al., 1990)
(vide infra). In these arguments, it is assumed that the DNA adducts formed by cis- and trans-
DDP have similar structures; however, the above discussion clearly shows that this is not the case
(Table 1). Thus, until the mechanisms underlying the antitumor activity of cisplatin are elucidated
fully, all DNA adducts remain potential candidates for the specific lesions that mediate
cytotoxicity of the drug.
B. Effects on DNA replication and transcription
It has been hypothesized that cisplatin exerts its cytotoxic effects through the inhibition of
DNA synthesis in rapidly dividing tumor cells. Indeed, cisplatin-DNA adducts have been shown
to block DNA synthesis in vitro (Pinto and Lippard, 1985b) and in vivo (Alazard et al., 1982;
Salles et al., 1983; Ciccarelli et al., 1985). However, several studies have demonstrated that DNA
adducts of the inactive cisplatin isomer, trans-DDP, are as effective as cisplatin-DNA adducts in
inhibiting DNA synthesis. In particular, both cis- and trans-DDP adducts block bacterial (Pinto
and Lippard, 1985b) and eukaryotic DNA polymerases (Harder et al., 1976; Bernges and Holler,
1988; Heiger-Bernays et al., 1990) efficiently in vitro. In addition, treatment of mammalian cells
in culture with cis- or trans-DDP resulted in equal inhibition of DNA replication by the two
compounds (Salles et al., 1983; Ciccarelli et al., 1985; Uchida et al., 1986). In the study by
Ciccarelli et al., 14 times more trans- than cis-DDP was required in the culture medium to inhibit
SV40 replication in SV40-infected African green monkey CV-1 cells, a result probably related to
greater inactivation of trans-DDP compared to cis-DDP by sulfur-containing molecules such as
glutathione in the cells (Eastman and Barry, 1987; Bancroft et al., 1990). However, the two
compounds were equally effective at blocking replication when equal numbers of platinum
adducts were bound to the SV40 DNA. By contrast, a subsequent study found that, at equivalent
levels of platinum damage, DNA synthesis was inhibited to a greater extent by cis-DDP than
trans-DDP (Roberts and Friedlos, 1987). These conflicting results may reflect differences in
experimental design (Sherman and Lippard, 1987).
Cisplatin may also exert its antitumor effects through the inhibition of RNA synthesis, a
process that, like DNA synthesis, is more critical for a rapidly dividing tumor cell than for a
stationary cell (Mauck and Green, 1973). Recent evidence suggests that, while the DNA adducts
of cis- and trans-DDP block DNA synthesis equivalently, the adducts of these platinum isomers
may inhibit RNA synthesis differentially. In vitro studies have demonstrated that the 1,2- and 1,3-
intrastrand cross-links of cisplatin completely block the processivity of both E. coli and wheat
germ RNA polymerases when present on the transcribed strand. By contrast, monofunctional
platinum adducts and the 1,3-d(GpTpG) intrastrand adduct of trans-DDP could be bypassed by
the polymerases (Corda et al., 1991; Corda et al., 1993; Brabec and Leng, 1993). Evidence has
also been presented in vivo in support of the hypothesis that trans-DDP adducts may selectively
inhibit transcription. A host-cell reactivation assay was used to compare levels of transcription
from a reporter gene on cis- and trans-DDP-modified plasmids after transfection into mammalian
cells (Mello et al., 1995). The results demonstrated a 2-3-fold higher level of transcription from
plasmids treated with trans-DDP as compared to cis-DDP-modified plasmids. Similar results
were obtained using cell lines deficient in nucleotide excision repair, indicating that more efficient
excision repair of the trans-DDP adducts is not responsible for the lower ability of trans-DDP to
block transcription in the assay. Furthermore, when elongation of nascent RNA was measured
using a ribonuclease protection assay, 4-fold more trans-DDP than cis-DDP adducts were
required for inhibition of elongation, indicating that the trans-DDP adducts are bypassed
preferentially by RNA polymerase II. Another study provided direct evidence in vivo that cis-
and trans-DDP-DNA adducts affect transcription initiation differentially (Mymryk et al., 1995).
Interestingly, treatment of cells in culture with cis-DDP had both positive and negative effects on
gene expression. Such differential effects were not observed in trans-DDP-treated cells (Evans
and Gralla, 1992a; Evans and Gralla, 1992b).
Taken together, the results described above suggest that inhibition of both DNA
replication and transcription may contribute to the antitumor activity of cisplatin. Interestingly, it
was demonstrated that Chinese hamster ovary cells are able to survive concentrations of cisplatin
high enough to block DNA synthesis, indicating that inhibition of DNA synthesis does not
correlate with cell death. In particular, the cells arrested in the G2 phase of the cell cycle, where
they remained for several days, at which point the arrested cells either recovered or underwent
apoptosis (Sorenson and Eastman, 1988a; Sorenson and Eastman, 1988b; Sorenson et al., 1990).
It is possible that cisplatin-DNA adducts trigger apoptosis by inducing changes in the delicate
balance of gene transcription or by inhibiting overall gene expression or that of a critical gene
required for passage to mitosis (Sorenson and Eastman, 1988b).
C. Repair of platinum-DNA adducts
1. Repair of platinum adducts in E. coli
Repair of cisplatin-induced DNA damage is one mechanism by which cells treated with
cisplatin may increase their survival. In E. coli, the Uvr(A)BC nucleotide excision repair system
excises bulky DNA adducts including those formed by UV light, cisplatin, psoralen, and
benzopyrene (Sancar, 1996). The general repair mechanism involves damage recognition, dual
incisions of the damaged strand, excision of an oligomer containing the damage, and resynthesis.
Together, the proteins UvrA, UvrB, and UvrC carry out the damage recognition and incision
steps in an ATP-dependent reaction. A dimer of UvrA in complex with UvrB binds to the site of
damage. Following an ATP-dependent conformational change, UvrA dissociates, leaving behind
a stable UvrB-DNA complex. UvrC binds to this complex and incisions to the 3' and 5' side of
the damage are made by UvrB and UvrC, respectively. UvrD facilitates dissociation of UvrC and
release of a 12-13 nucleotide fragment containing the damage. DNA polymerase I fills the gap,
displacing UvrB and DNA ligase seals the remaining nicks.
Toxicity studies in E. coli have demonstrated that strains deficient in Uvr(A)BC excision
repair (uvrA, uvrB, uvrC) are extremely sensitive to cisplatin, but are less sensitive to the cisplatin
isomer, trans-DDP (Alazard et al., 1982; Beck et al., 1985; Popoff et al., 1987). In vivo
transformation assays further showed that plasmids modified with trans-DDP were more
deleterious to cell survival than plasmids treated with cisplatin (Popoffet al., 1987). Interestingly,
induction of the SOS response, which acts to increase synthesis of repair enzymes, improved
survival of the cisplatin-modified plasmids, but not the plasmids modified with trans-DDP (Popoff
et al., 1987). Together, these observations suggest that the DNA adducts of cis- and trans-DDP
may be repaired differently in E. coli.
In vitro repair assays with purified UvrA, UvrB, and UvrC proteins have been used to
examine the molecular mechanism of repair of platinum-DNA adducts. DNA adducts formed by
both cis- and trans-DDP are substrates for the Uvr(A)BC system; however, the trans-DDP
adducts are excised less efficiently than the cisplatin adducts (Beck et al., 1985; Popoffet al.,
1987), in contrast with the in vivo experiments described above (Popoff et al., 1987).
Specifically, DNA fragments damaged with cisplatin are cut at the 8th phosphodiester bond 5' and
at the 4th phosphodiester bond 3' to adjacent guanine residues (Beck et al., 1985). In a separate
study, substrates containing site-specific adducts of the cisplatin analogs [Pt(en)C12] and
[Pt(dach)C12] were used to determine the relative repair efficiency of individual adducts in the
Uvr(A)BC system. The results demonstrated an adduct preference of 1,3-d(GpNpG) > dG
monoadduct > 1,2-d(ApG) > 1,2-d(GpG) (Page et al., 1990). By contrast, a more recent study
with specific adducts of cisplatin showed that the 1,2-d(GpG) intrastrand cross-link is excised 3.5-
times more efficiently than the 1,3-d(GpCpG) intrastrand adduct (Visse et al., 1994). The
conflicting results may stem from the use of different platinum complexes in these studies.
2. Repair of platinum adducts in mammalian cells
Nucleotide excision repair in mammalian cells is considerably more complex than in E.
coli, with 16 rather than 3 proteins needed for the dual incisions (Sancar, 1996; Wood, 1996).
The genes required for mammalian excision repair include those defined by the seven (A-G)
different complementation groups of the DNA repair disorder, xeroderma pigmentosum (XP), as
well as the excision repair cross-complementing (ERCC) genes isolated from UV-sensitive rodent
cell lines. The basic mechanism of damage recognition, incision, and repair synthesis is similar to
that of E. coli. A complex between XPA and the single-stranded binding protein RPA (also
known as HSSB) recognizes the site of damage and recruits TFIIH (XPB/XPD), a helicase with
dual functions in transcription and repair. TFIIH unwinds the DNA in an ATP-dependent
reaction and recruits XPC to the damaged strand as part of the preincision complex. Incisions 3'
and 5' to the damaged site are made by XPG and the XPF/ERCC-1 complex, respectively, and the
damage is excised in a 24-32 nucleotide fragment. DNA polymerase 5 or 6, in combination with
the accessory factor proliferating cell nuclear antigen (PCNA), carries out repair synthesis and the
patch is sealed by DNA ligase I or III. The recent reconstitution of mammalian nucleotide
excision repair in vitro (Mu et al., 1995; Aboussekhra et al., 1995) will aid in future studies to
elucidate the details of the repair mechanism.
a. Sensitivity of DNA repair-deficient cells to cisplatin
Several studies have demonstrated that mammalian cells deficient in DNA repair are
hypersensitive to cisplatin toxicity (Fraval et al., 1978; Poll et al., 1984; Hoy et al., 1985; Dijt et
al., 1988). Cells derived from XPA individuals are 3-4-fold more sensitive to cisplatin than
normal cells (Poll et al., 1984; Dijt et al., 1988) and are deficient in the repair ofcisplatin-DNA
adducts, as demonstrated by monitoring removal of the 1,2-d(GpG) and 1,2-d(ApG) intrastrand
adducts from genomic DNA immunochemically (Dijt et al., 1988). In addition, UV-20, a Chinese
hamster ovary cell line deficient in the ERCC-1 gene, exhibits a 50-fold higher sensitivity to
cisplatin than normal cells (Hoy et al., 1985) and shows a decreased capacity to repair cisplatin
interstrand cross-links (Meyn et al., 1982). This last result is consistent with the proposed dual
role for ERCC-1 in nucleotide excision repair and recombinational repair processes (Sancar,
1996; Wood, 1996; Chaney and Sancar, 1996). The study by Fichtinger-Schepman and
coworkers (Dijt et al., 1988) also examined the kinetics of repair in normal and XPA cells.
Normal cells exhibited a biphasic removal of cisplatin adducts in which a 4-6 h period of rapid
repair was followed by a period of slower adduct removal. XPA cells appeared deficient in the
fast repair process. Studies examining the kinetics of repair in cisplatin-treated patients also
demonstrated a period of fast adduct removal followed by diminished repair activity at later time
points (Fichtinger-Schepman et al., 1990) and persistance of the adducts for several days (Poirier
et al., 1992).
b. Repair of specific cisplatin-DNA adducts
The repair of individual cisplatin-DNA adducts has been investigated in two different in
vitro repair assays systems, one developed by Wood and coworkers (Hansson and Wood, 1989;
Szymkowski et al., 1992) and the other by Sancar and coworkers (Huang et al., 1994). The first
assay, known as repair synthesis, monitors a repair patch incorporated into platinum-damaged
plasmid DNA. The second, or excision repair assay, detects removal of the damage-containing
fragment from a duplex oligonucleotide substrate. Early results from the repair synthesis assay
demonstrated that human cell extracts could carry out repair synthesis on plasmids globally
modified with cisplatin (Hansson and Wood, 1989; Hansson et al., 1990). In a subsequent study,
repair synthesis was not decreased significantly when the cisplatin-damaged plasmids were
pretreated with cyanide to remove the 1,2-intrastrand cross-links, suggesting that the 1,2-d(GpG)
and 1,2-d(ApG) adducts are poorly repaired by human cell extracts in vitro (Calsou et al., 1992).
In support of this view, the 1,2-d(GpG) cisplatin adduct located at a specific site in plasmid DNA
failed to stimulate repair synthesis by human cell extracts (Szymkowski et al., 1992). By contrast,
repair of the 1,2-d(GpG) adduct was detected using the excision repair assay (Huang et al., 1994).
The relative repair efficiencies of the cisplatin intrastrand cross-links in this system were 1,3-
d(GpTpG) > 1,2-d(ApG) > 1,2-d(GpG) (Huang et al., 1994; Zamble et al., 1996) with the 1,3-
intrastrand adduct repaired -3-fold faster than the 1,2-d(GpG) adduct (Huang et al., 1994).
Repair of the 1,3-intrastrand adduct was also more efficient in a reconstituted system, suggesting
that differences in the rates of repair are due to structural differences in the platinum adducts
rather than to unidentified factors in the cell extract (Zamble et al., 1996). A very recent study by
Wood and coworkers demonstrated that the 1,3-d(GpTpG) intrastrand adduct was repaired -15-
20-fold more efficiently than the 1,2-d(GpG) and 1,2-d(ApG) adducts in human cell extracts and
in a reconsituted system (Moggs et al., 1997). These inconsistent results may be a reflection of
the different assay systems and/or site-specific substrates used in the two studies. Interestingly,
the 1,2-d(GpG) adduct was repaired 17-fold more efficiently when placed opposite one or two
thymines instead of cytidines, suggesting that a greater structural distortion favors recognition by
the nucleotide excision repair complex (Moggs et al., 1997). Taken together, the results detailed
above suggest that inefficient repair of the major 1,2-d(GpG) cisplatin adduct may contribute to
the antitumor activity of cisplatin.
Studies examining the incision sites on cisplatin-modified DNA have also yielded
inconsistent results. Sancar, Lippard, and coworkers concluded that the 1,3-d(GpTpG) adduct
and was incised at the 5th phosphodiester bond on the 3' side and the 22nd to 24th
phosphodiester bond on the 5' side of the lesion based on treatment of the excision products with
a 3'-5' exonuclease (Huang et al., 1994). Mapping of the nicks by primer extension and restriction
fragment end-labeling, however, revealed principal sites of incision at the 9th bond 3' and 16th
bond 5' to the site of the 1,3-d(GpTpG) adduct (Moggs et al., 1996). The analyses yielded a
repair patch of similar size, 26-29 nucleotides in length. This discrepancy is unresolved at present.
c. The relative repair efficiency of cis- and trans-DDP-DNA adducts
Several studies have examined the repair efficiency of trans-DDP adducts as compared to
cisplatin adducts. In vitro repair synthesis assays indicated that human cell extracts could carry
out repair synthesis 2-fold more efficiently on trans-DDP- than cis-DDP-modified plasmids
(Hansson and Wood, 1989). In addition, extracts prepared from XPA cells were deficient in
repair synthesis of cis-DDP and trans-DDP-modified plasmids, suggesting that both types of
adducts are repaired by the excision repair pathway (Hansson and Wood, 1989; Hansson et al.,
1990). In an SV40-based in vitro replication assay, preincubation of trans-DDP-modifed
plasmids, but not cis-DDP-modified plasmids, with human extracts resulted in restoration of DNA
synthesis by 30%, suggesting that an activity present in the extracts had repaired the trans-DDP-
damaged template preferentially (Heiger-Bernays et al., 1990).
In vivo studies, however, have yielded conflicting results. A study by Ciccarelli et al.
(1985) found that in SV40-infected CV-1 cells, cis-DDP-DNA adducts accumulated continuously
over a period of 48 hours, whereas trans-DDP adducts reached a maximum at 6 hours and then
dropped dramatically, a result consistent with preferential repair of the trans-DDP adducts
(Ciccarelli et al., 1985). A subsequent study, however, found that DNA adducts of cis- and
trans-DDP were removed from the DNA at similar rates when DNA replication was taken into
account in the measurement of platinum bound to the DNA (Roberts and Friedlos, 1987). In the
later work, the platinum compounds were dissolved in dimethyl sulfoxide, a substance known to
rapidly react with trans-DDP, and thus the two studies may not be directly comparable (Sherman
and Lippard, 1987). A recent study using a host-cell reactivation assay demonstrated that
preferential bypass of trans-DDP adducts by RNA polymerase II, rather than preferential repair,
was the cause of enhanced expression of a trans-DDP- compared to a cis-DDP-modified reporter
gene construct (Mello et al., 1995). In addition, significant repair of DNA adducts of both
isomers was observed in normal cells, but not in cells deficient in nucleotide excision repair, in a
period 15-48 hours after transfection, suggesting that excision repair is the main pathway by
which both cis- and trans- DDP adducts are removed from mammalian cells (Mello et al., 1995).
It remains to be determined whether preferential repair of trans-DDP-DNA adducts can account
for the differential toxicity between cis-DDP and trans-DDP.
d. Cisplatin-DNA adducts are substrates for transcription-coupled repair
Transcription-coupled repair is the phenomenon whereby transcriptionally active DNA is
repaired more efficiently than nontranscribed DNA (Drapkin et al., 1994; Friedberg, 1996). The
pausing of RNA polymerase II at damaged sites is believed to contribute to this preferential
repair. Several studies have shown that cisplatin-DNA adducts are substrates for transcription-
coupled repair. In particular, cisplatin intrastrand adducts are repaired more efficiently from
transcribed genes than from noncoding regions (Jones et al., 1991). Preferential repair of
intrastrand adducts also occurs on the trancriptionally active template strand as compared to the
nontranscribed strand (May et al., 1993). Interstrand cross-links are removed preferentially from
transcribed regions, but only when the cells are treated with low concentrations of cisplatin
(Larminat et al., 1993). These studies, however, used the Uvr(A)BC system to moniter the
presence of intrastrand cross-links, and thus adducts poorly recognized by this system would go
undetected. A novel assay that allows detection of low levels of modification may prove useful in
future studies examining transcription-coupled repair of cisplatin-DNA adducts (Rampino and
Bohr, 1994).
D. Recognition of cisplatin-DNA adducts by cellular proteins
1. Identification of cisplatin damage recognition proteins
The differences in toxicity of cis- and trans-DDP may stem from differential processing of
platinum-DNA adducts by cellular proteins. Much effort, therefore, has been focused on the
isolation and characterization of proteins that bind selectively to DNA adducts of cisplatin (Chu,
1994; Whitehead and Lippard, 1996). Electrophoretic mobility shift assays employing globally
platinated DNAs identified a cisplatin-DNA binding activity present in mammalian cellular
extracts (Chu and Chang, 1988; Donahue et al., 1990; Fujiwara et al., 1990; Andrews and Jones,
1991; Chao et al., 1991 a). The binding activity was also selective for DNA modified with
[Pt(en)Cl2] (en, ethylenediamine) and [Pt(dach)C12] (dach, 1,2-diaminocyclohexane), two other
therapeutically active platinum compounds. However, no binding to DNA modified with the
clinically inactive compound trans-DDP nor the monofunctionally coordinating [Pt(dien)Cl]Cl
(dien, diethylenetriamine) was observed (Donahue et al., 1990). The protein responsible for this
activity had an apparent molecular weight of 91 kDa and was shown to bind specifically to the
1,2-d(GpG) and 1,2-d(ApG) intrastrand cisplatin cross-links, but not to the 1,3-d(GpTpG)
intrastrand adduct. The apparent dissociation constant of the protein for cisplatin-modified DNA
was estimated to be 10-10 M (Donahue et al., 1990). The cisplatin-DNA binding activity was also
detected in extracts prepared from human ovarian, cervical, and testicular tumor biopies (Bissett
et al., 1993). Activity levels were similar in cisplatin-sensitive and cisplatin-resistant HeLa,
hamster V79, and ovarian carcinoma lines (Donahue et al., 1990; Andrews and Jones, 1991).
Southwestern blotting was also used to examine cisplatin-DNA binding activity in
mammalian cells. In this method, cellular extracts are resolved on SDS/polyacrylamide gels,
transferred to nitrocellulose, and the protein-bound filters are probed with radiolabeled DNAs that
are unmodified or modified with platinum compounds. This analysis has the advantage of
revealing the sizes of cisplatin-DNA binding proteins. Southwestern blotting of HeLa cell
extracts initially revealed bands of-100 kDa and -30 kDa on filters probed with cisplatin-
modified DNA, but not on filters probed with unmodified DNA or DNA modified with trans-
DDP (Toney et al., 1989; Chao et al., 1991a). A subsequent analysis employing gradient
SDS/polyacrylamide gels to separate cellular proteins demonstrated that the 100 kDa band could
be resolved into species of molecular weight 80-100 kDa (Treiber et al., 1994). Extracts prepared
from ovarian, bladder, and testicular cancer cell lines revealed cisplatin-DNA binding proteins of
similar sizes (Andrews and Jones, 1991; McLaughlin et al., 1993). Together, these results
demonstrated that multiple proteins in mammalian cells were responsible for the observed
cisplatin-DNA binding activity.
In parallel work, the screening of a human cDNA expression library with a cisplatin-
modified DNA probe yielded a cDNA clone encoding an 81 kDa cisplatin-DNA binding protein
termed SSRP1, structure-specific recognition protein 1 (Toney et al., 1989; Bruhn et al., 1992).
Amino acid sequence analysis revealed that SSRP1 contained a 75 amino acid conserved DNA
binding motif referred to as the high mobility group (HMG) domain (Grosschedl et al., 1994).
SSRP1 is the human homolog of a mouse protein T160 that binds to the V-(D)-J recombination
signal sequences required for generating antibody diversity (Shirakata et al., 1991). SSRP1 is also
the homolog of a protein from rat and chicken that binds to the enhancer region of the collagen II
gene (Wang et al., 1993). Employing the same methodology used to isolate SSRP1, a yeast
genomic library was screened with a cisplatin-modified DNA probe. A clone was isolated that
encodes an 80 kDa yeast cisplatin-DNA binding protein designated intrastrand cross-link
recognition protein (Ixrl) (Brown et al., 1993). This protein is also known as Ord1 for
oxygen/oxidase regulating defective protein (Lambert et al., 1994). Ixrl/Ordl contains two
tandem HMG domains and functions as a transcriptional repressor of the 5b subunit of
cytochrome c oxidase (Lambert et al., 1994).
A family of proteins possessing the HMG DNA binding domain has since been identified
(Grosschedl et al., 1994; Read et al., 1995). The prototype of this family is high mobility group
protein 1 (HMG1). HMG1 is a nonhistone chromosomal protein containing two tandem HMG
domains that has affinity for AT-rich sequences (Brown and Anderson, 1986), DNA cruciform
structures (Bianchi et al., 1989), and poly(CA).poly(TG) sequences (Gaillard and Strauss, 1994).
The function of HMG1 is not known; it may be involved in chromatin structure and gene
transcription (Landsman and Bustin, 1993). The homology between the HMG domains of HMG1
and SSRP1 suggested that HMG1 may also recognize cisplatin-modified DNA. When examined
in electrophoretic mobility shift assays, recombinant rat HMG1 bound selectively to DNA
modified with cisplatin, but not to DNA modified with trans-DDP. Moreover, the protein
recognized the 1,2-d(GpG) and 1,2-d(ApG) cisplatin intrastrand cross-links, but not the 1,3-
d(GpTpG) intrastrand adduct (Pil and Lippard, 1992), the same profile of adduct recognition
observed earlier for the cisplatin-DNA binding activity in mammalian extracts (Donahue et al.,
1990). HMG1 bound to a 100 bp DNA probe containing a single 1,2-d(GpG) intrastrand cross-
link with an apparent dissociation constant of 370 nM and exhibited a 100-fold selectivity over
unmodified DNA (Pil and Lippard, 1992). Parallel Southwestern and Western analyses using an
antiserum that recognized both HMG1 and the homologous protein HMG2 (Pil and Lippard,
1992) indicated that, together, these proteins comprised the 30 kDa band observed previously on
Southwestern blots (Toney et al., 1989). Selective immunoprecipitation of HMG1 with an
antibody raised against recombinant rat HMG1 confirmed these results (Pil and Lippard, 1992).
HMG1 and HMG2 were also identified as cisplatin-DNA binding proteins by using a cisplatin-
damaged DNA affinity precipitation technique (Hughes et al., 1992). Recent work has
demonstrated that HMG1 also binds to cisplatin interstrand cross-links, but not interstrand cross-
links of trans-DDP in electrophoretic mobility shift assays (Kasparkova and Brabec, 1995).
Another study showed increased binding of HMG1 to longer DNAs (up to 180 bps) containing
multiple cisplatin adducts (Turchi et al., 1996).
The HMG-domain protein human upstream binding factor (hUBF), a transcriptional
regulator of ribosomal RNA synthesis (Jantzen et al., 1990), exists as species of both 97 kDa and
94 kDa due to an alternative splicing event (Chan et al., 1991). Thus, it was hypothesized
(Treiber et al., 1994) that bands of 97 kDa and 94 kDa on Southwestern blots of HeLa cell
extracts may be hUBF. In support of this view, a Western blot probed with hUBF antiserum
revealed the 97/94 kDa doublet bands. The hypothesis was further confirmed by Southwestern
analysis of in vitro translated hUBF (Treiber et al., 1994). hUBF binds to the 1,2-d(GpG)
cisplatin adduct with a Kd() of 60 pM, an affinity comparable to that for its cognate promoter
sequence (K(,) = 18 pM) (Treiber et al., 1994).
Further studies indicated that a single HMG domain could mediate binding to cisplatin-
modified DNA (Lawrence et al., 1993; Chow et al., 1995; Locker et al., 1995; Farid et al., 1996).
In particular, domain B of HMG1 bound to the 1,2-d(GpG) intrastrand cross-link with a Kd,,) of
10-7 M, but exhibited a lower selectivity (4-fold) for cisplatin-modified DNA over unmodified
DNA compared to full-length HMG1. Recently, HMG1 domain A was shown to recognize the
1,2-d(GpG) adduct with a Ka~,) of 10-'- 10-9 M, depending on the base pairs immediately flanking
the adduct (S.U. Dunham and S.J. Lippard, manuscript submitted). The six HMG domains of
hUBF contribute to cisplatin-modified DNA binding in an additive way (X.Q. Zhai and J.M.
Essigmann, manuscript in preparation).
The HMG-domain protein family can be divided into at least two subgroups. One
subgroup contains ubiquitously expressed proteins with multiple HMG domains that bind to DNA
with little or no sequence specificity. A second subgroup contains cell-type specific proteins with
a single HMG domain that recognizes specific DNA sequences (Laudet et al., 1993; Grosschedl et
al., 1994; Baxevanis and Landsman, 1995; Read et al., 1995). Interestingly, the major 1,2-
intrastrand cross-links of cisplatin are recognized by HMG-domain proteins comprising both
subgroups, including full-length proteins HMG1 (Pil and Lippard, 1992; Hughes et al., 1992),
HMG2 (Pil and Lippard, 1992; Hughes et al., 1992), hUBF (Treiber et al., 1994), mitochondrial
transcription factor (mtTFA) (Chow et al., 1994), Ixrl (McArNulty et al., 1996), and murine
testis-specific HMG-domain protein (tsHMG) (Zamble et al., 1996) from the first subgroup and
the single HMG domains of lymphoid enhancer-binding factor 1 (LEF-1) and murine testis-
determining factor (mSRY) from the second subgroup (Chow et al., 1994). Table 2 summarizes
the binding affinities and specificities of these HMG-domain proteins for the 1,2-d(GpG) cisplatin
intrastrand cross-link. In general, the HMG domains alone exhibit a lower selectivity for cisplatin-
modified DNA over unmodified DNA compared to the full-length proteins (Chow et al., 1994;
Chow et al., 1995).
Cisplatin-DNA adducts are also recognized by proteins that do not contain HMG DNA
binding domains. A 125 kDa UV-damage recognition protein (UV-DRP) binds to DNA adducts
of UV light and cisplatin (Chu and Chang, 1988; Payne and Chu, 1994) and is overexpressed in
cisplatin-resistant cells (Chu and Chang, 1990; Chao et al., 1991a; Vaisman and Chaney, 1995).
The absence of the UV-DRP in a subset of xeroderma pigmentosum group E (XPE) patients (Chu
and Chang, 1988; Kataoka and Fujiwara, 1991; Keeney et al., 1992) suggests that this protein
(also called XPE-binding factor) may be involved in excision repair, but its precise role remains
undefined (Sancar, 1996; Wood, 1996). Other cisplatin-DNA binding proteins include the
xeroderma pigmentosum group A complementing protein (XPAC) (Jones and Wood, 1993;
Asahina et al., 1994) and the human single-stranded binding protein (HSSB or RPA) (Clugston et
al., 1992), which function in the damage recognition step in nucleotide excision repair (Sancar,
1996; Wood, 1996). Recently, the human mismatch repair protein hMSH2, either alone (Mello et
al., 1996) or as a heterodimer with GTBP (G/T binding protein)/p 160, a complex termed hMutSoc
(Duckett et al., 1996), has been shown to bind selectively to the 1,2-d(GpG) cisplatin adduct.
Cisplatin-modified DNA is also recognized by the human Ku autoantigen (Turchi and Henkels,
1996) which has been implicated in double-strand break repair (Finnie et al., 1995). Finally, the
bacteriophage T4-encoded endonuclease VII, a DNA junction-resolving enzyme, recognizes and
cleaves DNA containing 1,2-intrastrand cisplatin adducts or cisplatin interstrand cross-links
almost as efficiently as four-way junction DNA (Murchie and Lilley, 1993; Kasparkova and
Brabec, 1995).
2. Structural basis for recognition by HMG-domain proteins
A common property of HMG-domain proteins is the ability to bind to DNA involved in
structural deformations (Lilley, 1992). In particular, HMG1, SRY, and hUBF recognize four-way
junction DNA irrespective of sequence (Bianchi et al., 1989; Ferrari et al., 1992; Kuhn et al.,
1994). Upon binding to specific sequences in DNA, the HMG domains of SRY and LEF-1
induce bends of 80' and 1300, respectively, in the DNA helix (Giese et al., 1992; Ferrari et al.,
1992). Similarly, HMG1 can bend DNA efficiently, forming circles in ligase-mediated
circularization assays (Pil et al., 1993; Paull et al., 1993; Onate et al., 1994). Taken together,
these observations suggest that structural distortions induced in DNA by cisplatin adducts may
serve as structure-specific recognition signals for HMG-domain proteins. Moreover, these
proteins appear able to distinguish structural differences induced by individual cis- and trans-
DDP-DNA adducts (summarized in Table 1). In particular, the major 1,2-intrastrand adducts of
cisplatin, which bend the DNA 340 and unwind it 130, are recognized by HMG-domain proteins,
whereas the 1,3-intrastrand adducts which unwind the DNA to a greater degree (230) fail to
attract these proteins (Bellon and Lippard, 1990; Bellon et al., 1991; Pil and Lippard, 1992;
Zamble et al., 1996). Intriguingly, cisplatin interstrand cross-links, which induce a directed bend
(Sip et al., 1992; Malinge et al., 1994; Huang et al., 1995), are bound by HMG1, but interstrand
cross-links and 1,3-intrastrand adducts of trans-DDP, which introduce flexibility into the DNA
helix (Bellon and Lippard, 1990; Brabec et al., 1993), are not recognized (Pil and Lippard, 1992;
Kasparkova and Brabec, 1995). Together, these data suggest that recognition by HMG-domain
proteins is mediated by a combination of structural signals, namely bending, unwinding, and
flexibility of the DNA helix. A recent X-ray crystal structure determination of the 1,2-intrastrand
cross-link in duplex DNA further revealed a unique hybrid A/B-type DNA structure with a
significantly widened minor groove, suggesting that these structural features may also favor
binding by HMG-domain proteins (Takahara et al., 1995; Takahara et al., 1996).
Recently, high resolution solution structures of isolated HMG domains from HMG1,
HMG-D (from Drosophila melanogaster), and Sox-4 (SRY-related HMG box) have been
determined by NMR spectroscopy (Weir et al., 1993; Read et al., 1993; Jones et al., 1994;
Hardman et al., 1995; van Houte et al., 1995). These studies reveal that, despite an average
sequence identity of only 25% among unrelated HMG-domains (Read et al., 1995), the globular
structure is highly conserved. The HMG domain is composed of three alpha-helices that form an
L-shape, with an -80' angle between the arms defined by a cluster of conserved aromatic
residues. Solution structures of the HMG domains from SRY and LEF-1 bound to their putative
target sequences (Werner et al., 1995; Love et al., 1995) reveal that the L-shaped structure is
maintained within the protein/DNA complex. DNA binding occurs on the concave surface
formed by helices one and three, and extensive DNA contacts are made within the minor groove.
In the complexes, the DNA structure is an A/B-type hybrid with a widened minor groove and the
DNA is bent severely toward the major groove, owing to the partial insertion of a methionine or
isoleucine residue between AT base pairs. The striking resemblance between this novel DNA
structure induced by the HMG domains from LEF-1 and SRY and the intrinsically bent 1,2-
d(GpG) cisplatin adduct (Takahara et al., 1996) suggests that HMG-domain proteins may use a
single mode of binding to interact with both specific sequences and structures.
Only limited structural information exists for the interactions of HMG-domain proteins
with cisplatin-modified DNA. DNase I and hydroxyl radical footprinting studies with DNA
containing a single 1,2-d(GpG) cisplatin adduct revealed that hUBF, Ixrl, and the single HMG
domains A and B from HMG1 yielded similar cleavage patterns, including a 12-15 base pair
protected region centered at the adduct and hypersensitive bands to the 5' or 3' side of the adduct
(Treiber et al., 1994; Locker et al., 1995; McArNulty et al., 1996). The structure of the 1,2-
d(GpG) adduct in duplex DNA showed that the platinum atom is significantly displaced from the
guanine ring planes generating a strain that might be relieved by the binding of HMG-domain
proteins, perhaps by altering the DNA bend angle (Takahara et al., 1996). Indeed, gel
electrophoresis studies demonstrated that the binding of HMG1, mtTFA, Ixrl and single HMG
domains from HMG1 (domain B) and LEF-1 to the 1,2-d(GpG) cisplatin adduct increases DNA
duplex bending from 340 to 70-900 (Chow et al., 1994). Two recent studies have implicated
specific amino acids in HMG1 domains A and B as important for cisplatin-adduct binding.
Photochemistry was used to cross-link a 15 bp oligonucleotide containing a single 1,2-d(GpG)
cisplatin adduct to a single residue (Lys-6) in HMG1-domain B. Since the platinum is bound to
the N-7 guanine atoms in the major groove, the formation of a platinum-protein cross-link
suggests that the amino-terminus of domain B contacts the major groove of the DNA (Kane and
Lippard, 1996). A mutational analysis of HMG1 domain A binding to cisplatin-modified DNA
demonstrated that proteins mutant at Tyr-71 and Phe-19 exhibited reduced DNA binding
activities, indicating that these residues may interact directly with the cisplatin-modified DNA
(Farid et al., 1996). Modeling studies by the same group suggested that Tyr-71 may intercalate
partially into the DNA (Farid et al., 1996). Finally, recent NMR data is consistent with the
binding of a cisplatin-modified duplex DNA to the concave face of HMG1-domain A
(Berners-Price et al., 1997), the same binding surface used to interact with an unplatinated DNA
duplex (Hardman et al., 1995). Taken together, the structural studies detailed above suggest that
the 1,2-d(GpG) cisplatin intrastrand cross-link may attract HMG-domain proteins by closely
mimicing a stablized DNA structure that occurs during formation of a HMG domain/target DNA
complex. Furthermore, the interaction between the L-shaped HMG domain and the intrinsically
bent cisplatin adduct may approximate a lock and key fit initially, but with protein binding
inducing additional DNA bending.
3. Roles of cisplatin-damage recognition proteins
Several models have been proposed to explain how cisplatin-DNA binding proteins might
be involved in the mechanism of action of cisplatin (Toney et al., 1989; Donahue et al., 1990;
Brown et al., 1993; Treiber et al., 1994). The selective affinity of HMG-domain proteins for
cisplatin-DNA adducts, but not for DNA adducts of the clinically ineffective platinum compounds
suggests a role for these proteins in mediating cisplatin cytotoxicity. A first model (Figure 4)
proposes that the binding of HMG-domain proteins to cisplatin-DNA adducts may impede
removal of the lesions by the nucleotide excision repair machinery. Slow repair would allow the
adducts to persist on the DNA, enhancing their genotoxicity. Indeed, existing evidence is
consistent with the hypothesis that HMG-domain proteins can sensitize cells to cisplatin by a
repair-shielding mechanism. A yeast strain with an inactivated gene for the HMG-domain protein
Ixrl exhibited a 2-6-fold decrease in sensitivity to cisplatin (Brown et al., 1993; McA`Nulty and
Lippard, 1996) and accumulated fewer platinum adducts compared to the parental strain (Brown
et al., 1993). This differential sensitivity was ablated in a series of yeast strains deficient in
nucleotide excision repair, establishing a direct link to DNA repair (McArNulty and Lippard,
1996). Furthermore, the HMG-domain proteins HMG1, mtTFA, and tsHMG specifically inhibit
repair of the major 1,2-d(GpG) cisplatin intrastrand cross-link, but not the 1,3-d(GpTpG)
intrastrand adduct in an in vitro excision repair assay employing HeLa cell-free extracts (Huang et
al., 1994; Zamble et al., 1996). A similar concentration of tsHMG was required to achieve
comparable levels of repair inhibition in a reconstituted system containing purified repair proteins
(Zamble et al., 1996). The repair-shielding model is also supported by more indirect evidence.
DNase I footprinting experiments with DNA containing a single 1,2-d(GpG) cisplatin adduct
revealed that a 12-15 base pair region is protected from cleavage by the nuclease, suggesting that
this region might also be shielded from the cellular repair machinery (Treiber et al., 1994; Locker
et al., 1995). In addition, the XPAC protein, which is responsible for damage recognition in
excision repair (Sancar, 1996; Wood, 1996), exhibits a lower affinity in vitro for cisplatin-
modified DNA (K(a,) > 600 nM) (Jones and Wood, 1993) compared to hUBF (Kda), = 60 pM)
(Treiber et al., 1994), HMG1 (Kdap) = 370 nM) (Pil and Lippard, 1992), and Ixrl (Kapp) = 250
nM) (McA~Nulty et al., 1996), suggesting that XPAC may not easily displace HMG-domain
proteins from cisplatin-DNA adducts.
A second model (Figure 5) proposes that cisplatin-DNA adducts may act as molecular
decoys in cells, titrating HMG-domain proteins from their natural binding sites and thereby
disrupting their function. For example, the "hijacking" of transcription factors might impair the
expression of genes critical to a growing tumor cell and lead to cell death (Treiber et al., 1994).
This model stems from the observation that the ribosomal RNA transcription factor hUBF binds
to a cisplatin d(GpG) adduct (Kd,p) = 60 pM) and its cognate promoter sequence (Kdap) = 18
pM) with comparable affinities (Treiber et al., 1994). In a DNase I footprinting competion assay
(Treiber et al., 1994), the binding of hUBF to its rRNA promoter was competed with a cisplatin-
DNA adduct concentration (5 nM) significantly lower than that found in the DNA of cancer
patients (0.1-1 pM) (Reed et al., 1993). Additional studies indicated that cisplatin-DNA adducts,
but not trans-DDP adducts, could inhibit rRNA synthesis in a reconstituted system, further
suggesting that transcription factor hijacking may be operative in vivo (X.Q. Zhai and J.M.
Essigmann, manuscript in preparation). In recent immunofluorescence experiments by Billings
and colleagues, cisplatin-treated cells exhibited dispersed nuclear staining of hUBF, suggesting
that the protein was titrated away from its normal nucleolar location by cisplatin-adduct binding
(Chao et al., 1996). Similar results were obtained in earlier studies by X.Q. Zhai (unpublished
work). In contrast with the findings described above is an in vivo yeast study in which
transcriptional repression by the HMG-domain protein Ixrl was not reduced by cisplatin
treatment (McAtNulty et al., 1996). However, the relative binding affinities of Ixrl for its
promoter sequence and a cisplatin adduct are not known. The modest affinity of Ixrl for the 1,2-
d(GpG) cisplatin cross-link (Kd(,,) = 250 nM) (McA'Nulty et al., 1996) may explain why it could
not be titrated from its promoter sequence. This model may be viable only for a subgroup of
HMG-domain proteins that bind cisplatin-DNA adducts and their cognate promoter sequences
with very similar affinities.
A final model (Figure 6) suggests that cisplatin-DNA binding proteins may facilitate the
processing and/or repair of cisplatin-DNA adducts. Indeed, the non-HMG-domain containing
proteins XPAC and XPA/HSSB have established functions in nucleotide excision repair (Sancar,
1996; Wood, 1996). Although the exact role of the XPE-binding factor in repair is not known
(Sancar, 1996; Wood, 1996), the protein is present at higher levels in cisplatin-resistant cells
possessing an increased DNA repair capacity (Chu and Chang, 1990; Chao et al., 1991b) and is
inducible upon cisplatin treatment (Chao et al., 1991a; Vaisman and Chaney, 1995). By contrast,
only limited evidence exists in support of a direct role for HMG-domain proteins in the repair of
cisplatin-DNA adducts. One study demonstrated increased levels of HMG1 and HMG2 in
cisplatin-resistant HeLa cell lines (Billings et al., 1994), which have an enhanced DNA repair
capacity (Chu and Chang, 1990). However, these same resistant lines also contain increased
levels of the XPE-binding factor (Chu and Chang, 1990) and thus the contributions of HMG1 and
HMG2 to cisplatin resistance are unclear. HMG1 and HMG2 are believed to function in
manipulation and stabilization of DNA chromatin structure (Lilley, 1992; Landsman and Bustin,
1993). It has been proposed that the binding of these proteins to cisplatin-modified DNA may
induce local melting and unwinding of the DNA, allowing increased access of DNA repair
enzymes (Hughes et al., 1992). In an analogous way, HMG1 and HMG2 have been found to
stimulate DNA transcription, most likely by facilitating the binding of RNA polymerases II and III
and transcription factors to the DNA (Tremethick and Molloy, 1988; Singh and Dixon, 1990).
Finally, the selective affinity of the cisplatin damage recognition protein hMSH2 for the adducts of
therapeutically effective platinum compounds (Mello et al., 1996) suggests a role for this protein
in mediating cisplatin cytotoxicity. The shielding of adducts from repair has been proposed as one
mechanism by which hMSH2 may effect toxicity. Alternatively, abortive attempts by the
mismatch repair system to repair cisplatin damage may lead to accumulation of DNA strand
breaks that trigger programmed cell death, or apoptosis (Mello et al., 1996). The hMSH2 protein
was recently shown to be overexpressed in testicular tissue (Mello et al., 1996), a significant
finding in that testicular tumors are the most successfully treated by cisplatin (Loehrer and
Einhorn, 1984). Thus, hMSH2 may be involved in sensitizing testicular tumors to cisplatin. By
contrast, no correlation has yet been established between the levels of HMG-domain proteins and
the sensitivity of target tissues to cisplatin. Several testis-specific HMG-domain proteins have
been identified recently (Sinclair et al., 1990; Denny et al., 1992b; Boissonneault and Lau, 1993;
Connor et al., 1995; Takamatsu et al., 1995; Kanai et al., 1996; Larsson et al., 1996), however,
and these could potentially contribute to the specificity of cisplatin for testicular tumors.
E. Cisplatin resistance
The failure of cisplatin-based chemotherapy in cancer patients is often a result of drug
resistance. There are two types of cisplatin resistance, intrinsic and acquired. Intrinsic resistance
is encountered in patients whose tumors are inherently resistant and do not respond to cisplatin at
the time of first treatment. Acquired resistance can emerge in tumor cell populations after an
initial drug response. In vitro and in vivo model systems have been valuable in the identification
of cisplatin resistance mechanisms. Several laboratories have developed tumor cell lines that have
acquired cisplatin resistance by repeated or continuous exposure of the cells to cisplatin in vitro
(Andrews and Howell, 1990). By this method, the cell lines acquire varying degrees of resistance
relative to the drug-sensitive parental cells and often, very high levels of resistance (10-1000-fold)
are obtained. In contrast, the resistance acquired in vivo by tumors is only on the order of 2-4-
fold (Andrews et al., 1990; Enns and Howell, 1991), which suggests that mechanisms operating in
some in vitro drug-selected lines might not be clinically relevant.
Mechanisms potentially important to cisplatin sensitivity have also been studied in
unselected cell lines established from cisplatin-sensitive and -resistant tumors from patients. For
example, in order to gain insight into clinically acquired resistance, cell lines established from
untreated patients have been compared to lines derived from patients whose disease was
refractory to cisplatin treatment (Schilder et al., 1990; Godwin et al., 1992). In addition, cell lines
established from a single patient before and after the onset of cisplatin resistance have been
examined (Wolf et al., 1987; Lewis et al., 1988; Lai et al., 1988). Model systems aimed at
understanding intrinsic resistance have included testicular germ cell tumor lines and bladder or
colon carcinoma lines as representatives of intrinsically cisplatin-sensitive and -resistant tumors
types, respectively (Walker et al., 1987; Bedford et al., 1988; Fry et al., 1991; Masters et al.,
1993; Sark et al., 1995; Masters et al., 1996). Whether mechanisms operating in inherently
resistant cells are the same as those acquired by drug treatment remains to be established.
A limited number of investigators has examined resistance parameters in tumor biopsies
from untreated and treated patients (Murphy et al., 1991; Dabholkar et al., 1992a; Dabholkar et
al., 1994; Ali-Osman et al., 1994; Jones et al., 1994) and a few in vivo models of acquired
resistance have been established (Waud, 1987; Andrews et al., 1990; Teicher et al., 1990;
Timmer-Bosscha et al., 1993). Interestingly, some resistance mechanisms appear to operate only
at the level of the organism. In one study, murine mammary tumors made resistant to cisplatin in
vivo by treatment of tumor-bearing animals were surprisingly sensitive to cisplatin when the tumor
cells were established in vitro as monolayer cultures (Teicher et al., 1990). Furthermore, the
tumors were capable of altering drug pharmacokinetics when implanted into fresh host animals,
suggesting that the tumors secreted hormonal substances that affected drug distribution in the
host. Subsequent work revealed that the drug resistant phenotype could be rescued in vitro when
the cells were cultured under in vivo-like conditions as three-dimensional multicellular spheroids
(Kobayashi et al., 1993). The molecular basis for this multicellular resistance still needs to be
determined.
Several mechanisms of cisplatin resistance have been identified by the various model
systems, including (1) reduced drug accumulation; (2) increased drug inactivation by sulfhydral
molecules such as glutathione and metallothionein; (3) enhanced repair of cisplatin-DNA adducts;
(4) increased tolerance of cisplatin-DNA damage; and (5) altered expression of regulatory
proteins (Andrews and Howell, 1990; Scanlon et al., 1991; Timmer-Bosscha et al., 1992; Chu,
1994; Zamble and Lippard, 1995; Chaney and Sancar, 1996). The development of cisplatin
resistance is believed to be a multifactorial process and, therefore, a given tumor may become
resistant by one or more of these mechanisms.
1. Reduced cisplatin accumulation
Cisplatin is believed to mediate its toxic effects in cells by covalent interaction with DNA
(Bruhn et al., 1990). One way that resistant tumor cells might limit formation of cisplatin-DNA
adducts is by reducing the intracellular accumulation of the drug. There is evidence that
decreased drug accumulation is associated with cisplatin resistance in vitro (Andrews and Howell,
1990) and in vivo (Waud, 1987; Andrews et al., 1990), and several studies have demonstrated a
correlation between the decrease in cisplatin accumulation and the reduction in cisplatin-DNA
adduct formation in human and rodent resistant cell lines (Waud, 1987; Bungo et al., 1990; Parker
et al., 1991; Kelland et al., 1992b; Johnson et al., 1996). In general, reductions in accumulation
are often small (2-5-fold) and do not account quantitatively for the levels of cisplatin resistance,
suggesting that additional mechanisms are involved.
Reduced drug accumulation could be attributed to a decreased influx (uptake) and/or an
increased efflux of cisplatin in cells. In several studies of cisplatin-resistant cell lines, decreases in
accumulation were specifically associated with a slower rate of drug uptake, and increases in drug
efflux were not observed (Waud, 1987; Hromas et al., 1987; Teicher et al., 1987; Andrews et al.,
1988; Loh et al., 1992; Jekunen et al., 1994; Johnson et al., 1996). Other resistant cell lines,
however, have demonstrated an enhanced efflux of cisplatin (Mann et al., 1990; Parker et al.,
1991; Fujii et al., 1994). Despite their potential importance to cisplatin resistance, the
mechanisms responsible for decreased drug uptake and/or increased efflux in cells have not been
clearly elucidated. In particular, the pathway by which cisplatin enters cells is not known;
evidence exists for both passive diffusion and a carrier-mediated transport system (Gately and
Howell, 1993). Recent studies have indicated that an export pump may act to efflux cisplatin
from cells (Ishikawa and Ali-Osman, 1993; Fujii et al., 1994).
2. Inactivation by sulfhydral molecules
a. Glutathione
A second mechanism by which cells might limit cisplatin-DNA adduct formation is by
increasing the concentration of sulfhydral molecules that have affinity for cisplatin. The most
abundant thiol in the cell is glutathione (GSH), which has a concentration of 0.5-10 mM (Meister
and Anderson, 1983). As a potent nucleophile, glutathione can react directly with cisplatin in the
cytosol, preventing the drug from reaching its DNA target. Glutathione forms coordination
complexes with platinum in a 2:1 molar ratio, and these complexes represent a significant
proportion (60%) of the total platinum content in cells (Ishikawa and Ali-Osman, 1993).
Glutathione may also reduce cisplatin cytotoxicity by quenching cisplatin-DNA monofunctional
adducts before they can rearrange to the more toxic bifunctional cross-links (Eastman, 1987;
Bancroft et al., 1990). Furthermore, glutathione may have a role in DNA repair by stabilizing
repair enzymes or promoting the synthesis of DNA precursors (Lai et al., 1989).
In an early study, a two-fold elevation of glutathione levels in a normal fibroblast lung cell
line resulted in a 1.4-fold decrease in cisplatin sensitivity, demonstrating that glutathione can
modulate cisplatin cytotoxicity (Russo et al., 1986). Subsequently, elevated levels of glutathione
have been found in several human cell lines made resistant to cisplatin in vitro (Andrews and
Howell, 1990; Chu, 1994). Approximately three-fold increased glutathione levels were observed
in a 14-fold resistant ovarian carcinoma line (Hamilton et al., 1985), a 6-fold resistant small cell
lung carcinoma line (Hospers et al., 1988), and a 5-fold resistant colon carcinoma line (Fram et
al., 1990). Ovarian cell lines with very high degrees of resistance (30-1000-fold) had 13-50-fold
increased levels of glutathione (Godwin et al., 1992). In addition, glutathione levels have been
correlated with cisplatin sensitivity in a series of fourteen cell lines established from a range of
human tumor cell types (Hosking et al., 1990), in a panel of eight ovarian cancer cell lines derived
from treated and untreated patients (Mistry et al., 1991), and in two ovarian lines established from
a patient before and after the onset of resistance (Wolf et al., 1987). Significantly, a reduction in
interstrand cross-link formation has been reported in cisplatin-resistant cell lines with elevated
glutathione levels (Hospers et al., 1988; Fram et al., 1990; Johnson et al., 1994a) supporting a
mechanism in which glutathione interferes with the rearrangement of monoadducts to bifunctional
cross-links. However, when buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis,
is used to deplete glutathione levels in cells, cisplatin sensitivity is increased in some cell lines
(Hamilton et al., 1985; Hromas et al., 1987; Meijer et al., 1990; Mistry et al., 1991) but not in
others (Andrews et al., 1985; Richon et al., 1987; Teicher et al., 1987). Taken together, these
observations suggest that drug inactivation by glutathione may contribute to cisplatin resistance,
but additional mechanisms are probably involved.
Whether the reaction of cisplatin with glutathione occurs spontaneously or is catalyzed by
the enzyme glutathione S-transferase (GST) has not been determined. The relationship between
GST activity and cisplatin sensitivity is also unclear, as both increased (Teicher et al., 1987; Lewis
et al., 1988; Timmer-Bosscha et al., 1993) and unaltered (Hospers et al., 1988; Godwin et al.,
1992) GST activities have been reported in resistant cell lines. It is possible, however, that the
conjugation of cisplatin to glutathione may be mediated by a specific GST isozyme with levels
that have not been examined.
b. Metallothioneins
Metallothioneins are small, cysteine-rich proteins that function in the detoxification of
heavy metals (Hamer, 1986). In cells, cisplatin can react with the sulfhydral groups of
metallothionein, displacing the heavy metal ions (Andrews and Howell, 1990). Following
cisplatin treatment, a significant proportion (25%) of cytosolic platinum is complexed to
metallothionein in vivo (Sharma and Edwards, 1983), suggesting that these proteins may have an
additional role in drug inactivation/detoxification.
Cell lines made resistant to cadmium and containing elevated levels of metallothioneins
were cross-resistant to cisplatin (Bakka et al., 1981; Andrews et al., 1987) indicating that cisplatin
resistance may in part be mediated by these proteins. Additional studies demonstrated that
metallothioneins were overexpressed in some, but not all cisplatin-resistant cell lines (Andrews
and Howell, 1990; Chu, 1994). Teicher and coworkers observed elevated metallothionein levels
in four human cell lines selected in vitro for cisplatin resistance (Kelley et al., 1988). In addition,
levels of metallothionein were correlated with degrees of resistance in two cisplatin-resistant small
cell lung cancer lines (Kasahara et al., 1991). However, no correlation between metallothionein
expression and cisplatin sensitivity has been found in ovarian cell lines with in vitro acquired
resistance (Schilder et al., 1990), in cell lines established from ovarian cancer patients refractory
to cisplatin (Schilder et al., 1990), or in ovarian tumor samples from untreated and treated
patients (Murphy et al., 1991). Furthermore, transfection of a metallothionein gene construct into
mouse or Chinese hamster ovary cells has yielded inconsistent results (Kelley et al., 1988; Schilder
et al., 1990; Koropatnick and Pearson, 1993). Thus, a causative role for metallothioneins in
cisplatin resistance is unclear at present.
3. Enhanced repair of cisplatin-DNA adducts
Another mechanism by which cells may become resistant to cisplatin is by increasing their
capacity to repair drug-induced DNA damage. DNA repair activity has been examined in several
cell lines made resistant to cisplatin in vitro by chronic drug exposure (Andrews and Howell,
1990; Chu, 1994; Zamble and Lippard, 1995; Chaney and Sancar, 1996). Cisplatin-resistant
ovarian carcinoma cell lines demonstrated 2-3-fold increased levels of DNA repair as indicated by
DNA repair synthesis (Masuda et al., 1988; Lai et al., 1988) and loss of cisplatin-DNA adducts
(Masuda et al., 1990; Parker et al., 1991; Johnson et al., 1994a). Similarly, testicular tumor cell
lines selected for cisplatin resistance have exhibited an enhanced capacity to remove cisplatin-
DNA adducts compared to the parental lines (Kelland et al., 1992a; Hill et al., 1994b). Host cell
reactivation of a cisplatin-damaged expression vector is also an indication of cellular DNA repair
capacity. Cisplatin-resistant variants derived from ovarian and HeLa carcinoma cell lines were
better able to reactivate the cisplatin-damaged pRSVcat plasmid than the parental lines (Chu and
Chang, 1990; Parker et al., 1991; Chao et al., 1991b). Additionally, elevated levels of DNA
repair have bken reported in cisplatin-resistant cells derived from the murine leukemia cell line
L1210/0 (Eastman and Schulte, 1988; Sheibani et al., 1989). However, it was recently revealed
that the parental L1210/0 line has an XPG DNA repair defect. During selection for cisplatin
resistance, the XPG gene became functional again, restoring repair to nearly normal levels (Vilpo
et al., 1995).
Enhanced DNA repair has also been found in cell lines and primary tumor cells from
patients with in vivo acquired resistance to cisplatin. An ovarian carcinoma cell line established
from a cisplatin-treated patient after the onset of resistance had 3-fold higher levels of DNA repair
than a sensitive cell line derived from the same patient prior to the development of resistance (Lai
et al., 1988). A similar increase in repair was observed in cells of an oligodendroglioma obtained
after failed cisplatin therapy compared to tumor cells acquired before treatment (Ali-Osman et al.,
1994).
Intrinsic resistance to cisplatin is associated with an elevated DNA repair capacity, as
evidenced in cell lines and tumors from untreated patients. In a study of three human T
lymphocyte lines, cisplatin sensitivity/resistance was correlated with extent of platinum-DNA
adduct removal (Dabholkar et al., 1992b). Non-small cell lung cancer cell lines which were
intrinsically resistant to cisplatin had higher levels of DNA repair than the more sensitive small cell
lung cancer lines (Shellard et al., 1993; Zeng-Rong et al., 1995). Cisplatin sensitivity was also
correlated with DNA repair capacity in testicular and bladder tumor cell lines which represent
inherently cisplatin-sensitive and -resistant tumor types, respectively (Bedford et al., 1988;
Koberle et al., 1996). When an in vitro DNA repair assay was used to measure repair levels in
ovarian tumor biopsies (containing over 90% malignant cells) from untreated cancer patients,
differences up to 10-fold were observed, mirroring the variability in response to cisplatin seen
clinically (Jones et al., 1994). Significantly, platinum-DNA adduct removal in the leukocytes of
cisplatin-treated cancer patients was correlated with clinical resistance (Parker et al., 1993).
Thus, response to cisplatin chemotherapy may be a direct result of individual DNA repair
capacity.
Studies examining the removal of specific cisplatin-DNA lesions have demonstrated
enhanced repair of both 1,2-intrastrand cross-links (Bedford et al., 1988; Shellard et al., 1993; Hill
et al., 1994b; Johnson et al., 1994b) and DNA interstrand cross-links (Bedford et al., 1988; Hill et
al., 1994b; Johnson et al., 1994a) in cisplatin-resistant cell lines compared to sensitive lines.
Recently, the removal of cisplatin-DNA adducts from specific genes has also been examined.
Normal cells demonstrate gene-specific repair of platinum intrastrand and interstrand adducts
(Jones et al., 1991; Larminat et al., 1993; Rampino and Bohr, 1994). At the level of individual
genes, the repair of interstrand cross-links appears to be increased in several cisplatin-resistant
ovarian cell lines compared to the parental cells (Zhen et al., 1992; Johnson et al., 1994a; Johnson
et al., 1994b). However, enhanced repair of intrastrand adducts in specific genes has not been
observed in resistant cells (Zhen et al., 1992). Thus, the contribution of gene-specific repair to
cisplatin resistance remains to be determined.
Several studies have revealed overexpression of nucleotide excision repair genes in
cisplatin-resistant cells. Specifically, levels ofERCC-1 (excision repair cross-complementing-1
gene) and XPAC (xeroderma pigmentosum group A complementing gene) were increased 2-3-
fold and 10-fold, respectively, in ovarian tumor tissue from patients who were clinically resistant
to cisplatin therapy compared to patients who responded to treatment (Dabholkar et al., 1992a;
Dabholkar et al., 1994). In addition, ERCC-1 expression was 30-50-fold higher in an inherently
cisplatin-resistant ovarian carcinoma line (SKOV-3) compared to a sensitive testicular tumor line
(SuSa) 1 (Taverna et al., 1994), cell lines previously shown to be proficient and deficient,
respectively, in the repair of cisplatin interstrand cross-links and 1,2-d(ApG) intrastrand adducts
(Bedford et al., 1988; Shellard et al., 1991). In other studies, cisplatin-resistant HeLa cells
showed increased levels of an XPE DNA damage binding activity and were more proficient in
DNA repair than the sensitive parental lines (Chu and Chang, 1990; Chao et al., 1991b). Recent
evidence also suggests that levels of this activity were induced in cisplatin-resistant ovarian
carcinoma cells by cisplatin treatment (Vaisman and Chaney, 1995). Furthermore, overexpression
of PCNA (proliferating cell nuclear antigen), a protein required for repair synthesis, was observed
in cisplatin-resistant murine leukemia cell lines (Haneda et al., 1991). Elevated levels of DNA
polymerase 0 have also been reported in cisplatin-resistant cells (Scanlon et al., 1991; Ali-Osman
et al., 1994); however, this enzyme appears to have no role in nucleotide excision repair (Sancar,
1996; Wood, 1996). Together, these observations suggest that overexpression of certain repair
genes may contribute to enhanced DNA repair as a mechanism of cisplatin resistance. However,
further studies are clearly needed.
1Note, however, that this result could reflect inherently high ERCC-1 levels in SKOV-3 or
inherently low levels in SuSa.
In summary, elevated DNA repair has been demonstrated in intrinsically cisplatin-resistant
cells as well as in cells that have acquired resistance in vivo or in vitro. When resistant cell lines
have been selected in culture by continuous drug exposure, increases in DNA repair capacity have
occurred early in the development of resistance (Chu and Chang, 1990). A similar selection
process may occur in vivo. Increases in DNA repair are usually only 2-3-fold, even in cells that
have acquired 20-500-fold levels of resistance (Johnson et al., 1994a) suggesting that cells may
activate mechanisms other than repair in order to achieve very high degrees of resistance.
Enhanced DNA repair is not always associated with cisplatin resistance. In fact, a few studies
have described cisplatin-resistant cells that are deficient in cisplatin-adduct removal (Shellard et
al., 1991; Hill et al., 1992; Shellard et al., 1993).
4. Increased tolerance of cisplatin-DNA damage
An alternative strategy that cells may use to protect themselves against cisplatin is to
develop an increased tolerance to cisplatin-DNA damage. Indeed, several cisplatin-resistant cell
lines appear able to tolerate high levels of cisplatin-DNA adducts (Bedford et al., 1987; Eastman
and Schulte, 1988; Hill et al., 1990; Shellard et al., 1991; Hill et al., 1992; Shellard et al., 1993;
Johnson et al., 1994b; Johnson et al., 1996; Johnson et al., 1997). For resistant cells that have
little or no enhanced capacity for DNA repair, this mechanism may be particularly significant.
One way that resistant cells may exhibit damage tolerance is through enhanced replicative bypass
of cisplatin-induced lesions. In support of this hypothesis, two cisplatin-resistant ovarian
carcinoma lines were found to bypass cisplatin-DNA adducts more readily than their parental
counterparts, as determined by measuring inhibition of DNA chain elongation. Furthermore, this
enhancement in adduct bypass was correlated with degree of resistance (Mamenta et al., 1994).
Recently, it has been shown that calf thymus DNA polymerase 0 can efficiently bypass the
major 1,2-d(GpG) cisplatin-DNA adduct in vitro, whereas polymerases or, 5, s are effectively
blocked by this lesion (Hoffmann et al., 1995). These results are consistent with the possibility
that DNA polymerase 0 may catalyze translesion DNA synthesis in vivo and, furthermore, that
increased expression of this enzyme in cisplatin-resistant cells may directly enhance replicative
bypass of cisplatin-induced lesions. The levels of DNA polymerase 13 have been examined in both
tumor cell lines and tissue (Scanlon et al., 1991). In one study, cisplatin-resistant tumor cells from
two colon cancer patients showed enhanced expression of DNA polymerase 0 compared to
normal colon tissue (Kashani-Sabet et al., 1990). In addition, levels of DNA polymerase 0 were
elevated 4.5-fold in oligodendroglioma cells obtained from a patient after failed cisplatin therapy
compared to cells from the same patient before treatment (Ali-Osman et al., 1994). Other studies,
however, of cisplatin-resistant cells have not revealed overexpression of this enzyme (Katz et al.,
1990; Dempke et al., 1992; Hill et al., 1992). Thus, it remains to be established whether the
elevated expression of DNA polymerase 0 contributes to enhanced replicative bypass and
increased damage tolerance in cisplatin-resistant cells.
Interestingly, tolerance to alkylating agents, including cisplatin, has been shown to be
associated with defects in the mismatch repair system (Karran and Marinus, 1982; Fram et al.,
1985; Goldmacher et al., 1986; Kat et al., 1993; Aebi et al., 1996). Cisplatin-resistant cells
63
deficient in mismatch repair have been found to exhibit a RER' (replication error) phenotype,
suggesting that replicative bypass of cisplatin-induced lesions may be facilitated by defective or
otherwise altered mismatch repair proteins, albeit with decreased fidelity (Anthoney et al., 1996).
It has recently been proposed that the mismatch repair system, which binds selectively to cisplatin-
DNA adducts (Mello et al., 1996; Duckett et al., 1996), may potentiate cisplatin cytotoxicity
through abortive repair of cisplatin-induced damage (Mello et al., 1996). Misdirected repair
attempts at the sites of cisplatin adducts could lead to activation of programmed cell death, or
apoptosis, perhaps through the accumulation of DNA strand breaks. Defects in the mismatch
repair machinery would prevent the initiation of this process, and the cell would exhibit damage
tolerance. Indeed, a reduced apoptotic response has been observed in cisplatin-resistant cells
deficient in mismatch repair (Anthoney et al., 1996). It has also been suggested that higher
cisplatin adduct levels may be required for cisplatin damage tolerant cells to induce apoptosis
(Johnson et al., 1997). Further studies are needed to elucidate the mechanisms by which cisplatin-
resistant cells are able to tolerate very high levels of cisplatin-induced damage.
5. Altered expression of regulatory proteins
The altered expression of regulatory proteins by tumor cells may also contribute to a
cisplatin-resistant phenotype. For example, cisplatin-resistant cells have demonstrated increased
expression of the proto-oncogenes c-fos, c-myc, and H-ras (Scanlon et al., 1991). In addition,
recent studies suggest that the tumor suppressor gene p53 may play a significant role in cellular
drug sensitivity. The protein encoded by p53 is a transcriptional regulator that mediates cell cycle
checkpoints in response to DNA damage. DNA strand breaks that are generated by direct insult
or by abortive attempts to replicate and/or repair a damaged DNA template trigger an elevation in
cellular p53 levels (Nelson and Kastan, 1994). As a result, p53 can initiate a series of regulatory
events that lead to GI cell cycle arrest, thereby allowing more time for repair of damaged DNA
before progression to S phase (Gottlieb and Oren, 1996; Ko and Prives, 1996). Through
interaction with DNA repair proteins, such as XPB and XPD (Wang et al., 1995), p53 may also
modulate excision repair processes.
An involvement of p53 in cell cycle arrest and DNA repair suggests that p53-defective
cells would be more sensitive to DNA-damaging agents, including cisplatin, and have a reduced
repair capacity compared to normal cells. In support of this hypothesis, mouse embryonal
fibroblasts deficient in p53 (p53-1-) exhibited a two-fold increased sensitivity to cisplatin
compared to fibroblasts homozygous (p53+/+) and heterozygous (p53+/-) for wild-type p53
(Hawkins et al., 1996). Inactivation of p53 by association with human papillomavirus (HPV) E6
protein, which targets p53 for degradation through the ubiquitin pathway, was shown to sensitize
human foreskin fibroblasts (Hawkins et al., 1996), MCF-7 breast cancer cells, and colon
carcinoma RKO cells (Fan et al., 1995) to cisplatin. Significantly, increased cisplatin sensitivity in
p53-defective MCF-7 cells was correlated with a reduced capacity to repair cisplatin-damaged
DNA compared to control cells (Fan et al., 1995). These observations suggest that in some
tumor cells, loss of p53 function may result in increased sensitivity to cisplatin through defects in
cell cycle control and DNA repair.
In response to DNA damage, p53 can also activate programmed cell death, or apoptosis,
in several cell types, and this mechanism often overrides the GI checkpoint response (Gottlieb and
Oren, 1996; Ko and Prives, 1996; White, 1996). Significantly, p53 is required for the induction of
apoptosis by various anticancer agents (Lowe et al., 1993). Through this mechanism, inactivation
of p53 could lead to resistance to cisplatin and other DNA damaging agents. It is well established
that cisplatin can activate apoptosis in mammalian cells (Sorenson and Eastman, 1988a; Sorenson
and Eastman, 1988b; Sorenson et al., 1990; Barry et al., 1990; Evans and Dive, 1993; Shinomiya
et al., 1994). Recently, the role of p53 in cisplatin-induced apoptosis has begun to be examined.
In one study, lymphoma cell lines expressing mutant p53 exhibited a decreased sensitivity to
cisplatin and a reduced ability to undergo apoptosis compared to wild type p53 lines, following
drug treatment (Fan et al., 1994). Cisplatin resistance was also associated with a reduced
apoptotic response in two resistant ovarian carcinoma cell lines which harbored p53 mutations
(Perego et al., 1996). Furthermore, transfection of the A2780 ovarian carcinoma line with a
mutant p53 construct resulted in protection from cisplatin-induced apoptosis (Eliopoulos et al.,
1995). In other studies, wild type p53 has been shown to confer cisplatin sensitivity to lung
cancer cells in vivo. Injection of a wild type p53 adenovirus vector into inherently cisplatin-
resistant nonsmall cell lung tumors implanted into nude mice caused regression of tumors as a
result of apoptotic death following cisplatin administration (Fujiwara et al., 1994). Taken
together, these observations suggest that p53 gene status is an important determinant of the
susceptibility of tumor cells to undergo cisplatin-induced apoptosis. Indeed, inherently cisplatin-
sensitive testicular tumor cells, which rarely exhibit p53 mutations (Peng et al., 1993; Heimdal et
al., 1993; Murty et al., 1997; Riou et al., 1995) and express high levels of wild-type p53 protein
(Oren et al., 1982; Tesch et al., 1990; Bartkova et al., 1991; Riou et al., 1995), are unusually
sensitive to drug-induced apoptosis (Chresta et al., 1996; Lutzker and Levine, 1996).
In addition to p53, several other proteins have been implicated in the regulation of
apoptosis in cells (White, 1996). In particular, altered expression of the regulatory proteins mdm-
2, Bcl-2, and Bax has been observed in cisplatin-resistant cells. Mdm-2, which binds to p53 and
inactivates it, was found to be overexpressed in a cisplatin-resistant variant of the ovarian
carcinoma line IGROV-1, a result consistent with a role for mdm-2 in the relative failure of these
cells to undergo cisplatin-induced apoptosis (Fajac et al., 1996). Similarly, elevated expression of
the apoptosis inhibitor, Bcl-2, was demonstrated in two cisplatin-resistant ovarian carcinoma lines
(Eliopoulos et al., 1995). Low levels of Bax, an accelerator of apoptosis, were also reported in a
cisplatin-resistant ovarian cancer line which contained mutant p53 (Perego et al., 1996). Bax is a
target of p53 transactivation and thus, in this last study, reduced expression of Bax was attributed
to the inability of mutant p53 to induce its expression. Interestingly, Bcl-2 and Bax belong to a
multigene family of apoptosis inhibitors and promoters whose members can interact with each
other to modulate apoptosis (White, 1996).
F. Organotropic specificity of cisplatin for testicular tumors
Testicular cancer is relatively rare, accounting for less than 1% of all male malignancies.
However, it is the most common cancer in men aged 20-34 (Peckham, 1988; Einhorn, 1990;
Feuer et al., 1993). Germ cell neoplasms, which represent 90-95% of all testicular cancers, are
believed to arise from primitive germ cells that have undergone malignant transformation
(Campbell and Walsh, 1986). Testicular germ cell tumors are divided into two groups,
seminomas (40% incidence), which histologically resemble germ cells, and nonseminomas (60%
incidence), which resemble other cell types. Nonseminomas are further classified according to
their level of cellular differentiation. Embryonal carcinomas (EC) are nonseminomatous tumors
composed of pluripotent undifferentiated stem cells (Andrews, 1988). EC cells closely resemble
early embryonic cells, and they have the capacity to differentiate into the other nonseminomatous
tumor cell types which represent more advanced stages of embryogenesis (choriocarcinoma, yolk
sac tumor, teratoma). Tumors containing undifferentiated embryonal carcinoma cells as well as
mature teratoma structures such as cartilage and bone are designated teratocarcinomas. The
overall incidence rates of testicular germ cell tumors have been reported as follows: seminoma
(40%), embryonal carcinoma (20-25%), teratocarcinoma (25-30%), teratoma (5-10%),
choriocarcinoma (1-2%) (Campbell and Walsh, 1986).
Testicular cancer has become a model for a curable neoplasm (Einhorn, 1990). Over 90%
of all testicular cancer patients are cured (Feuer et al., 1993) largely through the use of cisplatin-
based chemotherapy (Peckham, 1988; Einhorn, 1990). In contrast, other types of human cancers
respond less well to similar chemotherapeutic regimens and long term survival is rare.
Interestingly, cell lines derived from testicular germ cell tumors retain higher sensitivity to
cisplatin in vitro compared to lines established from tumors of the bladder, ovary, cervix, lung,
colon, breast, and melanoma (Oosterhuis et al., 1984; Walker et al., 1987; Hill et al., 1987;
Bedford et al., 1988; Hosking et al., 1990; Kelland et al., 1992a; Shellard et al., 1993; Masters et
al., 1993; Hill et al., 1994a; Sark et al., 1995). In addition, xenografts of human testicular tumors
in immunosuppressed mice are more sensitive to cisplatin treatment than other types ofxenograft
tumors (Steel et al., 1983). These model systems suggest that the clinical responsiveness of
testicular cancer might not be significantly determined by host-related factors such as blood
supply and immunogenicity. Rather, sensitivity to cisplatin may be an inherent property of
testicular tumor cells.
Cellular sensitivity/resistance to cisplatin is believed to be controlled by several factors,
including intracellular drug accumulation, drug inactivation by glutathione and metallothionein,
DNA repair/tolerance of platinum damage, and p53 gene status. Accordingly, each of these
parameters has been analyzed in testicular tumor cells in an attempt to understand the molecular
basis for the inherent cisplatin sensitivity of this tumor cell type. In particular, the properties of
testicular tumor cell lines have been directly compared to those of cell lines derived from
intrinsically cisplatin-resistant tumors, such as bladder, colon, and ovary. Investigations of several
testicular tumor cell lines made resistant to cisplatin in vitro (SuSa-CP, GCT27cisR, Tera-CP,
H12. I1/DDP) have also provided insight into the mechanisms underlying cisplatin
sensitivity/resistance in testicular tumors. It is important to note that the testicular tumor cell lines
used in these various studies were derived from nonseminomatous germ cell testicular tumor
types, namely embryonal carcinoma or teratocarcinoma. Cell lines corresponding to seminoma
tumors have not yet been developed.
1. Intracellular drug accumulation is not significantly increased in testicular tumor cells
compared to other tumor cell types.
Studies examining intracellular drug accumulation have revealed both increased and
similar levels of platinum in testicular tumor cell lines compared to bladder and colon carcinoma
lines. In [l95mPt]cisplatin uptake studies, two testicular lines (SuSa, 833K) were found to
accumulate 2-4-fold more cisplatin than a bladder line (RT112) (Bedford et al., 1988). However,
similar levels of cisplatin accumulation were reported for the SuSa and RT 112 lines when the
platinum content was determined by atomic absorption spectroscopy (Koberle et al., 1996). A
similar investigation of testicular and colon lines revealed no significant correlation between
cisplatin sensitivity and cellular drug content (Sark et al., 1995).
2. Levels of gluathione are relatively low in testicular tumor cells.
Approximately 2-4-fold lower levels of the nonprotein sulfhydral glutathione have been
observed in testicular tumor cell lines compared to lines established from cancers of the lung,
colon, bladder, ovary, breast, stomach, and head and neck (Hosking et al., 1990; Meijer et al.,
1992; Sark et al., 1995; Masters et al., 1996). In addition, acquired resistance to cisplatin in two
testicular tumor cell lines (Tera-CP, SuSa-CP) was accompanied by increases in glutathione levels
(Timmer-Bosscha et al., 1993; Masters et al., 1996). In a comparative study of testicular and
colon cancer cell lines, an analysis of variance revealed a correlation between cisplatin sensitivity
and a combination of glutathione levels, glutathione S-transferase (GST) activity, and platinum
bound to the DNA (Sark et al., 1995). Together, these results suggest that drug inactivation by
glutathione may occur to a lesser extent in testicular tumor cells than other tumor cell types.
3. Metallothionein is highly expressed in testicular tumor cells.
Both testicular tumor cell lines (Masters et al., 1996) and nonseminomatous testicular
tumors (Chin et al., 1993) have demonstrated relatively high levels of metallothionein. In
addition, metallothionein expression was inversely correlated with cisplatin sensitivity in testicular
tumor cell lines compared to lines established from bladder (Masters et al., 1996) or colon
carcinoma (Sark et al., 1995). Thus, metallothionein may not to be a major determinant of
cisplatin sensitivity in testicular tumor cells.
4. Similar levels of cisplatin-DNA adducts are formed in testicular and other tumor cell
types.
Relatively low levels of the detoxifying agent glutathione suggest that more cisplatin may
reach the DNA of testicular tumor cells compared to that of other tumor cell types. However, a
higher level of platinum-DNA adducts has not been observed in testicular tumor cells. Moreover,
no overall direct relationship between initial levels of DNA platination and drug sensitivity has
been demonstrated in testicular and other tumor cell lines. In a panel of three testicular tumor cell
lines and three colon carcinoma lines, a relatively high amount of platinum was bound to the DNA
in two (833K, Scha) of three testicular lines, but a significant difference between the tumor cell
types was not found (Sark et al., 1995). Levels of intrastrand or interstrand cross-links did not
correlate with cisplatin cytotoxicity in an investigation of two testicular cell lines (SuSa, 833K)
and one bladder line (RT112) (Bedford et al., 1988). Additional studies indicated that total
platination was comparable for these tumor types (Walker, 1990; Koberle et al., 1996). Testicular
tumor cell lines have also been shown to be hypersensitive to gamma radiation (Parris et al., 1988)
and to other chemotherapeutic drugs that interact directly with DNA (Masters et al., 1993).
Taken together, these observations suggest that the inherent sensitivity of testicular tumor cells
may be controlled by processes which occur following cisplatin binding to DNA.
5. Testicular tumor cells are defective in removal of platinum-DNA adducts.
In early studies, testicular tumor cell lines were found to be as sensitive to cisplatin as cell
lines derived from patients with the DNA repair disorders xeroderma pigmentosum (XP) and
Fanconi's anemia (FA) (Pera et al., 1987). This suggested that the hypersensitivity of testicular
tumor cells to cisplatin might be related to a reduced capacity to repair cisplatin-induced DNA
damage. Indeed, several studies have shown deficient removal of platinum-DNA adducts in
human testictllar tumor cell lines. Quantitation of platinum-DNA adduct removal by atomic
absorption spectroscopy revealed that platinum levels were not significantly reduced in two
testicular tumor cell lines (GCT27, Ntera2.D 1) following cisplatin treatment (Kelland et al.,
1992a; Sark et al., 1995). During an 18 hr post-treatment incubation period, no significant
removal of the major 1,2-d(GpG) cisplatin intrastrand cross-link was detected immunochemically
in five tumor cell lines established from untreated testicular cancer patients (SuSa, GCT27cl.4,
GCT46, H12.1, H32) (Bedford et al., 1988; Hill et al., 1994a). Similar results were obtained for
the SuSa and GCT27 lines when repair of cisplatin-DNA adducts was measured in specific genes
by a quantitative polymerase chain reaction (Q-PCR) method (Koberle et al., 1996). In contrast,
Hill and colleagues demonstrated that the cisplatin-sensitive testicular tumor cell line 833K
established from a patient previously treated with chemotherapy (no cisplatin) was proficient in
the removal of the cisplatin 1,2-d(GpG) adduct (Bedford et al., 1988).
In other work, testicular tumor cell lines made resistant to cisplatin in vitro (GCT27cisR,
SuSa-CP, H12. 1/DDP) exhibited an enhanced capacity to remove cisplatin-DNA adducts
compared to the parental lines (Kelland et al., 1992a; Hill et al., 1994b) suggesting a relationship
between repair and the development of cisplatin resistance. However, quantitative PCR analysis
revealed no increased removal of cisplatin adducts in specific genes by the GCT27 and SuSa
resistant variants (Koberle et al., 1996).
Studies of animals and cancer patients following cisplatin treatment have also suggested
that cisplatin-DNA adducts may be not be efficiently removed from testicular tissue. Platinum
adducts were found to accumulate in the testes, but not the kidneys of rats after multiple doses of
cisplatin presumably because of slower adduct removal (Poirier et al., 1992). Examination of
platination levels in the liver, kidney, spleen, and testis of male rats 48 hrs after carboplatin
administration revealed that platinum adducts were removed less efficiently from the testis than
from the other tissues (Blommaert et al., 1996). Furthermore, cisplatin 1,2-d(GpG) adduct levels
were 10-fold higher in testicular tumor tissue obtained from a cancer patient on the third day
following cisplatin therapy compared to adduct levels in the patient's blood cells obtained on the
same day (Fichtinger-Schepman et al., 1990). In this last study, it is not known whether
differential adduct formation or removal contributed to the higher adduct levels in the target
tumor tissue.
Inefficient adduct removal in testicular tumor cells could be related to lower levels of
DNA repair enzymes. Recent studies have examined expression levels of the excision repair
cross-complementing-1 gene (ERCC-1) which is believed to play a dual role in the removal of
cisplatin interstrand and intrastrand cross-links (Sancar, 1996; Wood, 1996; Chaney and Sancar,
1996). Expression of ERCC-1 was found to be 30-50-fold lower in the cisplatin-sensitive
testicular tumor cell line SuSa compared to the intrinsically resistant ovarian cancer line SKOV-32
(Taverna et al., 1994), cell lines previously shown to be deficient and proficient, respectively, in
the repair of cisplatin interstrand cross-links and 1,2-d(ApG) intrastrand adducts (Bedford et al.,
1988; Shellard et al., 1991). Furthermore, ERCC-1 expression was increased two-fold in a
cisplatin-resistant testicular tumor cell line which was derived from the SuSa line (SuSa-CP) and
possessed an enhanced DNA repair capacity (Taverna et al., 1994; Hill et al., 1994b). In a
separate study, three additional testicular tumor cell lines defective in the removal of cisplatin
intrastrand adducts had low levels of ERCC-1 similar to that of the SuSa line (Hill et al., 1994a).
Thus, decreased expression of ERCC-1 may contribute to the limited repair capacity of testicular
tumor cells. It is interesting to note that increased levels of ERCC-1 were not found in the repair-
2Note, however, that this result could reflect inherently low levels ofERCC-1 in SuSa or
inherently high levels in SKOV-3.
proficient 833K testicular tumor line (Hill et al., 1994a). Also, levels of the repair gene
XPBC/ERCC-3 were not significantly different in any of the five testicular tumor cell lines
examined in this study (Hill et al., 1994a).
6. Testicular tumor cells may be less able to tolerate cisplatin-induced DNA damage.
The inherent sensitivity of testicular tumor cells to cisplatin may also be related to a lower
ability to tolerate cisplatin-DNA damage. Replicative bypass of cisplatin-DNA adducts is one
way in which cells might exhibit damage tolerance. Recently, it has been shown that DNA
polymerase 0 can efficiently bypass the major 1,2-d(GpG) cisplatin adduct in vitro (Hoffmann et
al., 1995) and, interestingly, this enzyme has been shown to be overexpressed in some cisplatin-
resistant cells (Scanlon et al., 1991; Ali-Osman et al., 1994). Examination of DNA polymerase 1
expression in testicular tumor cells revealed four-fold lower levels of this enzyme in four repair-
deficient testicular tumor cell lines established from untreated patients (SuSa, GCT27cl.4,
GCT46, H32) compared to a repair-proficient, but cisplatin-sensitive line derived from a drug-
treated (not cisplatin) patient (833K) (Hill et al., 1994a). These results are difficult to interpret
because cell lines from cisplatin-resistant tumor types were not examined for DNA polymerase 1
levels. However, if testicular tumor cells generally express low levels of DNA polymerase 03,
replicative bypass of cisplatin-DNA lesions may be prevented and the cells may exhibit a low
tolerance for damage. DNA polymerase 0 is not believed to be involved in nucleotide excision
repair synthesis (Wood, 1996; Sancar, 1996) and thus the elevated expression of this enzyme in
the 833K testicular tumor cell line, which is proficient in the repair of both cisplatin intrastrand
and interstrand cross-links (Bedford et al., 1988), was unexpected. Interestingly, recent evidence
suggests that nitrogen mustard interstrand cross-links may be repaired by base-excision repair
(Chaney and Sancar, 1996) which uses polymerase 0 as the repair synthesis enzyme (Wood, 1996;
Sancar, 1996). Whether cisplatin interstrand cross-links can be repaired by a similar pathway
remains to be determined.
Tolerance to alkylating agents, including cisplatin, has been shown to be associated with
defects in the mismatch repair system (Karran and Marinus, 1982; Fram et al., 1985; Goldmacher
et al., 1986; Kat et al., 1993; Aebi et al., 1996). Recent studies have demonstrated that the
mismatch repair protein hMSH2 binds selectively to cisplatin-DNA adducts (Mello et al., 1996;
Duckett et al., 1996). A model to explain the role of mismatch repair in cisplatin cytotoxicity
proposes that misdirected repair attempts at the sites of cisplatin adducts leads to activation of
apoptosis, perhaps through the accumulation of DNA strand breaks (Mello et al., 1996).
Tolerance results when defective mismatch repair proteins fail to initiate this abortive repair.
Interestingly, microsatellite instability of mononucleotide and dinucleotide repeats, a condition
usually associated with hMSH2 deficiency, was not observed in a panel of human testicular germ
cell tumors (Huddart et al., 1995) implying that hMSH2 is functional in these tumors. This
suggests that testicular tumor cells may be unable to exhibit damage tolerance by the model
described above. A recent observation that the hMSH2 protein is overexpressed in testicular
tissue further suggests that mismatch repair may play an important role in sensitizing testicular
tumors to cisplatin (Mello et al., 1996).
7. Testicular tumor cells are very sensitive to drug-induced apoptosis.
Finally, recent evidence suggests that the sensitivity of testicular tumor cells to cisplatin
may be related to a susceptibility of these cells to undergo apoptosis. Testicular tumors are
unusual because they rarely exhibit p53 mutations (Peng et al., 1993; Heimdal et al., 1993; Murty
et al., 1997; Riou et al., 1995), and they express high levels of the wild-type p53 protein (Oren et
al., 1982; Tesch et al., 1990; Bartkova et al., 1991; Riou et al., 1995). Drug-induced apoptosis
was recently examined in human (Chresta et al., 1996) and mouse (Lutzker and Levine, 1996)
testicular tumor cell lines. As expected, these lines exhibited high basal levels of wild-type p53
protein. Following treatment with etoposide, p53 expression was further elevated, and the
protein became transcriptionally active, as evidenced by increased expression of the p53-
dependent genes p21/waf-1 and mdm-2 (Chresta et al., 1996; Lutzker and Levine, 1996). Human
testicular tumor cell lines were found to undergo etoposide-induced apoptosis more readily than
cell lines established from bladder carcinoma (Chresta et al., 1996), a cancer in which p53
mutations are often acquired (Sidransky et al., 1991; Fujimoto et al., 1992). Similarly, apoptosis
was observed in two mouse testicular tumor lines, but not in a line derived from a p53-knockout
mouse (Lutzker and Levine, 1996). These results suggest that a functional p53 protein plays an
essential role in the susceptibility of testicular tumor cells to etoposide-induced apoptosis.
Activation of apoptosis by cisplatin was not examined in these testicular tumor cell lines.
However, cisplatin has been shown to increase the transcriptional activity of p53 and induce
apoptosis in ovarian cancer cell lines (Perego et al., 1996; Anthoney et al., 1996), and thus would
be expected to do so in testicular cancer lines also.
Testicular tumors and cell lines have been shown to express low levels of proteins that
suppress apoptosis. Specifically, the inhibitor Bcl-2 was not detected in three human testicular
tumor cell lines (Chresta et al., 1996), and the mdm-2 protein, a negative regulator of p53
transcriptional activity, was expressed at much lower levels than p53 in mouse testicular tumor
lines (Lutzker and Levine, 1996). In addition, amplification of the mdm-2 gene has been shown to
be an infrequent event in testicular tumors (Riou et al., 1995).
Conversely, high levels of apoptosis promoters have been detected in tumors and cell lines
from testicular cancer patients. The Bax protein was highly expressed in three human testicular
tumor cell lines that were extremely sensitive to drug-induced apoptosis (Chresta et al., 1996).
Interestingly, the recently identified human cellular apoptosis susceptibility gene CAS was
expressed at higher levels in testis than in other tissues (Brinkmann et al., 1995). Finally,
testicular tumor cell lines have been found to overexpress c-myc (Campisi et al., 1984; Tesch et
al., 1990), an oncogene that promotes p53-dependent apoptosis (Evan et al., 1992; Hermeking
and Eick, 1994; Wagner et al., 1994). Taken together, the observations detailed above strongly
suggest that testicular tumor cells may be poised for apoptosis. The exquisite sensitivity of
testicular tumors to chemotherapy may, therefore, be owed to the susceptibility of this tumor type
to undergo drug-induced apoptosis.
In conclusion, several potential mechanisms have been identified that may contribute to
the extreme cellular sensitivity of testicular tumors to cisplatin. It is hoped that an understanding
of the molecular basis for cisplatin hypersensitivity in this tumor cell type may lead to more
successful treatments for all types of cancers.
G. Testis-determining factor SRY
Sex determination is equivalent to testis determination in placental mammals. Expression
of the sex-determining gene on the Y chromosome induces testicular development in the genital
ridge of the embryo. If this gene (also called the testis-determining factor) is not expressed, the
embryo will develop as a female (Goodfellow and Lovell-Badge, 1993; Capel, 1996). In 1990,
P.N. Goodfellow, R. Lovell-Badge, and colleagues succeeded in cloning human SRY (Sex-
Determining Region Y), the proposed testis-determining factor (Sinclair et al., 1990). The
corresponding gene from the mouse Y chromosome Sry was also cloned (Gubbay et al., 1990).
Human SRY is expressed in the gonadal tissue of the male embryo (Poulat et al., 1995). In
addition, SRY is expressed in the adult testis, presumably in the germ cells (Sinclair et al., 1990;
Clepet et al., 1993). A sensitive RT-PCR assay also detected SRY in heart, liver, and kidney adult
tissues, albeit at lower levels than in the testis (Clepet et al., 1993). Sry is expressed in the genital
ridge of the mouse embryo, in the somatic cell lineage (Koopman et al., 1990; Hacker et al., 1995;
Jeske et al., 1995). Interestingly, Sry transcripts in the germ cells of the adult mouse testis are
circular and thus may not be translated into protein (Capel et al., 1993).
A growing body of evidence supports the function of SRY in sex determination. First, XY
individuals carrying mutations in SRY develop as phenotypical females (Berta et al., 1990; Jager et
al., 1990; Hawkins et al., 1992). Second, mouse Sry is expressed in the genital ridge at a time
coincident with the onset of testis development (Koopman et al., 1990). Finally, a 14 kb genomic
Sry fragment is sufficient to cause testis formation and male development in female transgenic
mice (Koopman et al., 1991). The function of human SRY in the adult testis is not known; its
expression in the germ cells, however, suggests a role in spermatogenesis (Goodfellow and
Lovell-Badge, 1993).
Amino-acid sequence analysis of the proteins encoded by the human SRY and mouse Sry
genes revealed a conserved DNA binding motif, the high mobility group (HMG) domain (Sinclair
et al., 1990; Gubbay et al., 1990), suggesting that the human (h) SRY and mouse (m) SRY
proteins should bind to DNA. Electrophoretic mobility shift assays revealed specific binding of
the recombinant human SRY protein to the enhancer sequence (AACAAAG) from the CD3E gene
(Harley et al., 1992), the target site for another HMG-domain protein, the T cell-specific
transcription factor (TCF-1). In addition, the related AT-rich sequences TTCAAAGG (Nasrin et
al., 1991) and AACAATG (Giese et al., 1992) are bound by the HMG domain of mSRY. A
random site selection method determined that the consensus binding sequence for hSRY is
A/TAACAAT/A (Harley et al., 1994). Human SRY induces a 60-80' bend in the DNA helix
upon binding to linear target sequences (Ferrari et al., 1992; Giese et al., 1994; Pontiggia et al.,
1994; Werner et al., 1995) and, interestingly, recognizes four way junction DNAs irrespective of
sequence (Ferrari et al., 1992; Peters et al., 1995).
The function of SRY in testis determination is believed to involve transcriptional
regulation. However, the downstream target genes for SRY regulation have not yet been
identified. Human SRY recognizes a putative target site in the 5' region of the Mullerian
inhibiting substance (MIS) gene, which is expressed during gonadal differentiation (Haqq et al.,
1993). Human SRY can activate transcription from the MIS gene promoter when an hSRY
expression plasmid and a MIS reporter plasmid are cotransfected into a cell line derived from the
differentiating gonadal ridge of a male rat embryo (Haqq et al., 1994). However, a mutation in
the MIS promoter region eliminates hSRY binding, but does not decrease transcriptional
activation (Haqq et al., 1994). hSRY also binds to the promoter region offra-1, afos-related
gene, and activates transcription from afra-1 promoter construct in cotranfection assays carried
out in Chinese hamster ovary cells (Cohen et al., 1994). However, hSRY could not activate
transcription of a reporter gene containing multiple copies of the AACAAT binding site in HeLa
cells (Dubin and Ostrer, 1994). Taken together, these studies suggest that hSRY may act through
other factors to induce transcription of downstream target genes. Two lines of evidence suggest
that these factors may be species-specific regulatory factors. First, gene transfer of a human
genomic DNA fragment carrying the SRY gene into female transgenic mice failed to induce testis
formation (Koopman et al., 1991). Second, despite a 90% sequence homology (Gubbay et al.,
1990), the HMG domains ofhSRY and mSRY differ significantly in their DNA binding properties
(Giese et al., 1994). The HMG domain of mSRY exhibits a higher DNA binding affinity and
specificity for the AACAATG sequence, makes more extensive contacts in the major groove of
the DNA, and induces a greater DNA bend angle compared to the HMG domain of hSRY (Giese
et al., 1994). Moreover, it has been proposed that SRY bends the DNA in order to promote
contact between other proteins in the assembly of a higher order nucleoprotein complex,
competent for transcription (Pontiggia et al., 1994).
Figure 2: DNA adduct profiles of cisplatin and trans-DDP. Numbers indicate percentage
compared to total adduct spectrum.
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Figure 3: Structures of the 1,2-d(GpG), 1,2-d(ApG), and 1,3-d(GpTpG) intrastrand cross-links
of cisplatin.
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Table 1: Structural Alterations Induced by Platinum-DNA Adducts
HMG
Adducts Bend Unwind Binding
cis-DDP monofunctional no 60 no
1,3-d(GpNpG) 340 230 no
1,2-d(GpG) 340 130 yes
1,2-d(ApG) 340 130 yes
d(G*pC) / (G*pC) 20o-40o 800 yes
trans-DDP 1,3-d(GpNpG) flexible 90 no
d(G*pC) / (GpC*) flexible, 260 120 no
Table 2: Binding Affinities and Specificities of HMG-Domain Proteins for the 1,2-d(GpG) Cisplatin Cross-link
Full-length protein MW (kDa) Species # HMG domains Kd(app) Specificity DNA probe
SSRP1 81 human 1 n.da n.da
Ixrl 80 yeast 2 250 nM 10-fold 92 bp
HMG1 28 rat 2 370 nM 100-fold 100 bp, 92 bp
HMG2 26.5 calf 2 n.d" n.d" -
hUBF 97/94 human 6 60 pM 10-30-fold 100 bp
00
tsHMG 23 mouse 2 40 nMb 100-foldb 20 bp
HMG domain only
mSRY 10 mouse 1 -10- 6 M < 4-fold 92 bp
LEF-1 10 mouse 1 -10- 7 M 4-10-fold 92 bp
HMG -A 10 rat 1 -10-7 Mc n.d" 15 bp
HMG1-B 10 rat 1 500 nM 3-4-fold 100 bp, 20 bp
tsHMG-A 10 mouse 1 350 nMb 100-foldb 20 bp
"Not Determined. bU.-M. Ohndorf, personal communication. cS.U. Dunham, personal communication
Figure 4: Model 1, HMG-domain proteins shield cisplatin-DNA adducts from repair.
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Figure 5: Model 2, HMG-domain proteins are regulatory proteins that are diverted by cisplatin-
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Figure 6: Model 3, HMG-domain and other cisplatin-DNA binding proteins facilitate the
processing and/or repair of cisplatin-DNA adducts.
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III. MATERIALS AND METHODS
A. Materials
The Escherichia coli MC15 strain containing pDS56/4xHis-hSRY was obtained from
D.R. Cohen (Australian National University). D. Page (MIT) provided the GST, GST/hSRY-
HMG, and GST/hSRY expression plasmids. S.J. Lippard (MIT) supplied recrystallized cisplatin.
The NTera2.D1 testicular embryonal carcinoma line was obtained from the American Type
Culture Collection (No. 1973-CRL). P.A. Sharp (MIT) provided the HeLa S3 cell line. ES
(embryonic stem) cell qualified fetal bovine serum and trypsin were purchased from Gibco/BRL.
B. Methods
1. Preparation of GST, GST/hSRY, and GST/hSRY-HMG domain fusion proteins
Full-length hSRY and the hSRY-HMG domain were expressed as fusions with the
carboxyl terminus of a 26 kDa glutathione S-transferase (GST) in E. coli strain DH5So. GST
alone was also expressed as a control. GST fusion protein purification was as described (Smith
and Johnson, 1988) with minor modifications. Cells containing the GST, GST/hSRY, or
GST/hSRY-HMG domain expression vectors were grown in LB media with 50 gtg/ml ampicillin
at 37 oC and induced at OD60o = 0.7 with 1 mM isopropyl 3-D-thiogalactopyranoside (IPTG).
After 6 h the cells were harvested by centrifugation and lysed in 6 M guanidine hydrochloride
(Mallinkrodt) dissolved in buffer A (20 mM Tris-HC1, pH 8, 50 mM NaCI, 1 mM EDTA, 1 mM
DTT, 10% glycerol, 0.5 mM phenylmethylsulfonylfluoride (PMSF), 10 CpM aprotinin, 20 ptM
95
leupeptin, and 20 gM pepstatin). After incubation for 20 min on ice, the cell debris was removed
by centrifugation. Protein supernatants were dialyzed (4 'C) into 1.5 M guanidine hydrochloride
in buffer B (20 mM Tris-HCl, pH 8, 50 mM NaCI, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.5
mM PMSF, 0.2 gpM aprotinin, 0.2 ýpM leupeptin, and 1 pM pepstatin) overnight, then into buffer
B for 4 h. Precipitated protein was removed by centrifugation and the protein supernatants were
added batchwise to Glutathione Sepharose-4B beads (Pharmacia) equilibrated in buffer A and
mixed for 10 min. Protein-bound beads were collected and washed two times with 5 bead
volumes of buffer A. The GST, GST/hSRY, or GST/hSRY-HMG domain proteins were eluted in
elution buffer (5 mM glutathione, 50 mM Tris-HCl, pH 8, 1 mM DTT, 10% glycerol, 0.5 mM
PMSF, 10 WpM aprotinin, 20 pM leupeptin, and 20 ýpM pepstatin). The proteins were shown to be
approximately 90% pure by SDS/PAGE with Coomassie blue staining. The GST, GST/hSRY,
and GST/hSRY-HMG domain proteins had estimated molecular weights of 26 kDa, 50 kDa, and
36 kDa, respectively. Protein concentrations were determined by the Bio-Rad microassay with
bovine serum albumin as the protein standard (Bradford, 1976).
2. Purification of full-length hSRY
The full-length human SRY protein (hSRY) modified with four histidine residues on the
amino terminus was expressed and purified from pDS56/4xHis-hSRY/E. coli MC15. The cells
were grown in LB media with 100 p.g/ml ampicillin and 25 lpg/ml kanamycin at 37 TC and induced
at OD, = 0.8-0.9 with 1 mM IPTG. After 2 h the cells were harvested by centrifugation and
lysed in buffer A (6 M guanidine hydrochloride (Mallinkrodt), 10 mM Tris-HC1, 100 mM sodium
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phosphate, pH 8.0) for 90 min at room temperature with rotation. Cell debris was removed by
centrifugation and the supernatant was loaded onto a Ni-NTA agarose (Qiagen) column
equilibrated in buffer A at room temperature, as described (Cohen et al., 1994). The column was
washed with buffer A and then buffer B (buffer A at pH 6.0) to remove nonbinding proteins. The
full-length hSRY protein was eluted in buffer C (buffer A at pH 5.0) and then dialyzed (4 'C) into
buffer D (20 mM Hepes-NaOH, pH 7.9, 50 mM NaCI, 1 mM EDTA, 1 mM DTT, 5% glycerol)
to renature. The dialyslate was loaded onto an SP-Sepharose column (Pharmacia) and the column
was washed with buffer D until the A280 returned to baseline. Protein was eluted with a linear
gradient from 0.05-1.0 M NaCI. Full-length hSRY eluted between 0.56 and 0.62 M NaCI. The
peak fractions were dialyzed into storage buffer (20 mM Hepes-NaOH, pH 7.9, 50 mM NaCl, 1
mM EDTA, 0.5 mM DTT, 5% glycerol) and stored in aliquots at -80 'C. The protein was
homogeneous by Coomassie blue staining of a SDS/polyacrylamide gel. The identity of hSRY
was confirmed by amino acid analysis (MIT Biopolymers Laboratory) and by N-terminal amino
acid sequencing (MIT Biopolymers Laboratory) which yielded MHHHHLSVFNSDD. DNA
sequencing was performed on the entire hSRY insert in the pDS56/4xHis-hSRY vector for further
verification. hSRY extinction coefficients determined by amino acid analyses (MIT Biopolymers
Laboratory) ranged from 20,000 to 60,000 M-'cm-' at 280 nM. Therefore, the hSRY protein
concentration was calculated by using the extinction coefficient (29,219 M-'cm-' at 280 nM)
measured by the Edelhoch method (Gill and von Hippel, 1989; Pace et al., 1995). Protein
extinction coefficients determined by this method are reported to have an average deviation of 2-
5% from literature values obtained by other methods (Pace et al., 1995). At dilutions less than
100 nM, hSRY exhibited a slow loss in DNA binding activity, probably due to tube surface
adsorption; therefore, the protein was diluted into storage buffer immediately before each binding
experiment.
3. Purification of the hSRY-HMG domain
The HMG domain of human SRY (residues D58-K136) was expressed as a GST fusion
protein in the protease-deficient E.coli strain BL21(DE3). Cells containing the GST/hSRY-HMG
plasmid were grown in LB media with 50 [tg/ml ampicillin at 37 oC to an ODoo of 1.0. IPTG was
added to 1 mM and the cells were induced for 2 h and then harvested. All of the following
procedures were performed at 0-4 oC. The cell pellets were washed in 20 mM Tris-HCI, pH 8, 20
mM NaCl, 1 mM EDTA and then resuspended in buffer A (50 mM Tris-HCI, pH 8, 150 mM
NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg/ml Pefabloc (Boehringer Mannheim), 20
[jM aprotinin, 50 jpM leupeptin, 50 jpM pepstatin). Lysis was achieved by sonication on ice with
30 sec bursts for a total of 5 min. Cell debris was removed by centrifugation and 5 M NaCI was
added to the supernatant to adjust the final concentration to 0.45 M. Nucleic acids were removed
by batch adsorption to DEAE-cellulose. The supernatant was diluted to approximately 0.3 M
NaCI, added batchwise to Glutathione Sepharose-4B beads (Pharmacia) equilibrated in buffer A
plus 1% Triton X-100, and mixed for 1 h. Protein-bound beads were collected and washed three
times with 10 bead volumes of buffer B (Ix PBS, 1 mM EDTA, 1 mM DTT and protease
inhibitors), buffer C (buffer B with 1 % Triton X-100), buffer D (50 mM Tris-HCl, pH 8, 150
mM NaCl) aiTd thrombin cleavage buffer (Buffer D plus 2.5 mM CaCI2). Cleavage of the
GST/hSRY-HMG fusion protein while still bound to the glutathione beads was achieved by
digestion with human thrombin (Sigma, 0.5% wt/wt fusion protein) for 1 h at room temperature.
The beads were poured into a 10 cm x 1 cm column and the hSRY-HMG domain protein was
eluted in buffer E (50 mM Hepes-NaOH, pH 7.9, 20 mM NaCI, 1 mM EDTA, 1 mM DTT, 0.5
mM PMSF, 5% glycerol). Fractions were combined and applied to a Mono S HR 5/5 FPLC
column (Pharmacia) equilibrated in 50 mM Hepes-NaOH, pH 7.9, 20 mM NaCI, 1 mM EDTA, 1
mM DTT, 5% glycerol. The column was washed until the A280 returned to baseline, and protein
was eluted in a 0.020-1.0 M NaCI linear gradient. The hSRY-HMG domain protein eluted
between 0.54 and 0.58 M NaCI. The peak fractions were dialyzed into storage buffer (20 mM
Hepes-NaOH, pH 7.9, 10 mM NaCI, 1 mM EDTA, 0.5 mM DTT, 5% glycerol) and stored in
aliquots at -80 oC. The protein was homogeneous by Coomassie blue staining of a
SDS/polyacrylamide gel. Amino acid analysis and N-terminal amino acid sequencing verified the
identity of the hSRY-HMG domain. The protein contained fifteen additional amino acid residues
(GSPGISGGGGGILDS) at the amino terminus due to the location of the thrombin cleavage site
within the GST fusion. Protein concentration was determined by using the extinction coefficient
(21,341 M-cm-' at 280 nM) measured by the Edelhoch method (Gill and von Hippel, 1989; Pace
et al., 1995). Amino acid analyses yielded a similar extinction coefficient (25,620 Ml-cm 1' at 280
nM) for the hSRY-HMG domain. Aggregation and/or tube surface adsorption caused a slow loss
in the DNA binding activity of the hSRY-HMG domain; the protein was, therefore, diluted into
storage buffer immediately before each binding experiment.
4. Preparation of DNA probes
Oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
IA) or synthesized on a Applied Biosystems PCR Mate 391 DNA synthesizer and purified by
polyacrylamide gel electrophoresis. A 20 base oligonucleotide, Pt-20-TOP: 5'-TCT CCT TCT
G*G*T CTC TTC TC, where the asterisks denote the cis-[Pt(NH3) 2{d(GpG)-N7(1),-N7(2)}]
intrastrand cross-link, was prepared as described (Bellon et al., 1991; Mello et al., 1996). A 250
jiM solution of DNA was combined with 1.4 molar excess of cisplatin in a reaction containing 3
mM NaCI, 1 mM Na2HPO 4 (pH 7.4) and incubated at 37 oC for 20 h. The Pt-20-TOP
oligonucleotide was purified from unreacted DNA on a denaturing 20% polyacrylamide gel. An
unmodified control oligonucleotide (Un-20-TOP) was carried through these same procedures but
without cisplatin in the reactions. The Pt-20-TOP oligonucleotide was analyzed by platinum
atomic absorption spectroscopy on a Varian AA-1475 spectrometer equipped with a GTA-95
graphite furnace and shown to contain a single atom of Pt per strand. The presence of platinum
was further demonstrated by treatment with cyanide ion to reverse the Pt adduct. Electrospray
mass spectrometry confirmed the molecular mass of the Pt-20-TOP oligonucleotide (calculated
molecular mass = 6181, observed molecular mass = 6178). Single-stranded oligonucleotide
concentrations were determined from A2 60 values and extinction coefficients calculated by
summation of the individual base extinction coefficients (Maniatis et al., 1989).
The Un-20, Pt-20, SRY-20, and Mut-20 double-stranded DNA probes (see Figure 9 for
sequences) were prepared by the following procedure. The top strands were 5'-end labeled with
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T4 polynucleotide kinase and [y-32P]ATP (6000 Ci/mmol, New England Nuclear) in 70 mM Tris-
HCI, pH 7.6, 10 mM MgCl2. The complementary bottom oligonucleotides were 5'-end
phosphorylated with nonradioactive ATP. Top and bottom strands were combined at a molar
ratio of 0.9:1.0 and NaCI was added to 100 mM. The solution was heated at 80 oC and then
cooled slowly to 4 oC to allow the strands to anneal. The 20 bp probes were purified on
Sephadex G-25 Quick Spin columns (Boehringer Mannheim), diluted into STE (10 mM Tris-HC1,
pH 8, 1 mM EDTA, 100 mM NaCl), and stored at 4 oC. Competitor DNAs were prepared
similarly, but both strands were 5'-end phosphorylated with nonradioactive ATP. By this
procedure, the DNA probes were greater than 96% double-stranded, as determined by
quantitation of the samples run on a 20% (19:1) native polyacrylamide gel. Concentrations of
32P-labeled DNA probes were calculated assuming a specific activity equal to that of the [y-
32P]ATP. Unlabeled double-stranded DNA concentrations were determined from A26o values and
estimates of A260 = 1 = 50 gpg/ml. Note that the concentration of Un-20 DNA obtained by this
method differed by only 4% from that calculated using the experimentally determined extinction
coefficients for Un-20-TOP (164,000 M-'cm"') and Un-20-BOTTOM (181,000 M-'cm 1') and a
hypochromicity effect of 20% (Poklar et al., 1996).
The 100 bp DNA fragment with a single, centrally located cis-[Pt(NH3)2{d(GpG)-N7(1),-
N7(2)}] intrastrand cross-link (Pt-100) and the unmodified control DNA (Un-100) were prepared
as described (Visse et al., 1991; Pil and Lippard, 1992) with minor modifications. The six
oligonucleotides used in the construction were: A: 5'-GAG ATC GAT GGA CTA GCC AGC
TGC CTT GAT ATC ACG TCA G; B: 5'-TGA TAT CAA GGC AGC TGG CTA GTC CAT
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CGA TCT C; C: 5'-TCG ACT GAG AAG AGA CCA GAA GGA GAC TGA CG; D: 5'-AGT
ACC CGG GTA GTC AAC AGC TGG AGC GAT ATC A; E: 5'-AGT CGA TGA TAT CGC
TCC AGC TGT TGA CTA CCC GGG TAC T; Un-20-TOP or Pt-20-TOP. In addition, a 100
bp DNA probe containing a centrally located AACAAAG sequence (SRY-100) was constructed
by replacing Pt-20-TOP and C oligonucleotides with SRY-20-TOP: 5'-CCA GAT TCT TTG
TTA CGT TA and SRY-32: 5'-TCG ACT TAA CGT AAC AAA GAA TCT GGC TGA CG,
respectively. A 100 bp probe containing the related central sequence AACAATG (TCR-100) was
also prepared by substituting the Pt-20-TOP and C oligonucleotides with TCR-20-TOP: 5'- GGC
ACC CAT TGT TCT CTC CC) and TCR-32: 5'- TCG ACT GGG AGA GAA CAA TGG GTG
CCC TGA CG, respectively.
For construction of SRY-100 and TCR-100 probes, oligonucleotides B, E, SRY-20-TOP,
SRY-32, TCR-20-TOP, and TCR-32 were 5'-end phosphorylated with ATP and T4
polynucleotide kinase at 37 TC for 1 h and then the kinase was heat inactivated at 68 TC for 20
min. Complementary strands were individually annealed at 1:1 molar ratios (12000 pmol A and
B; 12000 pmol D and E; 6000 pmol SRY-20-TOP and SRY-32; 6000 pmol TCR-20-TOP and
TCR-32) by heating to 95 oC and then cooling to room temperature over 9 h. Annealed DNAs
were mixed in 37 separate 300 pmol reactions, 19 containing the SRY-20-TOP/SRY-32 duplex
and 18 containing the TCR-20-TOP/TCR-32 duplex. Each reaction was 200 pl in volume and
contained 5 tl (2000 units) of T4 DNA ligase. The ligations were carried out at 16 oC for 12 h.
Ligated material was phenol-chloroform extracted, ethanol precipitated, resuspended in TE (10
mM Tris-HCl, pH 8, 1 mM EDTA), and passed over Sephadex G-25 Quick Spin columns. Full-
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length 100-mers were purified from unligated material on 7 M urea, 8% polyacrylamide gels,
eluted in TE, and ethanol precipitated. The DNAs were resuspended in 200 pl TE and reannealed
by the same procedure as above. The 100 bp duplexes were purified from single-stranded DNA
by 12% native PAGE, eluted in TE, ethanol precipitated, and resuspended in TE. Final yields
were 25%. The probes were radiolabeled with [y-32P]ATP and purified by passage over Sephadex
G-50 Quick Spin columns. Dilutions were made in STE and stored at 4 oC.
The DNA probe used for Southwestern blotting was a 272 bp DNA fragment unmodified or
modified with cisplatin to a bound drug/nucleotide ratio (rb) level of 0.043 or 0.058. Restriction
enzyme digestion of pSTR3 (Couto et al., 1989) with ClaI and SmaI generated 272 bp and 4095
bp DNA fragments. The cisplatin-modified DNA probes were prepared by treating the restriction
fragments (100 gtg/ml) with cisplatin in 3 mM NaCl, 1 mM Na2HPO 4 (pH 7.4) at appropriate
formal drug/nucleotide ratios for 16 h at 37 oC. Unbound platinum was removed by dialysis
against 10 mM Tris-HCI (pH 8), 1 mM EDTA (TE) for 24 h at 4 oC. An unmodified control
probe was carried through the same procedures but without cisplatin in the reactions. Bound
levels of platinum to DNA were determined by using atomic absorption spectroscopy. The 272
bp probes were radiolabeled with [a- 32 P]dCTP (6000 Ci/mmole, New England Nuclear) and
purified from the 4095 bp fragment on native 5% polyacrylamide gels.
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5. Electrophoretic mobility shift assays
For binding assays, full-length hSRY and the hSRY-HMG domain were diluted into their
respective storage buffers immediately before use. Varying concentrations of protein were added
to 0.1 nM 32P-labeled DNA probe (5000 cpm) in 10 ptl reactions containing 8% Ficoll, 10 mM
Hepes-NaOH, pH 7.9, 60 mM NaCl, 1 mM EDTA, 0.5 mM DTT, and 100 ýtg/ml BSA.
Reactions were incubated for 30 min on ice and then 2 pl of loading dye (30% glycerol, 0.125%
bromophenol blue, 0.125% xylene cyanol) were added. Samples were loaded onto prerun,
preequilibrated (4 'C) 10% (29:1 acrylamide:bis) polyacrylamide gels containing 2.5% glycerol
and 0.5x TBE (45 mM Tris, 45 mM boric acid, 1 mM EDTA). The gels were run for 100-120
min at 350 V and then vacuum dried. Bands representing bound and free DNA probe were
quantitated by using a Molecular Dynamics PhosphorImager. Under conditions of excess protein,
the apparent dissociation constant (Kd(app)) was defined as the protein concentration required for
half-maximal binding. The Kd(app) reported for each protein/DNA interaction is an average from
three or four experiments. The error was computed as the average deviation.
6. Stoichiometry assays
Binding experiments to determine the stoichiometry of DNA binding were performed as
standard electrophoretic mobility shift assays except that the hSRY protein was titrated into
binding reactions containing 0.1 nM 32P-labeled Pt-20 DNA probe (5000 cpm) and 1200 nM
unlabeled Pt-20 DNA. Similarly, the hSRY-HMG domain was titrated into reactions containing
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radiolabeled Pt-20 probe and 25 nM unlabeled Pt-20 DNA.
7. Competition assays
Unlabeled competitor DNAs (Pt-20, Un-20, SRY-20, Mut-20) were titrated into binding
reactions containing 0.1 nM 32 P-labeled Pt-20 DNA probe (5000 cpm) and 200 nM hSRY or 5
nM hSRY-HMG domain. The competitive binding of protein to labeled Pt-20 DNA probe and
unlabeled competitor DNAs is described by Eq. 1 (Lin and Riggs, 1972; Long and Crothers,
1995),
2Tt K Ke L[KT+( -f)Ct+Pt+Tt- [KT+(--i)Ct+Pt+TJ]2-4TtPt] (1)
where 0 is the fraction of bound DNA, PO, TO, and Ct are the concentrations of protein,
radiolabeled DNA probe, and competitor DNA, respectively, and K, and Kc represent the
apparent dissociation constants for the Pt-20 and competitor DNA probes, respectively.
Competition curves were fit for the best value of Kc by nonlinear least squares analysis. Errors
were based on the statistical fit of the data and represented ± 1 standard deviation. Relative DNA
binding affinities were determined by comparing values of Kc for the competitor DNAs. Relative
affinities were also approximated by comparing the concentrations of competitor DNAs required
for 50% competition. Experiments with each competitor DNA were performed 2-3 times.
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8. NTera2.D1 cells and culture conditions
Testicular embryonal carcinoma NTera.D 1 cells (Andrews et al., 1984) were grown in
culture flasks (75-cm2) in 24 ml Dulbecco's modified eagle medium (D-MEM) with 4.5 g/L
glucose (Sigma) supplemented with 10% ES cell qualified fetal bovine serum (Gibco/BRL) in a
5% C02/95% air atmosphere. The NTera.D 1 cells were maintained at a cell density of greater
than 5 x 106 cell/75-cm 2 flask. (Maintenance of cultures at a lower cell density promotes
spontaneous differentiation.) The cells were subcultured 1:4 every 3 days by treatment with a
0.1% (w/v) trypsin and 1 mM EDTA solution in PBS, by treatment with a 1 mM EDTA solution
in PBS, or by a scraping method. Scraping was achieved by gently rolling 10 sterile, acid-washed
3-mm glass beads (Thomas Scientific, # 5663-L13) over the cells in the presence of 10 ml
medium.
9. NTera2.D1 cell extracts
Nuclear and cytosolic extracts were prepared as described (Dignam et al., 1983; Stillman
and Gluzman, 1985) with minor modifications. The NTera2.D1 cells were grown to confluence
in 150-cm2 flasks with 45 ml media and harvested by treatment with 0.1% trypsin and 1 mM
EDTA. Cells (1 x 10') were washed in PBS, resuspended in a hypotonic buffer (20 mM Hepes-
NaOH, pH 7.5, 5 mM KCI, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF, 1 mM Pefabloc), and
allowed to swell on ice for 15 min. Cells were lysed with a Dounce homogenizer and the
homogenate was centrifuged for 10 min at 16,000 x g to pellet the nuclei. The supernatant was
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made 0.1 M NaCI and centrifuged at 100,000 x g for lh. The cytosolic (S-100) extracts were
aliquoted and stored at -80 'C. The nuclei were resuspended in buffer C (20 mM Hepes-NaOH,
pH 7.5, 25% glycerol, 420 mM KC1, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM
PMSF, 1 mM Pefabloc), lysed with a Dounce homogenizer, and dialyzed overnight against buffer
D (20 mM Hepes-NaOH, pH 7.5, 20% glycerol, 100 mM KC1, 0.2 mM EDTA, 1.5 mM MgCl2,
0.5 mM DTT, 1 mM PMSF, 0.4 mM Pefabloc, 0.2 pM leupeptin, 1 WpM pepstatin). The dialysate
was centrifuged at 16,000 x g to remove cell debris and the extracts were aliquoted and stored at
-80 oC.
Whole-cell extracts were prepared as described (Maniatis et al., 1989). The NTera2.D1
cells (1.5 x 107) were resuspended in either a Triton-detergent lysis buffer (50 mM Tris-HC1, pH
8, 150 mM NaCI, 1% Triton X-100, 1 mM EDTA, 5% glycerol, 20 pM leupeptin, 20 pM
pepstatin, 4 mM Pefabloc, 1 mM PMSF) or a NP40-detergent, high-salt lysis buffer (50 mM Tris-
HCI, pH 8, 500 mM NaCI, 1% NP-40, 1 mM EDTA, 5% glycerol, 20 ýpM leupeptin, 20 pM
pepstatin, 4 mM Pefabloc, 1 mM PMSF), lysed for 30 min at 4 'C, and centrifuged at 16,000 x g
for 10 min to remove cell debris. The extracts were aliquoted and stored at -80 "C. The protein
concentration of cell extracts was determined by the Bio-Rad assay using bovine serum albumin
as a standard (Bradford, 1976).
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10. Polyclonal antisera to hSRY
For production of polyclonal antisera, full-length hSRY modified with four histidine
residues at the amino terminus was purified by Ni-NTA affinity chromatography followed by
preparative Tris-Tricine-SDS/PAGE (Schagger and von Jagow, 1987) and electroelution (Harlow
and Lane, 1988). Following elution from the Ni-NTA column and dialysis, hSRY protein (0.5
mg) was loaded onto 20% Tris-Tricine-SDS polyacrylamide gels (17 cm x15 cm x 1.5 mm) and
electrophoresis was performed overnight at 4 oC in buffers containing 0.1 mM sodium
thioglycolate. The gels were stained for 30 min in 0.05% Coomassie blue, 30% isopropanol, 5%
acetic acid, destained in 16.5% methanol, 5% acetic acid for 10 min, and rinsed in water. The
hSRY band was excised, soaked in 25 mM Tris, 192 mM glycine, 2% SDS, 0.1% DTT for 1 h at
4 oC, and electroeluted into 25 mM Tris, 192 mM glycine, 0.1% SDS (Laemmli, 1970) using an
Elutrap (Schleicher & Schuell) for 15 h at 200 V at 4 oC. The hSRY protein was purified in high
yield by this method and was greater than 95% homogeneous. In addition, hSRY remained in a
denatured form due to the SDS in the buffers. Purified, denatured protein (0.5 mg protein/rabbit)
was combined with complete Freund's adjuvant and injected subcutaneously into four female New
Zealand White rabbits (designated #71-#74). Booster injections of 0.5 mg protein in incomplete
Freund's adjuvant were given 1, 2, 3.5, and 10.5 months later. Serum was collected and stored in
aliquots at -20 oC or -80 "C (designated 1 st-4th bleeds).
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11. Western blot analysis
Purified hSRY and hSRY-HMG domain proteins (0.4-2 .tg) were resolved by 15% Tris-
Glycine-SDS/PAGE (Laemmli, 1970) and 16.5% Tris-Tricine-SDS/PAGE (Schaigger and von
Jagow, 1987), respectively. NTera2.D 1 whole-cell and nuclear extracts (100 jig) were separated
on 5-15% gradient Tris-Glycine-SDS/polyacrylamide gels. Proteins were electroblotted onto
Immune-Lite nylon membranes (Bio-Rad) in 25 mM CAPS, pH 11, 0.01 % SDS transfer buffer.
The blots were probed with hSRY polyclonal antiserum at dilutions of 1:500, 1:5000, or 1:50,000
for 2 h at room temperature. Following washes to remove unbound primary antibody, the blots
were incubated for 30 min with a goat anti-rabbit IgG/alkaline phosphatase conjugated secondary
antibody (Bio-Rad) and then developed with a chemiluminescent substrate (AMPPD, Bio-Rad)
for 5 min. The blots were exposed to film for 15-30 min.
12. Southwestern blot analysis
NTera2.D1 whole-cell or nuclear extracts (100 jtg) and hSRY (-1 jtg) were resolved on
5-15% gradient Tris-Glycine-SDS/polyacrylamide gels (29:1 acrylamide:bis). GST and fusion
proteins GST/hSRY and GST/hSRY-HMG domain (1-1.5 jig) were separated by 10% Tris-
Glycine-SDS/PAGE. Proteins were transferred to nitrocellulose membranes (0.45 jtm; Schleicher
& Schuell) for 5 h at 500 mA and air dried. Southwestern blot analysis was performed as
described (Toney et al., 1989). 32 P-labeled DNA probes were 272 bp fragments unmodified or
modified with cisplatin to an rb of 0.043 or 0.058. The binding reactions contained radiolabeled
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DNA at 1 x 10s cpm/ml and nonspecific competitor poly(dI-dC)-poly(dI-dC) at 6.7 ptg/ml.
Protein-DNA complexes were detected by autoradiography with an intensifying screen at -80 OC
or by using a Molecular Dynamics Phosphorlmager.
13. Excision repair inhibition assays
The sequences, synthesis, and characterization of the oligonucleotides containing the 1,2-
d(GpG) and 1,3-d(GpTpG) intrastrand cross-links have been described previously (Bellon et al.,
1991; Zamble et al., 1996). Site-specifically platinated DNA probes (156 bp) with a radiolabel 4-
5 nucleotides 5' to the site of damage were prepared as described (Huang et al., 1994; Zamble et
al., 1996). The hSRY-HMG domain was diluted into storage buffer (20 mM Hepes-NaOH, pH
7.9, 10 mM NaCl, 1 mM EDTA, 0.5 mM DTT) immediately prior to use. Whole cell-free
extracts (CFEs) from HeLa S3 cells were prepared as described (Manley et al., 1980). The repair
inhibition experiments were performed as reported previously (Zamble et al., 1996) with a few
modifications. The hSRY-HMG domain protein was incubated with the site-specific cisplatin-
DNA repair probes for 10 min at 30 'C, then 75 ptg of HeLa CFE were added and the reaction
was incubated at 30 'C for an additional 50 min. The final 25 tl reaction contained 1.4-2.1 ptl of
protein in storage buffer, in addition to 54 ng ofpBR322 plasmid as a nonspecific competitor, 0.2
mg/ml BSA, 20 p.M of each dNTP, 28 mM Hepes-NaOH, pH 7.9, 48 mM KCI, 4.5 mM MgCl2,
0.36 mM EDTA, 3.6 mM ATP, 0.5 mM DTT, 40 mM NaCl, 10 mM Tris-HCl, 0.2 mM 2-
mercaptoethanol and 1.9% glycerol. The reaction was stopped by adding 10 ýpg proteinase K,
making the reaction 0.5% in SDS and incubating at 55 oC for 20 min. The reactions were
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extracted, precipitated and resolved by 10% PAGE as previously described (Zamble et al., 1996).
The data were quantitated by Phosphorlmager analysis (Molecular Dynamics).
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IV. RESULTS
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A. Southwestern analysis of GST/hSRY and GST/hSRY-HMG domain proteins binding to
cisplatin-modified DNA
The binding of human SRY to cisplatin-modified DNA was first examined by
Southwestern blot analysis. Glutathione S-transferase (GST) fusion proteins of full-length hSRY
(GST/hSRY) and of the hSRY-HMG domain (GST/hSRY-HMG domain) and GST alone were
expressed in E. coli and purified to greater than 90% homogeneity (data not shown). The
proteins were resolved by SDS/PAGE, transferred to nitrocellulose, and the protein-bound filters
were incubated with radiolabeled cisplatin-modified or unmodified DNA (Figure 7). Bands were
observed that corresponded to the molecular weights of GST/hSRY (50 kDa) and GST/hSRY-
HMG domain (36 kDa) in the Southwestern blot probed with cisplatin-modified DNA (left panel)
but not in the blot probed with unmodified DNA (right panel). No band corresponding to the
GST control (26 kDa) was detected in either blot. These results demonstrated that both
GST/hSRY and GST/hSRY-HMG domain bound to DNA modified with cisplatin. Similar results
were obtained when Southwestern blotting was performed with the hSRY-HMG domain after
cleavage from GST with thrombin (data not shown).
B. Polyclonal antisera raised against hSRY
For production of polyclonal antisera, full-length hSRY modified with four histidine
residues at the amino terminus was purified by Ni-NTA affinity chromatography followed by
preparative SDS/PAGE and electroelution (Harlow and Lane, 1988). This purification method
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was chosen because the protein was maintained in a denatured form due to the SDS in the buffers.
It was hypothesized that antisera raised against denatured hSRY protein would bind well to
nonnative antigen on Western blots. Polyclonal antisera against hSRY were produced in four
female New Zealand white rabbits (#71-#74). Western blot analysis indicated that antisera from
the four rabbits had similar affinity for hSRY, but demonstrated different patterns of cross-
reactivity to proteins in E. coli and HeLa extracts (data not shown). Interestingly, none of the
cross-reacting bands in HeLa extracts appeared to correspond to the molecular weights of known
mammalian HMG-domain proteins such as hUBF, HMG1, or HMG2 (data not shown). The
hSRY antisera reacted with both hSRY and the hSRY-HMG domain on Western blots when used
at dilutions of 1:5000-1:50,000. However, the affinity of the antisera was approximately 20-50-
fold higher for full-length hSRY than for the hSRY-HMG domain (data not shown). The
detection limit of the hSRY antisera was found to be 1-10 ng (0.04-0.4 pmol) of hSRY on
Western blots using the Bio-Rad chemiluminescent detection system (data not shown).
C. Purification of full-length hSRY and the hSRY-HMG domain
The full-length human SRY protein (hSRY) was purified by nickel chelate affinity
chromatography under denaturing conditions followed by renaturation and cation-exchange
chromatography. As shown in Figure 8A, the purified protein had an estimated molecular weight
of 24 kDa and was homogeneous by Coomassie blue staining of a SDS-polyacrylamide gel (Lane
1) and by Western blot analysis using polyclonal antiserum raised against hSRY (Lane 2). The
HMG domain comprising residues D58-K136 of human SRY (hSRY-HMG domain) was purified
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under native conditions from a protease-deficient E. coli strain. The resulting 11 kDa polypeptide
was homogeneous and free of proteolytic degradation products, as determined by SDS-PAGE
with Coomassie blue staining and Western blot analysis (Figure 8B).
The purifications of full-length hSRY and the hSRY-HMG domain were greatly aided by
Western blot analyses with hSRY antisera, which identified degradation product contaminants
present in protein preparations. For example, hSRY was degraded to a species of approximately
16 kDa when nickel-affinity purification was carried out under native conditions. Similarly, the
hSRY-HMG domain preparation contained a major 9 kDa proteolytic degradation product.
Degradation was averted by growth in protease-deficient E. coli cells and lysis by sonication in
the presence of large amounts of protease inhibitors.
D. Full-length hSRY and the hSRY-HMG domain bind to the major 1,2-d(GpG) adduct of
cisplatin.
Electrophoretic mobility shift assays with globally platinated DNAs (data not shown)
demonstrated that full-length hSRY and the hSRY-HMG domain bound specifically to DNA
modified with cisplatin, but not to DNA containing adducts of the clinically inactive compound
trans-DDP nor to unmodified DNA. The major DNA adducts formed by cisplatin are 1,2-
intrastrand cross-links at d(GpG) and (ApG) sites (Fichtinger-Schepman et al., 1985). In
contrast, trans-DDP cannot form the 1,2-intrastrand adducts owing to the geometry of its ligands
(Pinto and Lippard, 1985a). Thus, the specific binding of human SRY to cisplatin-modified DNA
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suggests that this protein may recognize the 1,2-intrastrand cross-links. To test this hypothesis, a
20 base pair duplex oligonucleotide containing a single, centrally located cis-[Pt(NH3)2{d(GpG)-
N7(1),-N7(2)}] cross-link was prepared. Sequences of the platinated 20 bp probe (Pt-20) and its
unmodified control (Un-20) are shown in Figure 9. In an electrophoretic mobility shift assay, full-
length hSRY and the hSRY-HMG domain bound selectively to the Pt-20 probe, but only very
weakly to the Un-20 probe (Figure 10). Binding to single-stranded DNA was not observed (data
not shown). These results demonstrated that the testis-specific hSRY protein recognized the
major 1,2-d(GpG) adduct of cisplatin and that the HMG domain was sufficient for this interaction.
E. Stoichiometry of hSRY and the hSRY-HMG domain binding
To determine the stoichiometry of the full-length hSRY/Pt-20 interaction, the protein was
titrated into binding reactions containing 1200 nM Pt-20 DNA (Figure 11), a concentration 10-
fold above the Kd,) of the interaction (vide infra), so as to favor formation of the protein/DNA
complex. At protein:DNA ratios below 1.2, a specific hSRY/Pt-20 complex was observed in the
gel as a single band, whereas at higher protein:DNA ratios, species of lower mobility appeared.
Saturation of the DNA occurred at a protein concentration of 1440 nM, which corresponded to a
hSRY:Pt-20 ratio of 1.2:1. These results suggested that the highest mobility species was a 1:1
complex. Above a protein:DNA stoichiometry of 1:1, the bands of lower mobility appeared,
suggesting that these species represented more than one protein molecule bound per DNA
molecule. Since the Pt-20 probe contains a single specific 1,2-d(GpG) site, the binding of
additional protein molecules may have occurred to lower affinity sites on the DNA, presumably in
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a nonspecific manner. Alternatively, the observed lower mobility species may have resulted from
protein/protein interactions. Stoichiometry of binding determined by this method relies on the
assumption that both the protein and DNA concentrations are accurately known. Because amino
acid analyses (MIT Biopolymers Laboratory) yielded protein extinction coefficients that differed
by over 60% between samples, the hSRY protein concentration was calculated using the
extinction coefficient determined by the Edelhoch method (Gill and von Hippel, 1989; Pace et al.,
1995). Protein extinction coefficients determined by this method are reported to have an average
deviation of only 2-5% from literature values obtained by other methods, such as amino acid
analysis (Pace et al., 1995). In addition, the active fraction of the hSRY protein preparation was
not known. The protein was purified by a procedure that involved denaturation/renaturation steps
(vide supra); the existence of six cysteine residues suggests the possibility of incorrect folding
during renaturation. Electrospray mass spectrometry analysis of the hSRY protein may reveal the
amount of folded protein in the preparation (J. Wishnok, personal communication).
Concentrations of the Pt-20 DNA were determined using the estimate of A260 = 1 = 50 ýtg/ml for
double-stranded DNA. The concentration of the analogous Un-20 DNA determined by this
method differed by only 4% from that calculated using the experimentally determined extinction
coefficients and a hyprochromicity effect of 20% (Poklar et al., 1996). Thus, the Pt-20 DNA
concentration may also be reasonably accurate. With the assumption that the errors in the protein
and DNA concentrations are each less than 20%, the results from Figure 11 indicate that hSRY
binds to Pt-20 DNA as a monomer. However, to confirm the stoichiometry of the hSRY/Pt-20
complex, a double-label experiment should be performed, in which, for example, the radioactivity
in a protein/DNA complex of 3sS-labeled hSRY and 32P-labeled Pt-20 DNA is accurately
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quantitated.
Experiments were also performed to determine the stoichiometry of the hSRY-HMG
domain/Pt-20 interaction (data not shown). Titration of the protein into binding reactions
containing 25 nM Pt-20 DNA produced a single protein/DNA complex. Saturation of the DNA
occurred at a protein concentration of 62.5 nM, which corresponded to a hSRY-HMG
domain:Pt-20 ratio of 2.5:1. These results suggested that the hSRY-HMG domain could be
binding to the Pt-20 DNA as a monomer or as a dimer. As for full-length hSRY, the
concentration of the hSRY-HMG domain was calculated by using the extinction coefficient
measured by the Edelhoch method (Gill and von Hippel, 1989; Pace et al., 1995). The average
protein extinction coefficient determined by amino acid analyses (MIT Biopolymers Laboratory)
differed by 20% from the Edelhoch value. The active fraction of the hSRY-HMG domain protein
preparation was not known. However, a slow loss in DNA binding activity of the protein due to
aggregation and/or tube surface adsorption (discussed below) suggested that the protein was less
than 100% active in DNA binding. Thus, it is difficult to interpret the results from the
stoichiometry experiment. To distinguish between the hSRY-HMG domain binding as a
monomer or as a dimer, a double-label experiment (as described above) needs to be performed.
In support of the hSRY-HMG domain binding to DNA as a monomer, 1:1 complexes formed in
solution between the hSRY-HMG domain and specific DNA target sequences have been
examined by NMR techniques (King and Weiss, 1993; Werner et al., 1995). In addition, Bianchi
and colleagues have demonstrated by gel filtration that the hSRY-HMG domain is a monomer in
solution (Ferrari et al., 1992). In contrast, protein-protein cross-linking experiments by Thomas
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and coworkers have indicated that while the hSRY-HMG domain is monomeric in solution in the
absence of DNA, it can dimerize when bound to supercoiled DNA (Teo et al., 1995).
Stoichiometry assays examining the interactions of full-length hSRY and the hSRY-HMG domain
with a 20 bp probe containing the putative hSRY target sequence AACAAAG (SRY-20) (See
Figure 9 for probe sequences) yielded similar results as the Pt-20 probe (data not shown).
F. Human SRY binds to a cisplatin adduct and the putative target sequence AACAAAG
with comparable affinities.
1. Method for determination of apparent dissociation constants
The apparent equilibrium dissociation constant (K(app)) of a given protein/DNA interaction
is defined by following equation:
K p [DNA ][protein]Kd(ap) [DNA-protein]
where [DNA] and [protein] are the concentrations of free DNA and free protein, respectively, and
[DNA-protein] is the concentration of the DNA-protein complex. Under conditions of protein
excess, the assumption can be made that the concentration of free protein is equivalent to that of
total protein. At 50% saturation of the DNA, Eq. 2 is reduced to Kapp) = [protein]. In this
method of determining Kap,,), all protein molecules are assumed to be active in DNA binding.
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In the present study, the apparent dissociation constants for the interactions of full-length
hSRY and the hSRY-HMG domain with DNA probes containing a single cisplatin 1,2-d(GpG)
adduct (Pt-20) or the putative target sequence AACAAAG (SRY-20) (See Figure 9 for probe
sequences) were determined in electrophoretic mobility shift assays. Protein was titrated into
binding reactions containing a fixed and limiting concentration of radiolabeled probe and the
reactions were incubated for 30 min. Time course studies had indicated that equilibrium was
established after a 5 min incubation (data not shown). The measurement of apparent dissociation
constants by this method assumes that the equilibrium is not perturbed when the binding reactions
are loaded onto the gel and electrophoresed. In particular, dissociation of protein/DNA
complexes can occur in the dead time while the free DNA is entering the gel. For these reasons,
the apparent dissociation constants reported in this dissertation should be confirmed by a method
that does not perturb the equilibrium, such as DNase I footprinting.
For calculation of apparent dissociation constants, the amounts of bound and unbound
radiolabeled probe were quantitated from each titration, and the fraction of bound probe DNA
was plotted as a function of the log of protein concentration. Attempts were made to fit the
binding data using nonlinear least squares analysis to the following equation derived from Eq. 2,
which describes a simple bimolecular equilibrium,
S [protein]
[protein] +Kd(app)
where 9 is the fraction of bound DNA and Kdapp) is the apparent dissociation constant for the
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protein/DNA interaction. The observed binding titrations for full-length hSRY and the hSRY-
HMG domain, however, were consistently steeper than the fit of the data to this equation. Such
steep transitions are often indicative of cooperativity. However, a presumed stoichiometry of 1:1
for the hSRY and hSRY-HMG domain/DNA interactions (Figure 11 and data not shown) and a
single cisplatin adduct or AACAAAG site on the DNA probes argues against cooperative binding.
In this case, the steep binding titrations may indicate the binding of multiple proteins to the DNA
probes. In support of this view, additional bands of lower mobility than the presumed 1:1
hSRY/DNA complex were observed in stoichiometry experiments with Pt-20 and SRY-20 probes
(Figure 11 and data not shown). The binding of additional proteins to these probes may have
occurred to lower affinity sites on the DNA, presumably in a nonspecific fashion. The addition of
nonspecific competitor DNA to the binding reactions might reduce some of this nonspecific
binding and result in more well-behaved titrations.
Because the binding data for hSRY and the hSRY-HMG domain could not be rigorously
fit to Eq. 3, apparent dissociation constants were estimated as the midpoint of each binding
transition. By this method, similar Kdapp) values were obtained when DNA present in all protein-
bound species or in the presumed 1:1 complex only were quantitated as bound material. In
addition, analysis of both the disappearance of free DNA probe and the appearance of
protein/DNA complexes yielded similar apparent dissociation constants. Since neither the active
fractions of the hSRY and hSRY-HMG domain preparations nor the stoichiometries of binding
have been established definitively, the apparent dissociation constants reported in this dissertation
should be considered estimates of the DNA binding affinities of hSRY and the hSRY-HMG
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domain.
2. hSRY/Pt-20 interaction
To quantitate the affinity of full-length hSRY for the major 1,2-d(GpG) adduct contained
within a 20 bp probe (Pt-20), the protein was titrated into binding reactions containing 0.1 nM of
radiolabeled Pt-20 DNA. A representative experiment is shown in Figure 12A. At hSRY
concentrations below maximal binding, a specific hSRY/Pt-20 complex was observed in the gel as
a single band. Experiments aimed at defining the stoichiometry of binding suggested that this
complex represented a 1:1 interaction (Figure 11). At hSRY concentrations above 250 nM,
species of lower mobility appeared, probably corresponding to multiple proteins bound to the
DNA. Half-maximal binding occurred at a hSRY concentration of 120 ±10 nM (Figure 12B).
3. hSRY/SRY-20 interaction
In view of the results described above, it was of interest to determine the affinity of full-
length hSRY for a DNA target sequence as compared to its affinity for cisplatin-modified DNA.
Although a physiological target site has not yet been identified, full-length hSRY has been shown
to bind to the sequence AACAAAG from the CD3s gene enhancer (Harley et al., 1992) and to
the related sequence AACAATG (Cohen et al., 1994; Harley et al., 1994). No apparent
dissociation constants were calculated in these earlier studies, however. To quantitate the affinity
of hSRY for the CD3s gene enhancer sequence, a 20 bp DNA probe (SRY-20) containing
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AACAAAG was synthesized with the same flanking sequences as Pt-20 (Figure 9) and used in
saturation binding experiments with full-length hSRY (Figure 12C). Similar to its interaction with
Pt-20 DNA, hSRY formed a specific complex with SRY-20 and at high concentrations, multiple
hSRY proteins apparently bound to the probe. The Kdapp) was determined to be 15 ±3 nM (Figure
12D). Thus, the results from titration experiments (summarized in Table 3) indicated that full-
length hSRY had an 8-fold higher affinity for the AACAAAG sequence than a cisplatin adduct
(K~, := 120 nM).
4. hSRY-HMG domain/Pt-20 interaction
To determine whether full-length hSRY and the hSRY-HMG domain differ in their DNA
binding properties, the affinities of the hSRY-HMG domain for the Pt-20 and SRY-20 probes
were measured under the identical conditions used for hSRY binding. Titration of the hSRY-
HMG domain into binding reactions containing a constant amount of the Pt-20 probe produced a
specific protein/DNA complex that increased to saturation. Maximal binding was achieved at a
protein concentration of 50-100 nM (Figure 13 A). At the plateau, the bound Pt-20 DNA fraction
was only 0.7, for reasons that are not completely known. The Pt-20-TOP oligonucleotide used to
construct the Pt-20 probe was fully platinated as demonstrated by atomic absorption spectroscopy
and mass spectrometry. At a protein concentration of 500 nM, however, the total fraction of
bound Pt-20 DNA increased to approximately 0.9 due to the appearance of a second band of
lower mobility (data not shown). This species probably represented a second protein bound to
the probe, presumably in a nonspecific fashion. The binding data yielded a Kdapp) of 4 ±0.7 nM for
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the specific interaction between the hSRY-HMG domain and the Pt-20 probe (Figure 13B).
Thus, the hSRY-HMG domain exhibited very high affinity for the 1,2-d(GpG) cisplatin adduct
compared to the full-length hSRY protein (Kapp) = 120 nM). This difference may in part be a
consequence of the small size of the DNA probe. In support of this view, the affinity of hSRY
was higher for the 1,2-d(GpG) cross-link contained within a larger 100 bp probe (vide infra).
In contrast with my data on the hSRY-HMG domain, Dr. C.S. Chow of the Lippard
laboratory has reported a Kd(app) of 500 nM for the binding of HMG1 -domain B to the Pt-20 probe
(Chow et al., 1995). This Kd(app, was determined under different assay conditions, however. Most
significantly, Dr. Chow's binding reactions included 10 mM MgCl2 and 0.05% NP-40, while my
reactions did not. In order to determine whether the difference in affinity of these proteins for a
cisplatin adduct was a consequence of the different assay conditions, the binding of the hSRY-
HMG domain and HMG1-domain B (kindly provided by S.U. Dunham and S.J. Lippard) to the
Pt-20 probe was examined under both sets of conditions (data not shown). Significantly, the
hSRY-HMG domain and HMGl-domain B bound with similar affinity to the Pt-20 probe under
Dr. Chow's assay conditions (Kd(app) - 500 nM). Surprisingly, the conditions optimized for the
hSRY-HMG domain binding to the Pt-20 probe resulted in poor binding of HMG1 -domain B to
the same probe, for reasons that are not completely known. It is interestingly to note, however,
that a greater than 6-fold increase in binding of the hSRY-HMG domain to the Pt-20 probe was
demonstrated in earlier experiments when the MgCl2 was removed from Dr. Chow's binding
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buffer (data not shown).3 The differing effects of MgCl2 on Pt-20 DNA binding by the hSRY-
HMG domain and HMG1-domain B were unexpected since both of these proteins are highly basic
with calculated isoelectric points above 10.
5. hSRY-HMG domain/SRY-20 interaction
Saturation binding experiments with the SRY-20 probe indicated that the hSRY-HMG
domain bound to the AACAAAG sequence with a Kapp) of 3 +0.4 nM (Figure 13C, D), a value
lower than the 20 nM reported previously for this sequence (Pontiggia et al., 1994). Note,
however, that the flanking base pairs differed in the previous work. These results demonstrated
that the hSRY-HMG domain interacted with the SRY-20 probe with a slightly higher affinity than
that of full-length hSRY (Kd(ap) = 15 nM). Additionally, the hSRY-HMG domain recognized
SRY-20 and Pt-20 (Kp~p) = 4 nM) with almost equal affinities. Taken together, the binding data
from titration experiments with full-length hSRY and the hSRY-HMG domain (summarized in
Table 3) indicated that human SRY bound to a cisplatin adduct and the target sequence
AACAAAG with comparable affinities. This view is further supported by competition binding
experiments (vide infra).
During the course of these binding experiments, it was discovered that when the hSRY-
HMG domain was diluted into its storage buffer (20 mM Hepes-NaOH, pH 7.9, 10 mM NaCl, 1
3No significant difference in binding was observed when NP-40 was removed from the
binding buffer.
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mM EDTA, 0.5 mM DTT, 5% glycerol) and stored on ice prior to DNA binding assays, the
protein exhibited a decreased DNA binding activity. In particular, storage of dilutions on ice for 2
hr reduced the overall DNA binding activity by approximately 2-3-fold (data not shown). Time-
course studies indicated that the loss in protein activity followed a first-order exponential decay
process (data not shown). Protein inactivation by aggregation or tube surface adsorption was
believed to be responsible for this decrease in binding activity. In order to minimize inactivation
of the hSRY-HMG domain, BSA was added to the protein dilution buffer at a concentration of
100 p.g/ml and the NaCl concentration was increased. Also, presiliconized eppendorf tubes and
pipet tips were used in all experiments. These steps, however, failed to prevent protein
inactivation. Significantly, the loss of binding activity was found to be minimal (less than 1.5-fold)
when the protein dilutions were made immediately before each experiment. In particular, the
identical protein dilutions were prepared and added to binding reactions containing Pt-20 or SRY-
20 DNA probes in order to ensure that the activity state of the protein was very similar in all
experiments. Thus, I am confident that the K(app) values obtained for the interactions of the
hSRY-HMG domain with the Pt-20 and SRY-20 probes are directly comparable. A slight
decrease in binding activity (less than 1.5-fold) was also observed for the full-length hSRY protein
at concentrations of less than 20 nM (data not shown). Therefore, binding experiments with full-
length hSRY were performed as described above for the hSRY-HMG domain. Subsequently, it
was discovered that inactivation of the hSRY-HMG domain could be prevented by the addition of
0.05% NP-40 to the protein dilution buffer. It was, therefore, of interest to determine the Kdapp)
of the interaction of the hSRY-HMG domain with the Pt-20 or SRY-20 probes in the presence of
NP-40. Data from one titration experiment indicated that the hSRY-HMG domain bound to the
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Pt-20 probe with a Kd) between 0.1 nM and 0.5 nM (data not shown). Thus, the addition of
NP-40 increased the affinity approximately 10-fold, as reported for other protein-nucleic acid
interactions (Brown et al., 1990; Batey and Williamson, 1996). This overall increase in affinity
may reflect both the enhanced activity of the hSRY-HMG domain and an increased affinity of the
protein for the Pt-20 probe in the presence of NP-40.
G. Full-length hSRY demonstrates higher DNA binding selectivity compared to its HMG
domain alone.
To determine the DNA binding specificities of full-length hSRY and the hSRY-HMG
domain, saturation binding experiments with negative control probes Un-20 and Mut-20 were
initially performed. As shown in Figure 9, Un-20 is the analogous unmodified control for Pt-20,
and Mut-20 has AACAAAG in SRY-20 replaced with CCGCGGT, a sequence shown previously
to be a poor binding site for hSRY (Harley et al., 1992). Titration of full-length hSRY into
binding reactions containing a constant amount of the Un-20 probe produced multiple bound
species, probably representing proteins bound to multiple sites on the DNA, presumably in a
nonspecific manner (Figure 14A). A plot of the fraction of bound Un-20 DNA as a function of
the log of hSRY concentration demonstrated a very sharp transition, consistent with nonspecific
binding (Figure 14B). A sharp binding transition was also observed when the hSRY-HMG
domain was titrated into reactions containing Un-20 (Figure 15). Experiments with Mut-20 DNA
yielded similar results as Un-20 (data not shown). Apparent dissociation constants could not be
determined with confidence from these titration experiments. Therefore, competition assays were
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performed to assess better the relative binding affinities of hSRY and the hSRY-HMG domain for
the negative control probes Un-20 and Mut-20 compared to the specific probes Pt-20 and SRY-
20.
To determine the DNA binding specificity of full-length hSRY, unlabeled competitor
DNAs Pt-20, SRY-20, Un-20 and Mut-20 were titrated into binding reactions containing constant
amounts of full-length hSRY and 32P-labeled Pt-20 probe. A plot of a representative set of
experiments is shown in Figure 16. These data were fit to a competitive binding equation (Eq. 1
in III. Materials and Methods) (Lin and Riggs, 1972; Long and Crothers, 1995) by nonlinear least
squares analysis to determine the apparent dissociation constants for competitor DNAs. The
equation yielded apparent dissociation constants of 115 ±20 nM and 50 ±10 nM for the Pt-20 and
SRY-20 DNAs, respectively (Table 3). These results were in reasonable agreement with titration
experiments (Figure 12) and demonstrated that full-length hSRY recognized a cisplatin adduct
and the sequence AACAAAG with comparable affinities. In contrast to the specific probes Pt-20
and SRY-20, the Un-20 and Mut-20 DNAs competed poorly for hSRY binding with apparent
dissociation constants of 2000 +350 nM and 3000 ±500 nM, respectively. A comparison of
hSRY affinity for Pt-20 and Un-20 DNAs yielded a reasonably high specificity of 20-fold, while
the preference of full-length hSRY for a specific target sequence (SRY-20) over a nonspecific
(mutated) sequence (Mut-20) was 60-fold (summarized in Table 3). Similar data as Figure 16
resulted from two other independent sets of competition experiments with hSRY.
The binding specificity of the hSRY-HMG domain was also investigated by competition
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assays. Unlabeled competitor DNAs were incubated with the hSRY-HMG domain and 32P-
labeled Pt-20 probe in binding reactions. One set of experiments is plotted in Figure 17.
Attempts were made to fit the data to the competitive binding equation (Eq. 1). However, a poor
fit was obtained when the 5 nM hSRY-HMG domain concentration used in the binding reactions
was applied to the equation. A better fit of the data resulted when a lower protein concentration
(0.5-1 nM) was applied to the equation, yielding apparent dissociation constants of 0.5-1 nM for
the binding of the hSRY-HMG domain to the Pt-20 or SRY-20 probes. These results suggested
that the active fraction of protein was less than 100%. Stoichiometry experiments had also
suggested that if the hSRY-HMG domain was binding to DNA as a monomer, it was less than
100% active (vide supra). In addition, at low hSRY-HMG domain concentrations, a reduction in
DNA binding activity was observed due to protein aggregation and/or tube surface adsorption;
this effect was determined to be less than 1.5-fold under the conditions employed in the binding
experiments (vide supra). Due to the poor fit of the data to the competitive binding equation,
apparent dissociation constants could not be determined with confidence. Therefore, relative
DNA binding affinities were approximated by comparing the concentrations of competitor DNAs
required to reduce Pt-20 binding by 50%. This method indicated that the hSRY-HMG domain
recognized the Pt-20 and SRY-20 DNAs with very similar affinities, in agreement with titration
experiments (Figure 13). The hSRY-HMG domain, however, exhibited an overall lower DNA
binding specificity than full-length hSRY (summarized in Table 3). In particular, the hSRY-HMG
domain displayed only a 5-fold preference for Pt-20 over Un-20 DNA. Additionally, the
selectivity of the hSRY-HMG domain for SRY-20 over Mut-20 was 20-fold, in reasonable
agreement with a 20-50-fold preference reported by Bianchi and colleagues (Ferrari et al., 1992).
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A second set of competition experiments with the hSRY-HMG domain confirmed the data in
Figure 17.
H. Interactions of full-length hSRY and the hSRY-HMG domain with 100 bp DNA probes
To test whether the affinity and specificity exhibited by full-length hSRY and the hSRY-
HMG domain were affected by the length of the DNA, the following 100 bp DNA probes were
constructed: Pt-100 containing a single, centrally located 1,2-d(GpG) cisplatin cross-link, Un-
100, the analogous unmodified control for Pt-100, and SRY-100 containing a centrally located
AACAAAG sequence. Figure 18 shows the binding of full-length hSRY and the hSRY-HMG
domain to these DNAs at protein concentrations of 20 nM and 5 nM, respectively. Saturation
binding experiments (not shown) were performed to determine the affinity of full-length hSRY
and the hSRY-HMG domain for the Pt-100 and SRY-100 probes. However, titrations with full-
length hSRY were complicated by the binding of multiple proteins to these probes at protein
concentrations above 20 nM, precluding the ability to determine specific apparent dissociation
constants. It is believed that the multiple protein/DNA complexes may have resulted from the
recognition by hSRY of several partial target sites present within the sequences flanking the
central oligonucleotide in these probes. DNAs containing the 1,2-d(GpG) cisplatin adduct or the
AACAAAG site with different flanking sequences may be useful in future studies. For this
dissertation, the relative affinities of hSRY for the Pt-100 and SRY- 100 DNAs compared to the
20 bp probes were estimated by comparing the fraction of total probe bound at protein
concentrations of 0.5-20 nM. At these hSRY concentrations, a single species predominated,
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presumably corresponding to a 1:1 specific protein/100 bp DNA complex. By this method, full-
length hSRY was found to bind to the Pt-100 probe with an approximately 3-fold higher affinity
(Kay)~ 40 nM) than to Pt-20. Likewise, hSRY appeared to recognize the SRY-100 probe with
a 2-fold increased affinity (Kda) - 8nM) compared to SRY-20, suggesting that the longer DNA
probe may be better able to accomodate the full-length protein (summarized in Table 3).
In contrast with full-length hSRY, the hSRY-HMG domain interacted with the Pt-100 and
SRY-100 probes to form predominantly a single complex that increased to saturation (Figure 18).
In titration experiments, half-maximal binding occurred at hSRY-HMG domain concentrations of
4 ±1 nM and 3 ±0.7 nM for the Pt-100 and SRY-100 probes, respectively. These apparent
dissociation constants were identical to those obtained for the 20 bp probes (summarized in Table
3). Competition assays indicated that the selectivity of the hSRY-HMG domain for Pt-100 over
Un-100 DNA was approximately 5-fold, a preference similar to that for the 20 bp DNAs (Table
3).
The sequence AACAATG has been reported to be a better target site for full-length hSRY
(Harley et al., 1994) and the hSRY-HMG domain (Giese et al., 1994; Pontiggia et al., 1994) than
AACAAAG. Therefore, a 100 bp DNA probe containing a centrally located AACAATG
sequence (TCR-100) was constructed and used in titration experiments with hSRY and the
hSRY-HMG domain (summarized in Table 3). In agreement with the earlier reports, full-length
hSRY bound to TCR-100 with an approximately 2-fold higher affinity (Kdapp) - 4 nM) than to
SRY-100. However, the hSRY-HMG domain bound to the TCR-100 (Kdapp) = 3 ±0.4 nM) and
131
SRY-100 (K(v, = 3 ±0.7 nM) DNAs with equal affinities. Significantly, the TCR-100 DNA
probe was recognized with very similar affinities by full-length hSRY and the hSRY-HMG
domain.
I. The hSRY-HMG domain specifically inhibits repair of the 1,2-d(GpG) cisplatin adduct
in vitro.
We have proposed that HMG-domain proteins may modulate cisplatin cytotoxicity by
shielding cisplatin-DNA lesions from the cellular repair machinery (Donahue et al., 1990; Brown
et al., 1993; McA'Nulty and Lippard, 1996). Indeed, several HMG-domain proteins have been
shown to inhibit repair of the 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-links, but not the 1,3-
d(GpTpG) intrastrand adducts (Huang et al., 1994; Zamble et al., 1996). In these studies, an in
vitro excision repair assay was employed in which incubation of site-specifically platinated DNA
substrates with HeLa cell-free extract released the adducts in 27-29 nucleotide fragments. To
investigate the ability of human SRY to influence the repair of cisplatin-DNA adducts, excision
repair assays were carried out by D.B. Zamble of the Lippard laboratory in which 156 bp DNA
substrates containing site-specific 1,2-d(GpG) or 1,3-d(GpTpG) intrastrand cross-links were
preincubated with the hSRY-HMG domain before addition of the HeLa cell-free extract. As
shown in Figure 19, repair of the 1,2-d(GpG) adduct was inhibited with increasing concentrations
of the hSRY-HMG domain (0.1-0.5 pM). In contrast, repair of the 1,3-d(GpTpG) adduct was
modestly stimulated at protein concentrations up to 0.3 [pM, perhaps by protein-induced bending
of the DNA substrate (Ferrari et al., 1992; Pontiggia et al., 1994; Giese et al., 1994; Werner et al.,
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1995), and then repair was inhibited at higher protein concentrations. These repair inhibition
assays were performed several times and, consistently, repair of the 1,2-d(GpG) adduct was
blocked by the hSRY-HMG domain at concentrations of 0.1-0.3 WM, whereas repair of the 1,3-
d(GpTpG) adduct was not inhibited at these protein concentrations. Electrophoretic mobility
shift experiments performed by D.B. Zamble under the preincubation conditions of the in vitro
repair assay (data not shown) indicated that at concentrations of 0.06-0.25 itM, the hSRY-HMG
domain exhibited an approximately 2-3-fold increased affinity for the 1,2-cross-linked substrate
compared to the 1,3-cross-linked probe or to an unmodified probe, suggesting that repair
inhibition was probably caused by specific binding of the hSRY-HMG domain to the 1,2-d(GpG)
adduct. Excision repair assays were also performed with the full-length hSRY protein,
demonstrating that repair of the 1,2-d(GpG) adduct was specifically inhibited at a concentration
of full-length hSRY similar to that of the hSRY-HMG domain (data not shown).
J. Southwestern and Western analyses of NTera2.D1 testicular tumor cell extracts
In previous studies, Southwestern analyses of HeLa cell extracts revealed cisplatin-DNA
binding species of 97, 94, and 28 kDa (Toney et al., 1989; Treiber et al., 1994), which were
identified as hUBF (97/94 kDa) (Treiber et al., 1994) and HMG1/2 (28 kDa) (Pil and Lippard,
1992). In light of the selectivity of cisplatin for testicular tumors, it was of interest to determine
the cisplatin-DNA binding proteins in testicular tumor cells and, in particular, to determine
whether the testis-specific HMG-domain protein human SRY was present. The human testicular
tumor cell line NTera2.D1, a cloned embryonal carcinoma line derived from the teratocarcinoma
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line Tera2 (Andrews et al., 1984), was chosen for these experiments. Previous studies have
shown that the NTera2.D 1 line is extremely sensitive to the cytotoxic effects of cisplatin (Meijer
et al., 1992; Timmer-Bosscha et al., 1993) and is deficient in the removal of cisplatin-DNA
adducts (Sark et al., 1995). Work by Goodfellow and colleagues had indicated that human SRY
was present at the RNA level in the NTera2.D 1 cells (Clepet et al., 1993). Southwestern analysis
ofNTera2.D1 whole-cell and nuclear extracts (Figure 20) revealed bands of 97/94 kDa and 28/26
kDa corresponding to the molecular weights of hUBF and HMG1/2, respectively, on the blot
probed with cisplatin-modified DNA (left panel, lanes 2-4), but not with unmodified DNA (right
panel, lanes 2-4). Lower levels of the 97/94 kDa bands in nuclear extracts (lane 3) compared to
whole-cell extracts (lanes 2, 4) have been seen previously in HeLa cells (Dr. X.Q. Zhai,
unpublished results). In contrast, no bands corresponding to the molecular weight of hSRY (24
kDa) were detected in the NTera2.D1 extracts. As a positive control, purified hSRY was run in
lane 5 of each blot. On a longer film exposure, hSRY (lane 5) was visible as a band below
HMG1/2 in the blot probed with cisplatin-DNA (data not shown). The hSRY sample used here
had been purified by preparative SDS/PAGE with Coomassie blue staining and electroelution in
the presence of SDS and thus may have irreversibly lost some of its DNA binding activity. Full-
length hSRY as a GST-fusion protein had been shown previously to bind to cisplatin-modified
DNA on a Southwestern blot (Figure 7). The results from Southwestern experiments indicated
that within the detection limit of the assay, hSRY was not detected in the extracts from the
NTera2.D 1 testicular tumor cell line. Furthermore, the major cisplatin-DNA binding proteins
present in these testicular tumor cells had molecular weights corresponding to hUBF and
HMG1/2.
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In parallel with Southwestern analysis, Western blotting with hSRY polyclonal antisera
was carried out in an effort to detect hSRY protein in the NTera2.D1 extracts (Figure 21).
Purified hSRY, run as a positive control, was clearly visible in lane 5 of the filter probed with
hSRY antiserum (right panel), but not on the filter probed with preimmune serum (left panel).
Very faint bands of molecular weight similar to hSRY were present in the whole-cell NTera2.D 1
extracts (lanes 2, 4) on the blot probed with hSRY antiserum. However, these bands were
equally or less intense than various cross-reacting species. Western analyses were performed with
hSRY polyclonal antisera from four different rabbits and with NTera2.D1 extracts prepared from
a variety of procedures (data not shown). The four antisera demonstrated different patterns of
cross-reactivity to proteins in the NTera2.D1 extracts, but a band corresponding to hSRY was
never consistently detected in any of the extracts above the background of cross-reacting bands.
Using a concentration of 233 pg of total protein per NTera2.D1 cell (Sark et al., 1995) and a
hSRY detection limit of 1 ng in the Western analysis (vide supra), one can calculate that hSRY
was present in the NTera2.D1 cells at a concentration of less than 105 molecules/cell. Because of
the difficulties in maintaining the NTera2.D1 cells as a pure population of undifferentiated
embryonal carcinoma cells (Andrews et al., 1984) and the demonstration that chemical-induced
differentiation of these cells can result in a reduction in hSRY RNA (Clepet et al., 1993),
Northern analysis should be performed in order to determine whether hSRY was present at the
RNA level in the NTera2.D 1 cells used in the Western experiments.
Subsequent to the work described above, Berta and coworkers demonstrated the presence
of hSRY protein in NTera2.D1 nuclear extracts by Western blotting (Poulat et al., 1995). In
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contrast with my Western analysis procedure, the NTera2.D1 nuclear extracts used by Berta and
colleagues were prepared by a sonication lysis method in SDS/PAGE sample buffer and the
Western blots were probed with a purified hSRY polyclonal antiserum raised against an hSRY
peptide sequence so as to minimize cross-reactivity. Interestingly, these workers commented in
their paper that hSRY was very difficult to detect in whole-cell extracts on Western blots, a result
they attributed to the low overall quantity ofhSRY present in the NTera2.D1 cells. Significantly,
they demonstrated by immunofluorescence that hSRY was localized in the nuclei of these cells.
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Figure 7: Southwestern analysis of GST/hSRY and GST/hSRY-HMG domain proteins.
GST/hSRY (lane 2, 1.5 pg), GST/hSRY-HMG domain (lanes 3 and 4, 1 jpg), and GST (lane 5, 1
pg) were resolved on a 10% SDS/polyacrylamide gel and transferred to nitrocellulose. The blots
were probed with 32P-labeled 272 bp DNA fragments unmodified (right panel) or modified with
cisplatin to an rb of 0.058 (left panel). Lane 1 of each blot contains molecular weight markers
(M).
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Figure 8: Analysis of purified full-length hSRY and the hSRY-HMG domain by Coomassie blue-
stained SDS/PAGE and Western blotting. (A) Purified full-length hSRY protein (2 gpg, lane 1;
0.4 jtg, lane 2) was resolved on a 15% SDS-polyacrylamide gel. Coomassie blue staining (lane 1)
and Western blot analysis using hSRY polyclonal antiserum at a 1:50,000 dilution (lane 2)
demonstrated that the protein was homogeneous. Comparison with molecular weight standards
indicated that hSRY had an apparent molecular weight of 24 kDa. (B) Purified hSRY-HMG
domain protein (2 jtg, lane 1; 1 jtg, lane 2) was resolved on a 16.5% Tricine-SDS polyacrylamide
gel. Coomassie blue staining (lane 1) and Western blot analysis using hSRY polyclonal antiserum
at a 1:5000 dilution (lane 2) demonstrated that the protein was homogeneous. The hSRY-HMG
domain had an apparent molecular weight of 11 kDa.
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Figure 9: Sequences of the 20 bp DNA probes used in binding studies. Pt-20 contains a single
1,2-d(GpG) intrastrand cross-link of cisplatin. Un-20 is the analogous unmodified control of Pt-
20. SRY-20 and Mut-20 contain the sequences AACAAAG and CCGCGGT, respectively, with
the same flanking sequences as Pt-20.
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TCTCCTTCTGGTCTCTTCTC
AGAGGAAGACCAGAGAAGAG
Pt-20 TCTCCTTCTGGTCTCTTCTC
AGAGGAAGACCAGAGAAGAG
SRY-20 TCTCCTTCTTTGTTCTTCTC
AGAGGAAGAAACAAGAAGAG
Mut-20 TCTCCTTACCGCGGCTTCTC
AGAGGAATGGCGCCGAAGAG
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Figure 10: Full-length hSRY and the hSRY-HMG domain bind to the major DNA adduct of
cisplatin. The radiolabeled 20 bp DNA probes Pt-20 containing a single 1,2-d(GpG) intrastrand
cross-link (lanes 2, 4, 6) and its unmodified control Un-20 (lanes 1, 3, 5) were incubated with no
protein (lanes 1, 2), 5 nM hSRY-HMG domain (lanes 3, 4) or 50 nM full-length hSRY (lanes 5,
6). Lanes 1-4, 5, and 6 are from three separate electrophoretic runs.
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Figure 11: Stoichiometry of the hSRY/Pt-20 interaction. (A) Titration of full-length hSRY (300-
3000 nM) into binding reactions containing 0.1 nM 32 P-labeled Pt-20 probe (5000 cpm) and 1200
nM unlabeled Pt-20 DNA. Lane 1 contains Pt-20 DNA in the absence of protein. (B) The
fraction of bound Pt-20 DNA in each lane from A was plotted as a function of the ratio of
[hSRY]/[Pt-20]. Saturation of the DNA occurred at a [hSRY]/[Pt-20] ratio of 1.2:1, suggesting
that hSRY bound to the Pt-20 probe as a monomer.
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Figure 12: Interactions of full-length hSRY with Pt-20 and SRY-20 probes. (A) Full-length
hSRY (1-1500 nM) was titrated into binding reactions containing 0.1 nM (5000 cpm) 32P-labeled
Pt-20 probe. Lane 1 contains Pt-20 probe in the absence of protein. (B) The fraction of bound
Pt-20 DNA in each lane from A was plotted as a function of the log of hSRY concentration. The
protein concentration giving half-maximal binding (K(app)) is indicated by the broken line. The
binding data yielded a K(app) of 120 ±10 nM. (C) Full-length hSRY (0.5-1000 nM) was titrated
into binding reactions containing 0.1 nM (5000 cpm) 32 P-labeled SRY-20 probe. SRY-20 probe
in the absence of protein is shown in lane 1. (D) The fraction of bound SRY-20 probe was
determined in each lane from C and is presented as a function of the log of protein concentration.
The data yielded a Kgdap) of 15 ±3 nM.
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Figure 13: Interactions of the hSRY-HMG domain with Pt-20 and SRY-20 probes. (A) Titration
of the hSRY-HMG domain (0.1-100 nM) into binding reactions containing 0.1 nM (5000 cpm)
32P-labeled Pt-20 probe. (B) Plot of the data from A. The protein concentration giving half-
maximal binding (K)app() is indicated by the broken line. The binding data yielded a Kd(app) of 4
±0.7 nM. (C) Titration of the hSRY-HMG domain (0.05-20 nM) into binding reactions
containing 0.1 nM (5000 cpm) 32P-labeled SRY-20 probe. (D) Plot of the data from C. The data
yielded a Kapp) of 3 ±0.4 nrM.
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Figure 14: Interaction of full-length hSRY with Un-20 probe. (A) Full-length hSRY (10-1500
nM) was titrated into binding reactions containing 0.1 nM (5000 cpm) 32P-labeled Un-20 probe.
Lane 1 contains Un-20 probe in the absence of protein. (B) Plot of the data from A.
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Figure 15: Interaction of the hSRY-HMG domain with Un-20 probe. (A) Titration of the hSRY-
HMG domain (1-1000 nM) into binding reactions containing 0.1 nM (5000 cpm) 32P-labeled Un-
20 probe. Lane 1 contains Un-20 probe in the absence of protein. (B) Plot of the data from A.
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Figure 16: Specificity of DNA binding by full-length hSRY determined by competitive binding
experiments. Unlabeled competitor DNAs Pt-20, Un-20, SRY-20, Mut-20 were titrated into
binding reactions containing 200 nM hSRY and 0.1 nM (5000 cpm) 32P-labeled Pt-20 probe.
Data from one set of experiments are plotted as the fraction of bound radiolabeled Pt-20 probe
versus the concentration of unlabeled competitor DNA. 0, SRY-20; *, Pt-20; A, Un-20; 0,
Mut-20.
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Figure 17: Specificity of DNA binding by the hSRY-HMG domain. Unlabeled competitor DNAs
Pt-20, Un-20, SRY-20, Mut-20 were titrated into binding reactions containing 5 nM hSRY-HMG
domain and 0.1 nM (5000 cpm) radiolabeled Pt-20 probe. A plot of one set of experiments is
shown. 0, SRY-20; *, Pt-20; A, Un-20; O, Mut-20.
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Figure 18: Binding of full-length hSRY and the hSRY-HMG domain to 100 bp DNA probes.
The radiolabeled 100 bp DNA probes Pt-100 containing a single 1,2-d(GpG) intrastrand cross-
link (lanes 2, 5, 8), its unmodified control Un-100 (lanes 1, 4, 7), and SRY-100 containing the
sequence AACAAAG at its center (lanes 3, 6, 9) were incubated with no protein (lanes 1, 2, 3), 5
nM hSRY-HMG domain (lanes 4, 5, 6) or 20 nM full-length hSRY (lanes 7, 8, 9).
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Table 3: DNA Binding Affinities and Specificities of hSRY and the hSRY-HMG Domain
hSRY hSRY-HMG Domain
DNA Probes Kd(app) Specificityb  Kd(app) Specificityb
Pt-20 120a", 115 nMb 20-foldc 4 nMa 5-foldc
SRY-20 15 ", 50 nMb 60-foldd 3 nM" 20-foldd
Pt-100 -40 nM" n.d! 4 nMa 5-folde
SRY-100 -8 nMa n.d! 3 nMa n.d!
TCR-100 -4 nM a  n.d! 3 nMa n.d!
a Determined by titration. b Determined by competition assays. c Preference for Pt-20 over
Un-20. dPreference for SRY-20 over Mut-20. e Preference for Pt-100 over Un-100. f Not
determined.
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Figure 19: Effect of the hSRY-HMG domain on excision repair of the 1,2-d(GpG) and 1,3-
d(GpTpG) cisplatin intrastrand cross-links in vitro. The 1,2-d(GpG) (0) and the 1,3-d(GpTpG)
(0) cross-linked 156 bp substrates were incubated with the hSRY-HMG domain (0.05-0.5 PLM)
for 10 min at 30 TC before addition of the HeLa cell-free extract and further incubation for 50
min. The level of repair in the absence of the hSRY-HMG domain is designated 100%. The
percent of excision repair is plotted as a function of the concentration of the hSRY-HMG domain
present in the repair reactions. Data points are averages of two or three experiments. Error bars
represent ±1 esd. Experiments were performed by D.B. Zamble of the Lippard laboratory.
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Figure 20: Southwestern analysis ofNTera2.D1 testicular tumor cell extracts. NTera2.D1 whole
(W) cell (lanes 2 and 4, 100 tg ) or nuclear (N) extract (lane 3, 100 [tg) and hSRY (lane 5, -1
jtg) were resolved on a 5-15% gradient SDS/polyacrylamide gel and transferred to nitrocellulose.
The blots were probed with 32P-labeled 272 bp DNA fragments unmodified (right panel) or
modified with cisplatin to an rb of 0.043 (left panel). Lane 1 of each blot contains molecular
weight markers (M).
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Figure 21: Western analysis ofNTera2.D1 testicular tumor cell extracts. NTera2.D1 whole (W)
cell (lanes 2 and 4, 100 tg ) or nuclear (N) extract (lane 3, 100 jtg) and hSRY (lane 5, -1 Pg)
were resolved on a 5-15% gradient SDS/polyacrylamide gel and transferred to an Immune-Lite
membrane (Bio-Rad). The blots were probed with preimmune serum (left panel) or hSRY
polyclonal antiserum (right panel) at a dilution of 1:500. Lane 1 of each blot contains molecular
weight markers (M).
166
Preimmune Serum
M
I W
NTera2.D1 hSRY
N W I
M
hSRY Antiserum
NTera2,D1
IW W
4
kDa
200
97
69
46
30
21.5
14.3
Probe
Protein hSRY
.···-~y·3 -Y·u,
'1i~a
·Y:
•, IpI ,i,ll,
V. DISCUSSION
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A. Human SRY binds to the major 1,2-d(GpG) adduct of cisplatin with high affinity and
specificity.
Specific binding of human SRY, a testis-specific protein containing a single HMG domain,
to the major DNA adduct of cisplatin has been demonstrated. Full-length hSRY bound to a 20 bp
DNA probe containing a single 1,2-d(GpG) cisplatin intrastrand cross-link (Pt-20) with a Kd(,P) of
115-120 nM (Figure 12A, B; Figure 16; Table 3). This affinity was increased approximately 3-
fold for a cisplatin adduct contained within a 100 bp probe (Pt-100) (Table 3), suggesting that the
longer probe may be better able to accomodate the full-length protein. Competition experiments
indicated that the preference of full-length hSRY for Pt-20 over Un-20, the unmodified control
probe was 20-fold (Figure 16; Table 3). The affinity and specificity of full-length hSRY for a
cisplatin-DNA adduct are similar to that reported previously for other members of the HMG-
domain protein family (see Table 2 in II. Literature Survey). High mobility group protein HMG1,
mitochondrial transcription factor mtTFA, and intrastrand cross-link recognition protein Ixrl,
proteins containing two HMG domains, have also been shown to bind to the 1,2-d(GpG)
intrastrand adduct with a Kd(app) on the order of 10" M (Pil and Lippard, 1992; Chow et al., 1994;
McA'Nulty et al., 1996). A significantly higher affinity for a cisplatin adduct (Kd(,p) = 60 pM) is
exhibited by human upstream binding factor hUBF, which contains six HMG domains (Treiber et
al., 1994). Full-length hSRY, hUBF (Treiber et al., 1994), and Ixrl (McArNulty et al., 1996)
display a similar selectivity for platinated DNA over unmodified DNA (10-30-fold) , whereas a
preference of 100-fold has been reported for HMG1 (Pil and Lippard, 1992).
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The HMG domain ofhSRY was sufficient for cisplatin-DNA recognition. The hSRY-
HMG domain bound to a single 1,2-d(GpG) cisplatin adduct contained within a 20 bp (Pt-20) or a
100 bp DNA probe (Pt-100) with a Kapp) of 4 nM (Figure 13A, B; Table 3). In contrast, single
HMG domains from HMG1 (domain B), LEF-1 (lymphocyte enhancer-binding factor 1), and
murine (m) SRY have been shown to bind to a similar 92 bp DNA probe containing the 1,2-
d(GpG) intrastrand cross-link with apparent dissociation constants of 10-7 M, 10-7 M, and 106 M,
respectively (Chow et al., 1994; Chow et al., 1995). Note, however, that the binding affinities
were determined under different assay conditions. Moreover, distinct DNA binding properties of
the mSRY- and hSRY-HMG domains have been described previously (Giese et al., 1994).
Competition experiments indicated that the hSRY-HMG domain exhibited a 5-fold selectivity for
platinated DNA over unmodified DNA (Figure 17; Table 3). Similarly, a specificity of 4-10-fold
has been reported for HMG1-domain B, and the HMG domains of LEF-1 and mSRY (Chow et
al., 1994; Chow et al., 1995).
A very recent study has demonstrated that the affinities of HMG1-domain A and HMG1-
domain B for a 1,2-d(GpG) cisplatin adduct varied depending on the identity of the base pairs
flanking the adduct (Dunham and Lippard, manuscript submitted). In particular, HMG1-domain
A demonstrated a preference of dA > dT > dC as the base 3' to the platinated d(GpG) site (a 3'
dG was not examined). In this regard, it is noteworthy that the Pt-20 and Pt-100 probes used in
the present study contained the central sequence 5'-TG*G*T-3', where the asterisks denote the
cisplatin intrastrand cross-link. In contrast, the platinated 92 bp probe used by Chow et al.
contained 5'-AG*G*C-3'. It is not yet known whether cisplatin-adduct binding by hSRY displays
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a sequence dependence.
B. Human SRY binds to a cisplatin adduct and a putative target sequence with
comparable affinities.
The binding of full-length hSRY and the hSRY-HMG domain to a putative DNA target
sequence was also examined under the identical conditions used for cisplatin-adduct binding. The
sequence AACAAAG from the CD3e gene enhancer has been identified previously as a preferred
binding site for human SRY (Harley et al., 1992; Ferrari et al., 1992). Full-length hSRY bound to
a 20 bp probe containing this sequence (SRY-20) with a Kdapp) of 15-50 nM (Figure 12C, D;
Figure 16; Table 3), whereas the hSRY-HMG domain bound to the same probe with a Kd(ap) of 3
nM (Figure 13C, D; Table 3). Competition experiments demonstrated that the preference for a
specific sequence (SRY-20) over a nonspecific sequence (Mut-20) was 60-fold and 20-fold for
hSRY and the hSRY-HMG domain, respectively. These data are in reasonable agreement with an
estimated 20-50-fold selectivity for the hSRY-HMG domain reported by Bianchi and colleagues
(Ferrari et al., 1992). Similarly, LEF-1 has been reported to bind to its target sequence with a
specificity of 20-40-fold (Giese et al., 1991). The relatively modest DNA binding selectivity
exhibited by hSRY and LEF-1 seems at variance with the function of these proteins as sequence-
specific transcriptional regulators. However, nonspecific binding may actually facilitate the linear
diffusion, or tracking, of these proteins to their specific target sites on the DNA. Such a model
has been suggested for how the prokaryotic DNA repair enzyme T4 Endo V locates damaged
sites on DNA (Nickell et al., 1992). Nonspecific interactions may also contribute to the high
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stability of the protein/DNA complex formed by hSRY and LEF- 1 with their target sites.
Taken together, the binding data from titration and competition experiments (summarized
in Table 3) demonstrated that the affinity of human SRY for the 1,2-d(GpG) cisplatin adduct was
comparable to that for the sequence AACAAAG. In studies complementary to ours, Bianchi and
colleagues have compared the binding of the hSRY-HMG domain to four-way junction DNAs
and specific DNA sequences (Ferrari et al., 1992; Pontiggia et al., 1994). They found that the
hSRY-HMG domain recognizes the four-way junction z (Kd(app) = 10 nM) and the sequence
AACAAAG (K(app) = 20 nM) with similar affinities (Pontiggia et al., 1994). Additionally, they
conclude from competition experiments that the hSRY-HMG domain exhibits a 'structure versus
sequence' selectivity of 4-100-fold, depending on the actual sequences present in the DNA
(Ferrari et al., 1992). Consistent with this view, the competitive binding data from Figures 16 and
17 indicated that the preference of full-length hSRY for a structure (Pt-20) over nonspecific
sequence (Un-20, Mut-20) was 20-fold, whereas the selectivity of the hSRY-HMG domain for
Pt-20 over Un-20 and Mut-20 DNAs was 5-fold and 13-fold, respectively.
C. Structural basis for the recognition of both structures and sequences by hSRY
Recent structural studies lend insight into the molecular basis for recognition of two
distinct targets by human SRY: intrinsically bent DNA structures (cisplatin adducts/four-way
junctions) and linear DNA sequences. The structural features of the 1,2-d(GpG) cisplatin
intrastrand cross-link are well established. Gel electrophoresis studies have demonstrated that the
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1,2-d(GpG) intrastrand adduct unwinds the DNA helix 130 (Bellon et al., 1991) and induces a
bend of 34-40 ° in the direction of the major groove (Rice et al., 1988; Bellon and Lippard, 1990).
A recent X-ray crystal structure of the 1,2-d(GpG) cross-link in duplex DNA (Takahara et al.,
1995; Takahara et al., 1996) has further revealed a hybrid DNA structure of A- and B-forms with
an expanded minor groove. Coordination of platinum to its guanine ligands destacks the bases,
and a considerable strain is generated by displacement of the platinum atom from the guanine ring
planes. It has been proposed that HMG-domain protein binding might relieve this strain, perhaps
by altering the DNA bend angle (Takahara et al., 1996). Indeed, gel electrophoresis studies have
revealed that the binding of the HMG-domain proteins HMG1, mtTFA, and Ixrl to the 1,2-
d(GpG) adduct can increase duplex bending to 70-90o (Chow et al., 1994). Four-way junction
DNA shares several structural features with the 1,2-d(GpG) cisplatin adduct, including sharp bend
angles, unstacked bases, and a widened minor groove at the crossover point of the junction
(Murchie et al., 1989; von Kitzing et al., 1990; Bhattacharyya et al., 1991).
A bent DNA structure is also induced by human SRY when it binds to specific sequences
in linear DNA. Circular permutation analyses have demonstrated that full-length hSRY and the
hSRY-HMG domain induce DNA bend angles of 830 and 760, respectively, upon binding to the
specific target sequence AACAAAG (Ferrari et al., 1992; Pontiggia et al., 1994). A recent NMR
solution structure of a complex between the hSRY-HMG domain and a specific DNA site
(GCACAAAC) in the Mullerian inhibitory substance gene promoter further revealed the severely
distorted nature of the bound DNA (Werner et al., 1995). In the complex, the DNA structure is
intermediate between the A- and B-forms, and the minor groove is significantly widened. The
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DNA is helically unwound and bent 70-80' toward the major groove owing to the partial
intercalation of an isoleucine residue between AT base pairs, as predicted in an earlier NMR study
(King and Weiss, 1993). The hSRY-HMG domain maintains an L-shaped structure within the
complex similar to that of the free HMG1-domain B (Weir et al., 1993; Read et al., 1993), and the
DNA conforms perfectly to the angular binding surface of the protein. The striking resemblance
between this distorted DNA conformation induced by the hSRY-HMG domain and the
intrinsically bent 1,2-d(GpG) adduct of cisplatin (Takahara et al., 1995; Takahara et al., 1996)
suggests a rationale for structure-specific recognition by human SRY. In particular, the 1,2-
d(GpG) adduct must attract hSRY by closely mimicing a stabilized DNA structure that occurs in
the specific hSRY/target DNA complex. Weiss and colleagues have shown that an isoleucine
intercalation also occurs when the hSRY-HMG domain binds to four-way junction DNA,
suggesting that the protein uses a single binding surface to interact with both specific sequences
and structures (Peters et al., 1995). The competitive binding of both full-length hSRY and the
hSRY-HMG domain to the sequence AACAAAG and the 1,2-d(GpG) cisplatin adduct (Figures 6
and 7) further supports this view.
D. Comparison of the DNA binding properties of full-length hSRY and the hSRY-HMG
domain
To date, no function has been attributed to the regions of human SRY outside the HMG
domain region and evidence suggests that the HMG domain may be the only functional part of the
protein (Goodfellow and Lovell-Badge, 1993). A comparison of SRY amino acid sequences from
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several mammalian species has revealed that the HMG domain is the only conserved region of the
protein and that the sequences outside of this region diverge completely (Whitfield et al., 1993;
Tucker and Lundrigan, 1993). In addition, the HMG domain alone has been shown to be
sufficient for binding to specific DNA sequences (Poulat et al., 1992; Ferrari et al., 1992; Haqq et
al., 1993; Pontiggia et al., 1994; Giese et al., 1994) and structures (Ferrari et al., 1992; Pontiggia
et al., 1994; Peters et al., 1995). Finally, nearly all mutations in hSRY associated with complete
gonadal dysgenesis in XY human females lie within the HMG domain region (Goodfellow and
Lovell-Badge, 1993) and recombinant proteins from these mutants have reduced DNA binding
activities (Harley et al., 1992; Pontiggia et al., 1994).
An objective of this study was to compare the DNA binding properties of full-length
hSRY and the hSRY-HMG domain under identical in vitro assay conditions. In agreement with
previous work, the HMG domain of hSRY was sufficient for both sequence- and structure-
specific DNA recognition. Results from titration experiments (Table 3) indicated that full-length
hSRY bound to a cisplatin adduct and the sequence AACAAAG with slightly lower affinity than
its HMG domain alone. These data suggest that the non-HMG domain regions of hSRY may
have a negative effect on DNA binding affinity, perhaps through a localized region of negative
charge. At pH 7.9 of the binding buffer, full-length hSRY and the hSRY-HMG domain have
calculated net charges of +12 and + 13, respectively. The results from competition studies
revealed that full-length hSRY displayed a higher DNA binding selectivity than the hSRY-HMG
domain (Figures 16 and 17; Table 3). Footprinting experiments have indicated that the hSRY-
HMG domain alone can mediate specific contacts in target DNA (Rimini et al., 1995; Haqq et al.,
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1993). The solution structure of a hSRY-HMG domain/DNA complex further demonstrates that
DNA binding occurs on the concave surface formed by helices one and three, and additional DNA
contacts are made by side chains from the N- and C-terminal regions (Werner et al., 1995). One
possible explanation for the increased DNA binding selectivity exhibited by full-length hSRY is
the generation of favorable DNA contacts by the regions of the protein just outside of the HMG
domain. In the solution structure, Arg-75, Pro-76, Arg-77, and Arg-78 at the far C-terminal end
of the hSRY-HMG domain are disordered in solution (Werner et al., 1995). The residues of
hSRY adjacent to this C-terminal region may help to anchor it to the DNA, resulting in additional
favorable interactions. Consistent with this view, a highly basic C-terminal region next to the
HMG domain of LEF-1 extends the DNA binding surface by making extensive contacts with the
sugar-phosphate backbone (Love et al., 1995). Full-length LEF-1 and the LEF-1-HMG domain
containing this basic C-terminal region exhibit very similar DNA binding properties in vitro
(Travis et al., 1991; Giese et al., 1991; Giese and Grosschedl, 1993). Residues adjacent to the N-
terminal region of the hSRY-HMG domain might also contact DNA in the full-length protein. In
a recent study (Kane and Lippard, 1996), photochemistry was used to cross-link a 15 bp
oligonucleotide containing a single, 1,2-d(GpG) cisplatin adduct to a single residue (Lys-6) in
HMG1-domain B. Since the platinum is bound to the N-7 guanine atoms in the major groove, the
formation of a platinum-protein cross-link suggests that the N-terminus of domain B contacts the
major groove of the DNA. A lysine residue (Lys-53, numbering according to (Whitfield et al.,
1993)) located just outside of the HMG domain of hSRY might interact with DNA in a similar
manner. Parallel footprinting studies employing full-length hSRY and the hSRY-HMG domain
need to be performed in order to identify any additional DNA contacts made by regions outside
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the HMG domain.
In addition to contributing to interactions with target DNA, the non-HMG domain regions
of hSRY may mediate contact with other DNA binding proteins. Indeed, recent studies indicate
that the function of LEF-1 in regulating gene expression is dependent on regions of the protein
outside the HMG domain. In particular, an activation domain in the amino-terminal end of LEF-1
is proposed to contribute to transcriptional regulation by interacting with other enhancer-bound
proteins (Giese and Grosschedl, 1993). Interestingly, SRY has been proposed to function in a
species-specific manner because gene transfer of the hSRY gene was unable to induce testis
formation in female transgenic mice (Koopman et al., 1991), suggesting that interactions with
species-specific regulatory factors may be needed for transcriptional regulation by hSRY. Indeed,
a cooperative interaction between the HMG domain protein hUBF and the species-selectivity
factor SL1 is required for regulation of ribosomal RNA synthesis (Bell et al., 1988; Jantzen et al.,
1992).
E. Models for the role of hSRY in the organotropic specificity of cisplatin for testicular
tumors
1. hSRY may shield cisplatin adducts from DNA repair enzymes.
In addition to providing an example of structure-specific DNA recognition, the selective
binding of human SRY to the major cisplatin-DNA adduct suggests a possible role for this testis-
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specific protein in the organotropic specificity of cisplatin for testicular tumors. Clinical
experience has indicated that testicular germ cell tumors are exquisitely sensitive to cisplatin-
based chemotherapy (Loehrer and Einhorn, 1984; Peckham, 1988; Einhorn, 1990). Interestingly,
cultured cell lines derived from these tumors retain higher sensitivity to cisplatin in vitro
compared to lines established from other tumor cell types (Walker et al., 1987; Bedford et al.,
1988; Hosking et al., 1990; Sark et al., 1995). In particular, testicular germ cell tumor cell lines
were found to be as sensitive to cisplatin as cell lines derived from patients with the DNA repair
disorders xeroderma pigmentosum (XP) and Fanconi's anemia (FA) (Pera et al., 1987),
suggesting that hypersensitivity may be related to a reduced capacity to repair cisplatin-induced
DNA damage. Indeed, several testicular tumor lines have demonstrated a defective ability to
remove DNA adducts of cisplatin (Bedford et al., 1988; Kelland et al., 1992a; Hill et al., 1994a;
Sark et al., 1995; Koberle et al., 1996).
One model proposed to explain how HMG-domain proteins may mediate cytotoxicity
(Figure 4) suggests that the binding of these proteins to cisplatin-DNA lesions may impede
removal of the adducts by DNA repair enzymes (Toney et al., 1989; Donahue et al., 1990). Slow
repair would allow the adducts to persist on the DNA, enhancing their genotoxicity. Indeed,
studies in vivo (Brown et al., 1993; McA'Nulty and Lippard, 1996) and in vitro (Huang et al.,
1994; Zamble et al., 1996) have suggested that HMG-domain proteins can sensitize cells to
cisplatin by a repair-shielding mechanism. Human SRY and other testis-specific HMG-domain
proteins may contribute to the specificity of cisplatin for testicular tumors by a similar mechanism.
Consistent with this hypothesis, human SRY has been detected in testicular tumor tissue (Tricoli
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et al., 1993) and the NTera2.D1 testicular embryonal carcinoma cell line (Cl6pet et al., 1993;
Poulat et al., 1995), which is deficient in cisplatin-adduct removal (Sark et al., 1995).
Furthermore, the present work has demonstrated that at a concentration of 0.1-0.3 pLM, the
hSRY-HMG domain selectively inhibited repair of the 1,2-d(GpG) cisplatin adduct in an in vitro
excision repair assay (Figure 19). A similar concentration of the full-length hSRY protein was
required to achieve comparable levels of repair inhibition (data not shown). These results
suggested that hSRY was not easily displaced by the excision repair complex when bound to the
1,2-d(GpG) adduct in vitro and, consequently, adduct removal was blocked. Consistent with this
view, the XPAC protein, which is responsible for damage recognition in nucleotide excision
repair, exhibits a slightly lower affinity in vitro for cisplatin-modified DNA (Kd(app) > 600 nM)
compared to hSRY (Jones and Wood, 1993).
Several factors need to be examined in order to evaluate critically a role for human SRY in
the blocking of cisplatin-adduct repair in vivo in testicular tumor cells. The results presented in
this dissertation have demonstrated that hSRY binds to the major 1,2-d(GpG) cisplatin intrastrand
cross-link with high affinity (Kd(app) = 115-120 nM, Figure 12 A, B; Table 3) and specificity (20-
fold, Figure 16; Table 3). Significantly, the 1,2-intrastrand adducts comprise 90% of cisplatin
lesions in drug-treated patients (Fichtinger-Schepman et al., 1987), and total adduct levels of 104-
10s/cell (0.1-1 CpM) have been observed (Reed et al., 1993). However, recognition of platinum
lesions by hSRY would likely be competed by the estimated 105 sites (1 ýpM) in human cells that
conform to the consensus DNA binding site for hSRY, as determined by random site selection
(AACAAT) (Goodfellow and Lovell-Badge, 1993). The comparable affinity ofhSRY for the 1,2-
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d(GpG) cisplatin adduct and the sequence AACAAAG (Figures 12 and 16) supports this view.
Nonspecific binding interactions exhibited by hSRY (Figures 12 and 18) might also decrease the
amount of protein available for platinum-adduct specific binding. Finally, an estimate of the in
vivo concentration of hSRY is needed in order to evaluate a possible role for this protein in repair
shielding of cisplatin-DNA adducts. Although the levels of hSRY in testicular cells have not been
quantitated, two studies have suggested that hSRY expression is low in the adult testis and the
NTera2.D1 embryonal carcinoma line (ClIpet et al., 1993; Poulat et al., 1995). Significantly,
immunofluorescence staining demonstrated that hSRY is localized in the nucleus of the
NTera2.D 1 cells (Poulat et al., 1995). The results from the in vitro excision repair inhibition
assay (Figure 19) suggest that a nuclear concentration of hSRY on the order of 0.2 WpM may be
required to inhibit repair of cisplatin-DNA adducts in testicular tumor cells. Assuming that the
volume of a cell is 1012 1 (based on 10'5 m3 dimensions) (Darnell et al., 1986) and the nucleus
constitutes 1/10 of the cell volume, one can calculate that a concentration of 0.2 ptM is
approximately equivalent to 104 molecules of hSRY per cell nucleus. Whether this concentration
of hSRY occurs in vivo is not known.
The feasibility of repair shielding by hSRY can be gauged by an estimate of the fraction of
platinum adducts bound by hSRY in the presence of hSRY target sites. This estimate can be
obtained by application of the competitive binding equation (Eq. 1 in III. Materials and Methods)
(Lin and Riggs, 1972; Long and Crothers, 1995) where ® = fractional saturation of platinum-
DNA adducts by hSRY, P, = nuclear concentration ofhSRY, T, = concentration of platinum-
DNA adducts, Ct = concentration of hSRY consensus target sites, KT = K.app) for the interaction
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of hSRY with a cisplatin adduct, Kc = Kd(app) for the interaction of hSRY with a target site. Using
the parameters P, = 0.2 pM, Tt = 1 p.M (Reed et al., 1993), Ct = 1 pM (Goodfellow and
Lovell-Badge, 1993), KT = 150 nM (Table 3), Kc = 50 nM (Table 3), one can calculate from Eq.
1 that approximately 5% of the platinum adducts would be bound by hSRY in vivo. Similarly,
using the same parameters except letting Pt = 0.02 ~M (103 molecules hSRY/nucleus), one can
calculate that only 0.5% of the adducts would be bound by hSRY. If the parameters above are
valid estimates under in vivo conditions, the calculations suggest that hSRY, alone, may play a
limited role in repair shielding of cisplatin adducts in testicular tumor cells. However, the in vivo
concentration of hSRY is unknown at present and, therefore, it is difficult to speculate further on
this issue.
Recently, several testis-specific HMG-domain proteins other than hSRY have been
identified that, together with hSRY, could potentially contribute to the specificity of cisplatin for
testicular tumors. In particular, several members of the Sox (SRY-related HMG bx) gene family
(Denny et al., 1992a), including the mouse genes Sox5 (Denny et al., 1992b; Connor et al., 1994),
Sox6 (Connor et al., 1995; Takamatsu et al., 1995), and Sox17 (Kanai et al., 1996), are most
highly expressed in the adult testis and share with hSRY the ability to bind to the DNA target
sequence AACAAT. The human homologs of Sox5 and Sox6 have also been cloned (Denny et
al., 1992a). It is reasonable to speculate that these testis-specific Sox proteins may bind to
platinum-DNA lesions and inhibit cisplatin-adduct repair similar to hSRY. Furthermore, a mouse
testis-specific HMG-domain protein (tsHMG) containing two tandem HMG domains has also
been identified (Boissonneault and Lau, 1993; Larsson et al., 1996). Significantly, tsHMG has
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been shown to bind to the 1,2-d(GpG) intrastrand cross-link with a Kd(app) of 40 nM (U.-M.
Ohndorf, manuscript in preparation) and, at a concentration as low as 0.025 p.M, tsHMG inhibits
repair of the 1,2-d(GpG) adduct in an in vitro excision repair assay (Zamble et al., 1996). Recent
evidence has also indicated that the human mismatch repair protein hMSH2, which does not
contain an HMG domain, binds to cisplatin-DNA adducts with an estimated Kd,) of 67 nM and
is overexpressed in testicular tissue (Mello et al., 1996). Taken together, these results suggest
that if the aforementioned or other as yet undentified testis-specific proteins are expressed in
testicular tumors and are able to inhibit repair of cisplatin-DNA adducts, they, in conjunction with
hSRY, may contribute to the limited ability of testicular tumor cells to remove cisplatin-DNA
adducts.
A complication with the above prediction is that expression of testis-specific proteins in
normal testicular tissue does not indicate necessarily that testicular tumors will also express these
proteins. In fact, expression of testis-specific HMG-domain proteins is often limited to the germ
cells during specific stages of spermatogenesis. Immunofluorescence and/or
immunohistochemical staining have demonstrated that Sox5 (Denny et al., 1992b) and Sox6
(Takamatsu et al., 1995) are expressed in the haploid spermatids, tsHMG is expressed in both the
meiotic spermatocytes and the haploid spermatids (Boissonneault and Lau, 1993; Larsson et al.,
1996; Alami-Ouahabi et al., 1996), and Soxl7 is expressed in the premeiotic spermatogonia
(Kanai et al., 1996). However, it is generally believed that primordial germ cells are the
precursors of both sperm (Willison and Ashworth, 1987) and testicular tumor cells (Campbell and
Walsh, 1986; Skakkebaek et al., 1987; de Jong et al., 1990), and thus protein expression profiles
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in these cells could be potentially similar. It is also interesting to note that testicular cancer
patients are often azospermic (without sperm) at time of presentation and that cisplatin treatment
produces nearly universal, but potentially reversible azospermia (Loehrer and Einhorn, 1984;
Peckham, 1988; Hansen et al., 1989). Studies examining the levels of the testis-specific proteins
in testicular tumor cell lines and tissues are clearly needed in order to evaluate a possible role for
these proteins in the organotropic specificity of cisplatin for testicular tumors.
Several lines of evidence suggest that the HMG-domain proteins HMG1 and HMG2 may
be expressed at high levels in testicular tumors, and thus these proteins could be involved in
sensitizing testicular tumor cells to cisplatin through a repair-shielding mechanism. In general,
HMG1 and HMG2 are very abundant in mammalian cells;estimates of 106 molecules/cell for both
these proteins have been reported (Goodwin and Mathew, 1982). Additionally, HMG1 and
HMG2 expression has been strongly correlated with cellular proliferation (Bustin et al., 1992).
HMG1 levels were found to be elevated 8-fold in rat hepatoma cells compared to normal liver
(Shastri et al., 1982). These observations are significant because testicular tumors are very
rapidly growing tumors (Campbell and Walsh, 1986). Furthermore, HMG2 levels are
approximately 3-fold higher in normal testis than in other proliferating tissues, owing to an
abundant, rapidly migrating subtype of HMG2 (Seyedin and Kistler, 1979; Bucci et al., 1984;
Mosevitsky et al., 1989). Ten different species were found to express the HMG2 subtype in their
testicular germ cells (Bucci et al., 1985). Overall, the levels of HMG1 and HMG2 have been
estimated to be greater than 1 x 106 and 2 x 106 molecules per cell nucleus, respectively
(Mosevitsky et al., 1989). Taken together, these data suggest that HMG1 and particularly HMG2
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could be highly expressed in testicular tumor cells. In one study, levels of a protein similar in size
to HMG1 (28 kDa) were not elevated in testicular tumor cell lines compared to bladder
carcinoma lines when examined by Southwestern analysis (McLaughlin et al., 1993). However,
the testicular tumor cell line SuSa, which is deficient in the removal of cisplatin-adducts (Bedford
et al., 1988), contained high levels of a protein similar to HMG2 in molecular weight (26.5 kDa),
and these levels were reduced two-fold in a cisplatin resistant variant of the SuSa line (SuSa-CP)
(McLaughlin et al., 1993), which has an enhanced DNA repair capacity (Hill et al., 1994b). This
last result is consistent with a role for HMG2 in repair-shielding of cisplatin-DNA adducts in
testicular tumor cells. Significantly, HMG1 and HMG2 have been shown to bind selectively to
cisplatin-modified DNA (Pil and Lippard, 1992; Hughes et al., 1992). HMG1 binds to the 1,2-
d(GpG) cisplatin intrastrand adduct with a Kd(app) of 370 nM and a 100-fold specificity over
unmodified DNA (Pil and Lippard, 1992) and, in the in vitro excision repair assay, repair of the
1,2-d(GpG) and 1,2-d(ApG) cisplatin intrastrand adducts was inhibited with HMG1
concentrations of 1-2 CtM (Huang et al., 1994; Zamble et al., 1996). Assuming that the volume of
a cell is 1012 1 (based on 10'5 m3 dimensions) (Darnell et al., 1986), one can calculate that 106
molecules/cell is approximately equal to a concentration of 2 p.M. Thus, the concentrations of
HMG1 and HMG2 in tumor cells might be sufficient for these proteins to inhibit repair of
platinum adducts. The potentially high levels of HMG1 and especially HMG2 in testicular tumor
cells also suggest a possible role for these proteins in conferrring cisplatin sensitivity to this target
tissue. However, it is difficult to argue for such a role, given the likely high concentrations of
these proteins in all rapidly growing tumor cells.
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Moreover, the abundantly expressed HMG1 and HMG2 proteins would likely compete
with the aforementioned testis-specific proteins for occupancy of cisplatin-DNA adducts in
testicular tumor cells. In addition, the HMG-domain protein hUBF binds to the 1,2-d(GpG)
cisplatin adduct with extremely high affinity (K.app) = 60 pM) (Treiber et al., 1994), and its role as
a transcriptional regulator of ribosomal RNA synthesis suggests that it may also be elevated in
rapidly proliferating testicular tumor cells. However, hUBF is localized in the nucleolus (Roussel
et al., 1993), whereas the testis-specific HMG-domain proteins are found more generally
distributed in the nucleus (Boissonneault and Lau, 1993; Poulat et al., 1995; Kanai et al., 1996),
suggesting that hUBF may not necessarily compete with the testis-specific HMG-domain proteins
for cisplatin adducts in testicular tumor cells. It is also interesting to note that higher
concentrations of HMG1 (1-2 [AM) are required to achieve the same level of repair inhibition of
the 1,2-d(GpG) adduct in vitro (Huang et al., 1994) compared to the testis-specific proteins
hSRY (0.2 pM) (Figure 19) and tsHMG (0.025 WtM) (Zamble et al., 1996), even though these
proteins bind cisplatin-DNA with comparable affinities (Pil and Lippard, 1992) (Figure 12 A,B;
U.-M. Ohndorf, unpublished results). Thus, the concentration needed to achieve repair inhibition
may differ among individual HMG-domain proteins and may not be directly related to the K•,pp) of
cisplatin-adduct binding. Moreover, further information about cellular concentration, affinity for
cisplatin-DNA compared to target DNA, and DNA binding selectivity is needed in order to
evaluate critically a role for the testis-expressed HMG-domain proteins in shielding platinum
adducts from repair in testicular tumor cells. To date, no correlation has yet been established
between the levels of HMG-domain proteins and the repair of cisplatin-DNA adducts in tumor
cells.
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2. Cisplatin adducts may act as molecular decoys for hSRY.
A second, equally plausible model (Figure 5) proposes that cisplatin-DNA adducts may
act as molecular decoys in testicular tumor cells, titrating hSRY and other testis-specific HMG-
domain proteins from their natural binding sites and thereby disrupting their function. Indeed,
DNase I footprinting studies (Treiber et al., 1994) demonstrated that the binding of the ribosomal
transcription factor hUBF to its cognate promoter sequence was competed with a cisplatin-DNA
adduct concentration significantly lower than that found in the DNA of cancer patients (Reed et
al., 1993). The function of hSRY in testis determination in the embryo is believed to involve
transcriptional regulation. Additionally, the expression of hSRY in the adult testis suggests a role
in regulating gene expression during spermatogenesis (Sinclair et al., 1990; Clepet et al., 1993).
Although a physiological target for hSRY has not been identified conclusively, the protein has
been shown to stimulate transcription from thefra-1 promoter (Cohen et al., 1994) and from the
Mullerian inhibitory substance gene promoter (Haqq et al., 1994) in cotransfection experiments.
If the function of hSRY in testicular tumor cells is transcriptional regulation of a critical gene,
then titration of hSRY away from its natural binding site by cisplatin-DNA adducts might lead to
cell death. Additionally, several other testis-specific HMG-domain proteins are believed to be
transcriptional regulators (Denny et al., 1992b; Connor et al., 1995; Takamatsu et al., 1995; Kanai
et al., 1996), and thus these proteins might contribute to cisplatin toxicity in testicular tumor cells
by a similar mechanism.
In support of a 'transcription factor hijacking' model for hSRY in testicular tumor cells,
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the results presented in this dissertation have demonstrated that hSRY bound to the major 1,2-
d(GpG) cisplatin adduct and a putative target sequence AACAAAG with comparable affinities
(Figures 12 and 16; Table 3). Furthermore, cisplatin-DNA adducts competed effectively with the
AACAAAG sequence for the binding of hSRY in vitro (Figure 16). The binding of full-length
hSRY to the SRY-20 probe was completely competed with a cisplatin-DNA adduct (Pt-20)
concentration of 1 ýpM (data not shown); this adduct concentration is similar to that found in the
DNA of cancer patients (Reed et al., 1993), suggesting that titration of hSRY from its target sites
might occur in vivo.
There are several possible complications with the above model, however. One caveat is
the modest DNA binding selectivity (20-60-fold, Figure 16; Table 3) exhibited by hSRY. In vivo
where the concentration of nonspecific DNA binding sites is considerably higher than that of
cisplatin-DNA adducts or hSRY target sites, nonspecific binding would be expected to largely
inhibit specific binding by hSRY. However, it is reasonable to predict that the mechanisms used
by transcriptional regulators to evade nonspecific binding in vivo (possibly tracking, vide supra)
might also be used for the specific binding to cisplatin-DNA adducts. A second issue is whether
cisplatin-adduct binding could reduce target site binding by hSRY in testicular tumor cells.
Platinum adducts form at a level of 104-105 per cell in cancer patient DNA (Reed et al., 1993) and
more than 105 sites in the human genome conform to the consensus DNA binding site for hSRY
(Goodfellow and Lovell-Badge, 1993). Cisplatin-adduct binding in vivo would likely depend on
the amount of unbound hSRY which, in turn, would be related to the level of nonspecific binding.
However, since the concentration ofhSRY in testicular tumor cells is not known, it is difficult to
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speculate further on this issue. A third complication with the titration model is the availability of
cisplatin-DNA adducts for hSRY binding in testicular tumor cells, given the potentially high
concentrations of HMG1 and HMG2 in these cells (vide supra). Finally, the titration model
assumes that the function of hSRY in testicular tumor cells is transcriptional regulation of a gene
critical to cell growth and survival. However, the identity of such a critical gene remains elusive.
To date, the biologically relevant target genes for hSRY in sex determination and in
spermatogenesis have also not been identified. Thus, it remains to be determined whether hSRY
or other testis-expressed HMG-domain proteins can sensitize testicular tumor cells to cisplatin by
a 'transcription factor hijacking' mechanism.
F. Role for DNA bending in the function of hSRY in sex determination
Finally, the ability of hSRY to bend DNA and to bind to prebent structures like cisplatin-
DNA suggests that DNA bending may be central to the biological function of hSRY in sex
determination. In a recent study, the HMG domains from XY individuals carrying mutations in
hSRY were found to differ in their DNA bending and binding activities. Interestingly, one mutant
protein bound to the sequence AACAAAG with almost normal affinity but produced a
considerably smaller DNA bend angle (Pontiggia et al., 1994). In a subsequent study, the HMG
domains of SRY from human and seven different primates were found to induce extremely similar
DNA bend angles (Pontiggia et al., 1995). The apparent requirement for a precise geometry in
the hSRY/DNA complex suggests that hSRY may bend the DNA in order to promote contact
between proteins bound on either side of the hSRY binding site. Thus, hSRY may modulate
188
transcription by acting architecturally in the assembly of a higher order nucleoprotein complex
(Pontiggia et al., 1994), as proposed for LEF-1 (Grosschedl et al., 1994; Giese et al., 1995).
Moreover, the exact spatial arrangement of this transcriptional complex may be critical for sex
determination by hSRY. In support of a functional role for protein-induced bending by SRY,
Grosschedl and colleagues demonstrated that the HMG domain of mSRY was able to replace the
LEF-1 domain partially in its ability to stimulate transcription from a modified T cell receptor a
gene enhancer construct in which the LEF-1 binding site was replaced with a SRY site (Giese et
al., 1995).
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VI. CONCLUSIONS AND FUTURE EXPERIMENTS
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The work presented in this dissertation has shown that the testis-specific HMG-domain
protein human SRY binds selectively to DNA modified with cisplatin and that the HMG domain is
sufficient for this interaction. The results have also demonstrated that hSRY recognizes the major
DNA adduct of cisplatin and a putative target sequence with comparable affinities. The
significance of this work is three-fold. First, the binding of hSRY to both the intrinsically bent
1,2-d(GpG) cisplatin adduct and a linear DNA sequence suggests that these DNAs may have a
similar conformation when complexed to hSRY. Recent structural studies of both a specific
hSRY-HMG domain/target DNA complex (Werner et al., 1995) and the 1,2-d(GpG) intrastrand
cross-link in duplex DNA (Takahara et al., 1996) lend support to this view. Second, recent
evidence suggests that the extreme sensitivity of testicular tumors to cisplatin may be related to
defective removal of cisplatin-DNA adducts (Bedford et al., 1988; Kelland et al., 1992a; Hill et
al., 1994a; Sark et al., 1995; Koberle et al., 1996). In collaboration with D.B. Zamble in the
Lippard laboratory, it was demonstrated that the binding of the testis specific protein hSRY to the
1,2-d(GpG) cisplatin adduct inhibits its repair in an in vitro excision repair assay, suggesting that a
repair-shielding mechanism may be operative in testicular tumor cells. Finally, the comparable
affinities ofhSRY for a 1,2-d(GpG) adduct and a putative target sequence suggests that cisplatin
adducts may compete with specific sequences in vivo for the binding of hSRY, leading to the
proposal that the adducts may act as molecular decoys for hSRY in testicular tumor cells. Based
on the results of this dissertation, the following are suggested as future experiments.
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1. Further optimization of titration experiments
Subsequent to the binding studies described in this dissertation, it was discovered that
inactivation of the hSRY-HMG domain could be prevented by the addition of NP-40 to the
protein dilution buffer. Data from a preliminary titration experiment indicated that the affinity of
the hSRY-HMG domain for the Pt-20 probe was increased approximately 10-fold in the presence
of NP-40, as reported for other protein-nucleic acid interactions (Brown et al., 1990; Batey and
Williamson, 1996). Although I am confident that under the conditions of the binding experiments
the apparent dissociation constants obtained for the interactions of the hSRY-HMG domain with
the various DNA probes are directly comparable, the experiments should be repeated using NP-40
in the protein dilution buffer to verify the relative K(app) values. Furthermore, the addition of
nonspecific competitor DNA to the binding reactions may reduce some of the nonspecific binding
seen at high protein concentrations and may result in more well-behaved tirations for both the
hSRY-HMG domain and full-length hSRY. Data obtained from such titration experiments may
produce a better fit to Eq. 3 (in IV. Results) which describes a bimolecular equilibrium.
2. Footprinting studies
The interactions of full-length hSRY and the hSRY-HMG domain with the 1,2-d(GpG)
cisplatin adduct should be examined further in DNase I and/or hydroxyl radical footprinting
experiments. Previous footprinting studies with full length hUBF (Treiber et al., 1994), full-
length Ixrl (McANulty et al., 1996), and HMG1-domains A and B (Locker et al., 1995) have
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revealed a 14-15 bp protected region centered on the cisplatin adduct, suggesting that contact is
mediated by a single HMG domain. Parallel footprinting studies employing full-length hSRY and
the hSRY-HMG domain may reveal whether the observed increase in DNA binding selectivity for
full-length hSRY compared to the hSRY-HMG domain (Figures 16 and 17) stems from additional
DNA contacts. The Pt-100 DNA probe may be suitable for these studies. Alternatively, a DNA
probe with different sequences flanking the central platinated oligonucleotide may be useful,
considering the relatively high nonspecific binding observed for full-length hSRY on Pt-100
(Figure 18). Footprinting experiments with a DNA probe containing a putative hSRY target site
should also be performed to determine whether human SRY produces similar cleavage patterns on
platinated and target site DNAs. A region of 7 base pairs in the (G)AACAAAG sequence has
previously been shown to be protected from hydroxyl radical cleavage by the hSRY-HMG
domain (Rimini et al., 1995). No footprinting studies have yet been performed with full-length
hSRY.
3. Investigation of a sequence dependence for cisplatin-adduct binding by human SRY
A recent study has demonstrated that the affinities of HMGl-domain A and HMG1-
domain B for the 1,2-d(GpG) cisplatin adduct varied depending on the sequence context of the
adduct (Dunham and Lippard, manuscript submitted). The apparent dissociation constants ranged
over two orders of magnitude for HMG1-domain A binding to a series of nine probes containing
the 1,2-d(GpG) adduct with different base pairs flanking the adduct. In particular, HMG1-domain
A exhibited a preference for dA > dT > dC as the base 3' to the platinated d(GpG) site. A
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sequence preference for HMG1-domain B was less pronounced. The Pt-20 and Pt-100 probes
used in the present study for hSRY binding contained the central sequence 5'-TG*G*T-3', where
the asterisks denote the cisplatin intrastrand cross-link. In preliminary experiments, the hSRY-
HMG domain exhibited higher DNA binding affinity and selectivity for the Pt-100 probe
compared to a platinated 92 bp probe containing the central sequence 5'-AG*G*C-3'. However,
a sequence dependence for cisplatin-adduct binding by hSRY needs to be examined in a
systematic study like that of Dunham and Lippard.
4. Analysis of cisplatin-adduct binding by HMG domains of hSRY containing single amino
acid mutations
The following GST/hSRY-HMG constructs (D58-K136) derived from human XY
individuals with complete gonadal dysgenesis were provided by D. Page (MIT). The amino acid
numbering is that of Goodfellow and colleagues. (Sinclair et al., 1990; Whitfield et al., 1993).
Sequence-specific binding is as reported by the Page laboratory to 25 bp oligonucleotides
containing a central AACAAAG or AACAATG sequence.
Mutant nt change AA change Sequence Binding
WHT1899 T-G W70G no
WHT2050 G-C K92N yes
WHT2057 TTAC deletion 116 no
WHT2080 C-A P83T yes
WHT2242 ? P131L ?
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It would be interesting to examine the cisplatin-adduct binding activity of these mutants and to
determine whether cisplatin-DNA binding parallels sequence-specific binding. In particular, the
mutants WHT2080 and WHT2242 represent substitutions of conserved prolines. Presently, the
mutant expression plasmids are in the E. coli strain DH5(x. To avoid proteolytic degradation of
resulting HMG domain proteins, the plasmids should be transfected into the protease-deficient
strain BL21(DE3). In a similar analysis, Bianchi and colleagues found that a set of mutant HMG
domains (distinct from those above) differed in their DNA binding and bending activities for the
AACAAAG sequence but, interestingly, bound to four-way junction DNA with similar affinities
(Pontiggia et al., 1994).
5. Structural studies
The determination of a hSRY/cisplatin-DNA adduct structure would provide information
about specific protein/DNA contacts in addition to lending insight into how HMG-domain
proteins may modulate the activity of an important anticancer drug. The work in this dissertation
has demonstrated that both full-length hSRY and the hSRY-HMG domain form specific
complexes with a 20 bp DNA probe containing a single 1,2-d(GpG) cisplatin adduct (Pt-20). The
hSRY-HMG domain may also bind to DNA probes as small as 15 base pairs, as has been
demonstrated by the Lippard laboratory for HMG1-domain B (Chow et al., 1995; Kane and
Lippard, 1996) and HMG1-domain A (Dunham and Lippard, manuscript submitted). A minimal
complex between the hSRY-HMG domain and a small cisplatin-modified probe may be amenable
to detailed structural analysis by NMR and/or X-ray diffraction methods. A comparison between
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a hSRY-HMG domain/cisplatin adduct structure and the recently reported structure of a specific
hSRY-HMG domain/target DNA complex (Werner et al., 1995) may provide insight into the
structure-specific and sequence-specific modes of DNA binding exhibited by this protein.
6. Southwestern and Western analyses of extracts from testicular tumors and testicular
tumor cell lines
Studies examining the levels of cisplatin-DNA binding proteins in testicular tumor tissues
and cell lines may help to evaluate a possible role for these proteins in the organotropic specificity
of cisplatin for testicular tumors. To this end, we have obtained several testicular tumor samples
from the NCI Cooperative Human Tissue Network. Sixteen of the tumor samples are seminomas,
two are mixed nonseminomas (with embryonal carcinoma, yolk sac carcinoma, and teratoma), and
two are mixed germ cell tumors containing both seminomatous and nonseminomatous elements.
Two samples represent metastasis to lymph node tissue. Significantly, matched, adjacent normal
testicular tissue was provided with three of the tumor samples.
7. Cisplatin sensitivity of a HeLa cell line stably transfected with human SRY
Recently, a HeLa cell line stably expressing full-length hSRY has been described (Poulat et
al., 1995). If we could obtain this cell line and the hSRY-nonexpressing (negative control) line,
experiments could be performed to directly investigate the effect of hSRY expression on cisplatin
sensitivity. A specific increase in cisplatin sensitivity in the HeLa cell line expressing hSRY would
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be consistent with our repair-shielding model, whereby unrepaired lesions persist on the DNA,
enhancing lethality. Increased levels of hSRY may also compensate for its diversion away from
its target site, as predicted by the titration model, but this would also lead to inhibition of DNA
repair, since the two models are not mutually exclusive. Thus, it is unlikely that a cell could
become resistant to the effects of hSRY hijacking by increasing hSRY levels.
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